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Preface 
 
This thesis presents data obtained during the research work developed at the Instituto 
de Medicina Molecular and at the National Institute for Medical Research in the 
period between January 2004 and April 2009 in the scope of my PhD project and 
under the supervision of João T. Barata, PhD. 
This thesis is organized in 6 chapters, which are preceded by a summary written in 
Portuguese and by an abstract. Before the description of the results obtained, an 
introductory review of the subject is provided in chapter 1 and the aims of the work 
are also detailed at the end of chapter 1. In chapters 2, 3, 4 and 5 the original data 
obtained during this research project is presented and discussed. A general discussion, 
which integrates and puts into perspective all the results, is presented in chapter 6.  
The data presented in this dissertation is purely the result of my own work and it is 
clearly acknowledged in the text whenever data or reagents produced by others were 
utilized. I was financially supported by a scholarship from Programa SFRH, Fundação 
para a Ciência e Tecnologia, Portugal. This work has not been submitted for any 
degree at this or any university.  
 
The opinions expressed in this publication are from the exclusive responsibility 
of the author. 
 
The impression of this thesis was approved by Comissão Coordenadora do 
Conselho Científico da Faculdade de Medicina de Lisboa on the 8th of April 
2009. 
 
 
 
 
 
 iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
v 
Acknowledgements 
First of all, I am very grateful to my supervisor, Dr. João T. Barata, for his infinite 
support during these years. Without his compelling enthusiasm and motivation 
throughout my PhD, this work would have never come to fruition. An outstanding 
scientist that I will always remember with great respect and admiration. More 
important a friend for the rest of my life.  
 
A special thanks to my co-supervisor Dr. Leonor Parreira, for being such an inspiring 
person and for her interest and support in my work. 
 
I acknowledge to Dr. Benedict Seddon for the great opportunity to work and learn in 
his lab. Also, I thank to all Seddons’ lab team . 
  
To all my colleagues from the laboratory that made the daily bench work much more 
pleasant. A special thanks for Bruno for all the scientific and futebolistic discussions, 
patience and early morning coffees, thanks ! Cristina for all the amazing theories 
and for being such a great friend . Leila for all the support and friendship . Inês C. 
for the challenge of learning something from me . Leonor for her determination and 
interesting conversations. Catarina, Ana Gírio, Nádia and Daniel for the amusing 
company everyday. A big thank you for all the UBH team, Isabelinha , Ricardo, 
Pedro (a tasca é sempre uma alternativa  ) and Tiago. Paulo for his avantgarde 
thoughts , SLB games, but special for being a great friend! Joana Costa for being 
such a good friend in the University and final part of my PhD. Ana Lu for all the 
funny moments in and out the citometry room. Maria G. and Inês A. for amasing 
friendship and for turning London into a even more interesting city!!! 
 
I thank all my friends without whom I would not have enjoyed this period half as 
much. Todos os eventos da Confraria da Escada, todas as viagens, todos os concertos, 
todas as idas ao cinema, todos os jogos de beach volley, and so on and so on!!!! Em 
especial, à amizade da Joana Jinagre, recente mas para durar. À Sílveca pelos 
momentos de “patarequice”, muito, muito bons!!!! Ao Diogo, sim eu sou de Biologia 
. Aos momentos de qualidade e amizade com a Paula, Gugu, Rui, Rita e pequena 
Margaret, Sílvia F., Batista, Nuno... Thanks, as palavras são pouquinhas!!!! Um 
grande beijinho a todos que não menciono, mas também não esqueço! 
 
I thank my family for their unconditional care, love and support. Most of all for the 
capacity to understand all delays, absent dinners and weekends! Mãezinha e Paizinho 
vocês são os maiores, beijocas, adoro-vos . Mano, tu és aquele que eu mais admiro! 
Ticha tu és simplesmente única e linda, gosto muito de ti!!! Vanexa, “como macaco 
gosta de banana eu gosto de tiiiiii”!!! Tátá, a tua amizade e apoio são muito 
importantes para mim. Gosto muito, obrigada! A todos os meus avós, beijinhos do 
coração. 
ACKNOWLEDGEMENTS 
vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMÁRIO 
vii 
Sumário 
A leucemia linfoblástica aguda (LLA) resulta da expansão clonal de células linfóides 
bloqueadas durante o processo de diferenciação celular. Aproximadamente 15% dos 
casos de LLA apresentam um fenótipo de células T imaturas (LLA-T). Apesar dos 
regimes quimioterâpeuticos em uso terem permitido significativas melhorias nas taxas 
de remissão dos doentes, ainda há um número considerável de recidivas e estes 
tratamentos estão frequentemente associados a graves efeitos secundários. Como tal, 
para melhor compreender a fisiopatologia da LLA-T e identificar novos alvos de 
intervenção terapêutica, é muito importante estudar os mecanismos celulares e os 
factores microambientais que contribuem para a leucemia. 
Em cancro são muito frequentes as mutações no gene supressor tumoral que codifica 
a fosfatase PTEN, resultando na sua delecção. Em amostras primárias de LLA-T, 
demonstrámos que a inactivação pós-traducional da proteína PTEN era mais 
frequente que a ocorrência de mutações no seu gene. No entanto ambos os 
mecanismos contribuem para a activação da via de sinalização associada a viabilidade 
e proliferação - PI3K/Akt, uma vez que PTEN é o seu regulador negativo. Estudos 
prévios demonstraram que existem vários mecanismos pós-traducionais da proteína 
PTEN que controlam a sua actividade. Neste trabalho estudámos o papel da oxidação 
e da fosforilação pela cinase CK2. Os nossos resultados demonstraram que inibidores 
de CK2 e antioxidantes reconstituem a actividade de PTEN e inibem a via de 
sinalização PI3K/Akt em LLA-T. Assim, as evidências indicam que o uso de 
inibidores farmacológicos que controlem a activação da via de sinalização PI3K/Akt, 
podem constituir um tratamento promissor para LLA-T (Capítulo 2). 
Outro aspecto muito importante na progressão da leucemia é a contribuição 
proveniente do microambiente tumoral. A interleucina- (IL-) 7 é produzida pelas 
células epiteliais do timo e pelas células estromais da medula óssea, o que significa 
que está presente no microambiente onde as células de LLA-T surgem e para onde 
estas metastizam. Recentemente o nosso grupo demonstrou que a IL-7 aumenta a 
viabilidade, a proliferação e o uso de glucose em células de LLA-T, através da 
activação da via de sinalização PI3K/Akt. Por outro lado, as espécies reactivas de 
oxigénio (ERO) consequentes da sinalização por citocinas, foram identificadas como 
intermediários na modulação da viabilidade, proliferação e transporte de glucose. 
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Neste trabalho demonstrámos que em células de LLA-T, a sinalização por IL-7 
promove um aumento de ERO através da activação da via de sinalização PI3K/Akt e 
do transporte de glucose. Curiosamente, o aumento dos níveis intracelulares de ERO 
parece ser também determinante para a activação da via de sinalização PI3K/Akt após 
o estímulo com IL-7, constituindo assim um mecanismo de feedback positivo. Os 
nossos dados sugerem que ERO funcionam como segundos mensageiros na 
sinalização por IL-7 promovendo a viabilidade e a proliferação das células de LLA-T 
in vitro. Em conjunção com os estudos descritos no capítulo 2, estes resultados 
indicam que o uso de antioxidantes poderá ser eventualmente considerado como uma 
estratégia terapêutica em LLA-T (Capítulo 3). 
Tendo em conta que estudos prévios em modelos de ratinhos transgénicos para a IL-7 
lhe atribuem um papel oncogénico, decidimos investigar a contribuição da IL-7 para o 
desenvolvimento da leucemia T humana num sistema in vivo. Primeiro, 
demonstrámos que a IL-7 murina promove a expansão de células humanas leucémicas 
in vitro. De seguida, gerámos quimeras com células humanas de LLA-T 
xenotransplantadas em ratinhos γCKO /Rag2KO deficientes ou selvagens para o gene 
da IL-7. Os nossos resultados demonstraram que a IL-7 acelera a progressão da 
leucemia in vivo, uma vez que aumenta a viabilidade das células e a sua proliferação 
(Capítulo 4).  
Apesar da importância do papel da IL-7 em leucemia, sabe-se que ratinhos AKR/J, 
que apresentam sobre-expressão do receptor da IL-7 (IL-7Rα) em timócitos, 
desenvolvem tumores espontâneos com fenótipo de células T. Neste projecto usámos 
um modelo de ratinho transgénico com expressão indutível do IL-7Rα, para estudar o 
potencial oncogénico do receptor da IL-7 na linhagem T. Observámos que animais 
que expressem continuamente o receptor da IL-7, desenvolvem uma hiperplasia 
tímica que precede o desenvolvimento de tumores e consequente morte do animal. 
Estas células malignas acabam por tornar-se independentes do receptor da IL-7 e 
adquirir outros mecanismos comuns a células tumorais, como a activação da via de 
sinalização PI3K/Akt, a perda do supressor tumoral PTEN e/ou a diminuição da 
expressão do inibidor do ciclo celular, p27Kip1. Estes resultados demonstram a 
importância da sinalização pelo receptor da IL-7 em tumorigénese in vivo (Capítulo 
5). 
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O conjunto dos nossos estudos sugere um papel crucial para a via PI3K/Akt em LLA-
T, cuja activação pode resultar quer de mecanismos inerentes à própria célula, quer 
devido à sinalização pelo eixo IL-7/IL-7R. Os nossos resultados levam a considerar os 
reguladores da via de sinalização PI3K/Akt como alvos terapêuticos promissores em 
LLA-T. 
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Abstract  
Acute lymphoblastic leukemia (ALL) results from the clonal expansion of lymphoid 
cells arrested at different stages of differentiation. Approximately 15% of ALL 
patients present with a T cell phenotype (T-ALL). Despite significant improvements 
in treatment outcome, a considerable number of relapses still occur and the intensive 
therapeutic regimens in use are often associated with long term, severe complications. 
Thus, to better understand the pathophysiology of T-ALL and identify new targets for 
therapeutic intervention, it is crucial to unravel cell autonomous mechanisms and 
microenvironmental factors contributing to leukemogenesis.  
Mutations in the phosphatase and tensin homolog (PTEN) gene leading to PTEN 
protein deletion are the second most common in cancer. In primary T-ALL cells, we 
demonstrated that PTEN posttranslational inactivation was more frequent than PTEN 
mutations, yet both promoted activation of the PI3K/Akt signaling pathway. Several 
posttranslational mechanisms are known to inactivate PTEN activity. In this study, we 
reported the role of oxidation and phosphorylation by casein kinase 2 (CK2) in 
inhibiting PTEN function in T-ALL. Accordingly, both reactive oxygen species 
(ROS) scavengers and CK2 inhibitors restored PTEN activity and impaired PI3K/Akt 
signaling in leukemia cells. These results indicate that manipulation of PI3K/Akt 
pathway using pharmacological inhibitors is promising for T-ALL treatment (Chapter 
2). 
IL-7 is present in the microenvironment where leukemia arises and develops, because 
it is produced by thymic epithelial and bone marrow stromal cells. Previously, we 
have shown that IL-7 increases viability, proliferation and glucose uptake in T-ALL 
cells in a PI3K/Akt pathway dependent manner. It is known that ROS are generated in 
response to cytokines, acting as intracellular messengers to modulate viability and 
proliferation. Here, we demonstrated that IL-7 upregulated ROS in T-ALL cells and 
this occurred in a PI3K pathway and glucose transport (GLUT) dependent manner. 
We further demonstrated that IL-7-mediated activation of PI3K/Akt signaling 
pathway was dependent on ROS generation, indicating the existence of a positive 
feedback loop. Our results implicate ROS as second messengers in IL-7 mediated 
viability and proliferation in vitro. Together with the studies described in chapter 2 
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our data indicate that the use of ROS scavengers maybe regarded as a possible 
therapeutic strategy in T-ALL (Chapter 3). 
Previous studies showed that IL-7 can act as an oncogene in transgenic murine 
models. In this section, we studied the role of IL-7 in vivo using a mouse model of 
human T-ALL. We first demonstrated that murine IL-7 promoted the expansion of 
human leukemic cells. Next, we xenografted T-ALL cells into γCKO /Rag2KO mice 
that were either IL-7 wild type or IL-7 deficient. Our data demonstrate that IL-7, 
accelerated the progression of leukemia in vivo, by increasing the viability and 
proliferation of T-ALL cells. This was associated with upregulation of Bcl-2 and 
downregulation of the cell cycle inhibitor p27Kip1 (Chapter 4). 
The aberrant expression of IL-7 receptor can also induce spontaneous T-cell tumors, 
as shown in AKR/J mice, which overexpress IL-7 receptor α chain (IL-7Rα) in 
thymocytes. We used tetracycline-inducible IL-7Rα transgenic mice (TreIL-7Rα) to 
further characterize the oncogenic potencial of IL-7Rα expression in the T cell 
lineage. Interestingly, we observed that thymic hyperplasia preceded tumor-associated 
death in IL-7Rα−expressing animals. Moreover, malignant cells become IL-
7Rα−independent and acquire other tumor signatures related to PI3K/Akt pathway 
activation, such as loss of the tumor suppressor PTEN and downregulation of p27Kip1. 
These results confirmed the importance of the IL-7R axis in T-cell tumorigenesis in 
vivo (Chapter 5). 
Altogether, our data establish PI3K/Akt pathway as an important signaling node in T-
ALL, and demonstrate that this critical pathway can be activated by cell autonomous 
aberrations and/or by the IL-7/IL-7R axis. Furthermore, we provide clear evidence for 
considering the regulators of PI3K/Akt signaling pathway as promising targets for 
therapeutic intervention in T-ALL. 
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1. Introduction 
1.1. Leukemia  
Hematopoiesis occurs through lifetime but if cell self-renewal and differentiation 
become deregulated or uncoupled it can result in leukemia. This cancer of the blood 
or bone marrow (BM) is generally characterized by an accumulation of immature 
blasts that fail to differentiate into functional cells. Leukemia is a greek-derived word 
meaning white blood (leukos “white”; aima “blood”) and covers a spectrum of 
diseases that can be clinically and pathologically subdivided. The main subtypes of 
leukemia are classified according to whether they represent acute or chronic forms of 
disease and according to the type of blood cell affected, either lymphoid or myeloid. 
Acute leukemias have a rapid progression of immature blood cells and are the most 
common forms of leukemia in children whereas chronic leukemias result from the 
accumulation of relatively mature, but abnormal, blood cells through time (1). 
Although being a rare disease in childhood, leukemia is the most common cancer in 
children and adolescents accounting for about 33% of all pediatric cancers (2). Of the 
estimated children who will develop leukemia, about 3 out of 4 will be diagnosed 
with acute lymphocytic leukemia (ALL) and most of the remaining cases will be 
acute myelogenous leukemia (AML). Chronic leukemias are rare in children (1).  
 
1.2. Acute lymphoblastic leukemia (ALL) 
ALL is a type of leukemia in which lymphoid precursors arrested in an early stage of 
development, proliferate and replace the normal hematopoietic cells (3). The precise 
pathogenetic events leading to the development of ALL are still unknown, but they 
are likely to affect gene expression and chromosome integrity resulting in a 
deregulated control of lymphoid cell homeostasis and clonal expansion of immature 
progenitor cells (3). The malignant lymphoblasts replace the normal hematopoietic 
elements, resulting in a marked decrease in the production of normal blood cells (2). 
The malignant clone may be of B- or T-cell origin, and the leukemia is thought to 
arise in the BM or thymus (4).  
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1.2.1. Ethiology and epidemiology. 
ALL is more common in early childhood, accounting for 25% of the pediatric cancers 
(2). It occurs at an annual rate of approximately 30 to 40 cases per million, and affects 
mainly children younger than 15 years old, being the incidence peak between 3 to 4 
years of age. Interestingly, it occurs more often in boys and in white children as 
compared to black children. Geographically the highest incidence of ALL occurs in 
Italy, the United States, Switzerland, and Costa Rica (5). 
The specific cause of ALL is unknown in the vast majority of the cases. However 
there is an increased risk of developing ALL in several well-known constitutional 
genetic syndromes, such as Down syndrome (6), neurofibromatosis (7), and ataxia-
telangiectasia (8). In addition hereditary diseases with chromosomal instability like 
Fanconi anemia (9) and Bloom syndrome (10) are associated with a higher risk to 
develop ALL.  
Many cases of ALL that develop in children have a prenatal origin. Evidence comes 
from the observation that immunoglobulin or T-cell receptor antigen rearrangements 
unique to the leukemic cells can sometimes be detected in blood samples obtained at 
birth. Similarly, patients with ALL characterized by specific chromosomal 
abnormalities can have blood cells carrying the same abnormalities at birth (11). 
Genetic studies of identical twins with concordant leukemia further support the 
prenatal origin of some leukemias (12). 
There are few identified factors associated with an increased risk of ALL. The 
primary accepted nongenetic risk factors for ALL are prenatal exposure to x-rays and 
postnatal exposure to high doses of radiation (e.g., therapeutic radiation as previously 
used for conditions such as tinea capitis and thymus enlargement). Other potential 
environmental factors that have been implicated but not confirmed are the exposure to 
tobacco smoke, pesticides, ionizing radiation and electromagnetic fields (13). 
 
1.2.2. Biology and pathogenesis. 
In general, ALL arises from the monoclonal proliferation of immature lymphocytes, 
either B-cell or T-cell precursors. In what concerns to morphology, ALL cells are 
small and round with a large nucleus with fine nuclear chromatin and a thin rim of 
cytoplasm. However this observation alone is unreliable for ALL diagnosis. Therefore 
it is complemented with cytochemical stain such as periodic acid-Schiff (PAS), and 
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immunophenotype characterization. Based on the reactivity of lymphoblasts towards 
a panel of lineage-associated antibodies, ALL can be broadly classified as B (85%) or 
T (13-15%). T-ALL can still be subdivided depending on the maturation stage of the 
arrested thymocytes. In our studies, we adopted the criteria of Uckun and collegues 
(14) and the European Group for Immunological Charactherization of Leukemias 
(EGIL)(15). The first defines three stages of maturation: pro-thymocytes (CD7+ only), 
immature thymocytes (CD7+, CD2 and/or CD5+, CD3-) and mature thymocytes 
(CD7+, CD2+, CD5+, CD3+). The latter use a further marker, CD1 and consider the 
following stages: pro-T-ALL (CD7+ only), pre-T-ALL (CD7+, CD1-, CD2 and/or 
CD5 and/or CD8+, CD3-), cortical T-ALL (CD1+, independently of the presence of 
other markers) and mature T-ALL (CD1-, CD3+). 
ALL presents cytogenetic abnormalities involving chromosome number and 
rearrangements, which can also be used to subdivide the malignancy. The Lund 
classification considered 10 hierarchical groups. According to the modal number of 
chromosomes, ALL can be classified into 5 major groups: diploid (46 chromosomes 
with no evident structural abnormalities, 31-40%); pseudodiploid (46 chromosomes 
with structural abnormalities, 18-26%); hypodiploid (< 45 chromosomes, 6%); low 
hyperdiploid (47-50 chromosomes, 10-11%) and high hyperdiploid (>50 
chromosomes, 23-26%). In what concerns to translocations, ALL can be divided into: 
t(9;22)(q34;q11.2) or a Philadelphia chromosome (Ph+); t(4;11)(q21;q23); 
t(8;14)(q24;q32) or del(8q); other 14q+ abnormalities, del(6q). The cytogenetic 
findings influence the disease aggressiveness and response to therapy, and hence are 
useful for diagnostic. However, they are not 100% predictive of treatment outcome. 
For example, up to 20% of children with favorable genetic features (TEL-AML1 
fusion and hyperdiploidy >50 chromosomes) will eventually relapse, although a third 
of those with high-risk abnormalities (the Philadelphia chromosome with BCR-ABL 
fusion and the t(4;11) with MLL-AF4 fusion) can be cured with chemotherapy alone 
(16). 
 
1.2.3. Symptoms and treatment. 
Most of the ALL symptoms are a consequence of the collapse of normal 
hematopoiesis. The clinical signs are palor, weakness and fatigue, all of which are 
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associated with anemia; gum and nose bleeding due to a reduction of platelet levels; 
fever and frequent bacteria infections as a consequence of neutropenia (2).  
Currently the 5 year event-free survival of children with ALL treated with 
contemporary risk-directed therapy ranges from 63-83%. Nonetheless, remission still 
occurs and 80% or more of patients that enter remission can be cured (16). These 
successful rates largely rely on the remarkable advances in the characterization of 
molecular abnormalities involved in leukemogenesis and their impact in drug 
resistance. In ALL the basic approach to therapy consists of a brief remission-
induction phase, followed by intensification (consolidation) therapy and the long-term 
continuation treatment (17). The basic principle of therapy is to use combinations of 
chemotherapy designed to prevent the emergence of drug-resistant leukemia cells, 
adjusted to the patient diagnosis. The first goal is to induce complete remission with 
restoration of normal hematopoiesis, normal peripheral blood cell counts and less than 
5% of leukemic blasts in the BM and cerebrospinal fluid. This regimen includes 
glucocorticoids (prednisone, prednisolone, or dexamethasone), vincristine, and at 
least one other agent (asparaginase or an anthracycline) (16). It is important to 
achieve remission at this phase of treatment to diminish the risk of relapse.  
With restoration of hematopoiesis, patients in remission are good candidates for 
intensification (consolidation) therapy. This consists in a repetition of the initial 
treatment 3 months after remission (16, 17). Different protocols in various clinical 
trials have identified effective treatment components for certain subtypes of leukemia 
(18). Nevertheless, the most successful post-remission intensification regimens are 
associated with continuous therapy instead of high-dose pulse therapy (19, 20). 
Finally, the continuation treatment consists in extending the therapy for a total 
duration of 2.5-3 years, depending if it is a boy or a girl (21). In this phase, tailoring 
dosage to the limits of tolerance has been associated with better clinical outcome (22). 
In addition, patients with increased risk of central nervous system (CNS) relapse 
require a more intensive CNS-directed therapy (23). Also, patients that present a 
Philadelphia chromosome or an early hematological relapse are clearly indicated for 
allogeneic hematopoietic stem-cell transplantation (24, 25). 
Treatment protocols have changed over time and so has the range of late therapy–
related sequelae. Most protocols avoid the use of regimens that can induce second 
cancers and emphasize the use of other drugs, such as glucocorticoids, 
antimetabolites, and asparaginase (16). However, ALL patients still suffer from long-
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term side-effects from treatment, such as osteonecrosis (26), decreased bone mineral 
density (27), thrombocytic complications (28) and cognitive impairment (29). Efforts 
are being made to identify new antileukemic drugs (new drug targets) and new 
approaches to therapy (drug doses and combinations, pharmacodynamics and 
pharmacogenomics studies) to improve cure rates and minimize late adverse side-
effects. 
 
1.3. T-cell acute lymphoblastic leukemia (T-ALL) 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of 
thymocytes that is diagnosed in children, adolescents (15%) and adults (25%) (30). 
Historically T-ALL has been reported with poorer prognosis and inferior treatment 
outcome than B-ALL (31). This was associated with the fact that T-ALL frequently 
presents with very high white blood cell (WBC) counts (>50,000/µL), enlargement of 
spleen and liver, massive lymphadenopathy including an anterior mediastinal mass 
and CNS leukemia (32-35). However, recent treatment protocols, adjusted to the risk 
at diagnosis, demonstrated an event-free survival of approximately 70% in children, 
which is equivalent to B-ALL(36). In adults with T-ALL the long-term survival rate 
only reaches 30-40% (37).  
The leukemic transformation of immature thymocytes is believed to be caused by 
multistep pathogenesis involving proliferative advantage and differentiation 
impairment. These alterations can be the consequence of deregulated cell-autonomous 
mechanisms induced by genetic and/or epigenetic lesions, frequently provoking 
abnormal signaling, but can also be stimulated by external microenvironmental 
factors (38, 39).  
 
1.4. Cell-autonomous mechanisms in T-ALL 
Since the discovery of the T-cell receptor (TCR) and its involvement in translocations 
and inversions in T-cell leukemia (40), many studies have added to the list of genes 
affected by chromosomal rearrangements and other genetic defects in T-ALL (39). In 
parallel, other studies have characterized the importance of signaling aberrations in T-
cell pathogenesis (38), as illustrated in Figure 1.  
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1.4.1. Genetic abnormalities in T-ALL. 
Deregulated expression of transcription factors is common in T-ALL and is 
consequently responsible for the alteration of the gene expression programs and 
impairment of T-cell differentiation (3). This is often the result of chromosomal 
rearrangements juxtaposing promoter and enhancer elements of TCR genes TRA@ 
(14q11), TRB@ (T-cell receptor b, 7q34-35), TRG@ (T-cell receptor g, 7p15) and 
TRD@ (T-cell receptor d, 14q11) to a small number of developmentally important 
transcription factor genes (39). For example, the ectopic expression of the helix-loop-
helix (bHLH) transcription factor T-cell acute leukemia 1 (TAL-1), occurs in the 
majority of T-ALL cases and can result from a translocation (1;14)(p32;q11) that 
juxtaposes TAL-1 with the TCR regulatory elements (3% of the cases) (41-43), or 
from a critical deletion that fuses TAL-1 to the SIL gene promoter (17% of the cases) 
(44), amongst other ill-defined reasons. The exact role of TAL-1 in leukemogenesis 
remains unknown but its oncogenic potential may result from inappropriate activation 
of TAL-1 target genes or by acting with LMO proteins as a negative regulator of the 
E2A transcription factors (45).  
One of the major cancer features is cell cycle deregulation. Cell cycle defects are in 
the basis of tumorigenesis since the genomic integrity and the coordination between 
cell growth and cell division are compromised. In T-ALL, one of the most common 
genetic abnormalities is the inactivation of CDKN2A and CDKN2B by deletion of a 
genomic region of the chromosome 9p21 (46, 47). These genes encode for inhibitors 
of the cyclin-CDK complexes INK4 proteins (p16 and p15, respectively) (48, 49). 
The deletional mutations of CDKN2A and CDKN2B promote cell cycle progression 
by allowing the phosphorylation of the retinoblastoma protein (Rb1) (50). In addition, 
the CDKN2A locus encodes for the p14 ARF protein, by alternative reading frame, a 
negative regulator of HDM2 (51). In the lack of p14 ARF protein, HDM2 targets the 
tumor suppressor p53 for degradation. In turn, absence of p53 abrogates the cell cycle 
arrest induced by p21 to repair DNA damage. Consequently, cells fail to enter 
apoptosis in the case of irreversible DNA damage. and mutations will accumulate in 
the proliferating cells.  
NOTCH1 activating mutations constitute another frequent genetic aberration in T-
ALL (52). Notch is a transmembrane receptor identified as an important regulator of 
stem-cell maintenance (53), and self-renewal potential (54). Furthermore Notch plays 
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a major role in lineage commitment of lymphoid progenitors towards T-cell 
development (55). NOTCH involvement in T-ALL was first described in three 
patients with t(7;9)(q43;q34.3), which juxtaposes the TCRβ locus to the C-terminal 
coding region of the NOTCH1 gene (56). This translocation leads to the expression of 
a truncated, cytoplasmic form of Notch1 receptor with constitutive activity, 
independent of the cascade of proteolytic cleavages necessary for Notch 
signaling(56). Other studies implicate aberrant Notch1 signaling in the pathogenesis 
of T-ALL, since 56% of the analyzed primary samples presented with NOTCH1 
activating mutations (52). These mutations increase the production of the intracellular 
Notch (ICN) without ligand stimulation and/or extend the half-life of ICN (57). 
Therefore, targeting Notch1 signaling by inhibiting the cleavage into ICN with γ-
secretase inhibitors (GSIs) used in patients with Alzeihmer’s disease was considered a 
potential therapeutic strategy in T-ALL (52, 58). Despite the evidence that GSI 
treatment can induce cell cycle arrest and, less frequently, apoptosis in T-ALL cell 
lines and primary samples cultured in vitro, the success of clinical trials involving the 
use of GSIs in T-ALL has been limited due to reduced in vivo efficacy and patient 
toxicities (59, 60).  
 
1.4.2. Aberrant signaling in T-ALL 
1.4.2.1. TCR signaling. 
The engagement of the TCR, a non-tyrosine kinase receptor, is essential for T-cell 
survival and proliferation (Figure1). Mutations and chromosome rearrangements 
affect multiple components of the (pre)TCR signaling pathway in T-ALL, indicating 
their importance for T-cell leukemogenesis (40). Few T-ALL cases present ectopic 
expression of LCK, a tyrosine kinase of the SRC family that is critical for TCR 
signaling. ABL1 is a downstream target of LCK (61) and although the BCR-ABL1 
fusion is rare in T-ALL, other ABL1 fusions (NUP214-ABL1;  ETV6-ABL1 and 
EML1-ABL1) are constitutively phosphorylated in some T-ALL cases presenting an 
overactivation of survival and proliferation pathways (62). These patients currently 
have a good prognosis since they respond to a specific inhibitor of ABL1 kinase, 
imatinib (63). RAS is small GTPase involved in many signaling pathways including 
TCR-dependent signal transduction. Although RAS presents activating mutations in 
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one third of human cancers, only 4-10% of T-ALL cases present with mutations in 
this gene (64). However, RAS activation in T-ALL samples can occur independently 
of direct mutations of RAS protein, instead being a consequence of activation of 
upstream molecules (65) or inactivating mutations in the negative regulator NF1 (66). 
 
 
Figure 1. Schematic representation of the signaling pathways that appear to contribute to 
proliferation and survival of T-ALL cells. Several signaling components have been implicated in the 
regulation of T-ALL. The Notch pathway was shown to be constitutively activated in more than 50% 
of T-ALL patients. Mutations in MAPK family members have not been reported in T-ALL. However, 
tumor-supportive signals from the microenvironment likely activate Erk1/2 and Erk5. Erk1/2 
phosphorylates the T-cell oncogene Tal1 and Erk5 phosphorylates NF-kβ, contributing to the viability 
and proliferation of leukemic cells. Constitutive activation of PI3K/Akt pathway was demonstrated in 
T-ALL cell lines and our own data indicates that it is highly frequent in primary leukemia cells. This 
essentially results from PTEN inactivation by different mechanisms. This pathway is highlighted since 
is the aim of our studies. The loss of Smad3 expression was demonstrated in some T-ALL cases, and 
may synergize with other oncogenic events in the development of this malignancy. Mutations and 
chromosome rearrangements affect multiple components of the (pre)TCR signaling pathway in T-ALL, 
indicating their importance for T-cell leukemogenesis The chimeric TEL-Jak2 protein is expressed in 
T-ALL due to t(9;12)(p24;p13) and is capable of phosphorylating STAT1 and STAT5, which could 
promote T-ALL proliferation. Similarly, as described further, extracellular cues 
(cytokines/chemokines, growth factors, adhesion molecules, Notch ligands, etc) leading to the 
activation of Notch or JAK/STAT pathway are probably present within the leukemic milieu. Although 
microenvironmental signals are unlikely to trigger the oncogenic process, they appear to contribute to 
the maintenance/proliferation of the malignant clones. Adapted from (38). 
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1.4.2.2. TGFβ  pathway. 
Transforming growth factor-β (TGF-β) plays an important role in cellular 
homeostasis(67), and Smad2 and Smad3 are the principal cytoplasmic intermediates 
involved in the transduction of signals from TGF-β receptors(68). Interestingly, some 
primary T-ALL cells lack Smad3 protein, although no mutations in the Smad3 gene 
(MADH3) were identified and samples display normal mRNA levels (67). 
Additionally, lack of Smad3 can synergize with oncogenic events, such as loss of 
p27Kip1, in promoting T-cell leukemogenesis in mice. These data suggest that Smad3 
can act as a T-cell tumor suppressor and that defective TGF-β signaling may 
contribute to T-cell leukemogenesis (69) (Figure 1). 
 
1.4.2.3. MAPK pathway. 
Mitogen-activated protein kinases (MAPKs) are a family of Ser-Thr kinases, which 
play a central role in transducing extracellular signals, such as growth factors and 
stress stimuli, into a variety of intracellular responses including the modulation of cell 
proliferation, differentiation and apoptosis (70). MAPKs can be classified into three 
sub-families: the extracellular signal-regulated kinases (Erk), the c-Jun N-terminal 
kinases (JNK) and the p38 MAPK (70). The involvement of MAPKs in T-ALL is not 
clearly established. However, there is evidence that in the human T-ALL cell line 
Jurkat, Erk-1 phosphorylates and activates TAL-1 contributing to T-ALL biology 
(71). In addition, Erk5 can promote the transcription of survival genes through the 
phosphorylation and activation of p65/RelA subunit of NF-κB. This decreases 
apoptosis and has been proposed to be essential for the survival of leukemic T-cells 
(72, 73) (Figure1). However, there are no reported Erk-activating mutations in 
primary T-ALL cells. The inactivation of Erks with the use of pharmacologic 
inhibitors is currently being studied for cancer treatment, although not specifically in 
the context of T-ALL(73). Neither JNK nor p38 have been reported as being altered 
in T-ALL, however drugs such as glucocorticoids and dexamethasone, which lead to 
the activation of these stress-induced MAPKs, are used in T-ALL treatment (74). 
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1.4.2.4. JAK/STAT pathway. 
The evolutionarily conserved Janus kinase-signal transducer and activator of 
transcription (JAK/STAT) pathway plays an important role in biological processes 
mediated by growth factors and cytokines (75). Binding of cytokines results in a 
conformational change and activation of Jak tyrosine kinases (76). Once the signaling 
cascade is initiated, STATs are phosphorylated, dimerize and migrate to the nucleus 
where they regulate gene transcription (76). In pediatric T-ALL, the genetic 
juxtaposition between JAK2 and TEL/ETV6 results from t(9;12)(p24;p13) 
chromosomal translocation, and originates a constitutively active TEL/ETV6-JAK2 
fusion protein (77) (Figure 1). Strikingly, TEL/ETV6-JAK2 transgenic mice develop 
fatal B and T-cell leukemia, suggesting that the fusion protein can act as an oncogene 
in vivo (77, 78). However, TEL/ETV6-JAK2 gene fusion does not require TCR 
signaling to induce T-cell leukemia, but cooperates with pre-TCR complex to 
accelerate the onset (79). JAK1 somatic activating mutations were very recently 
reported in ALL and particularly in adult T-ALL, where they account for 18% of the 
cases. JAK1 mutations appear to associate with poor response to therapy and reduced 
disease-free and overall survival (39, 80). Furthermore, activation of STAT5 in T-
ALL may arise from the cryptic t(9;14)(q34;q32), that results in the aberrant 
expression of a constitutively active fusion protein EML1-ABL1 (39, 81). In addition 
to STAT5, STAT1 was reported to be constitutively active in primary T-ALL (82). 
Moreover, SHP-1 the tyrosine phosphatase that acts as a negative regulator of the 
JAK/STAT pathway, was found methylated and inactivated in primary ALL cells and 
in the T-ALL cell line Jurkat (83). The therapeutic potential of targeting this pathway 
remains largely speculative at this stage. 
 
1.4.3. PI3K/Akt pathway. 
1.4.3.1. Classification of PI3Ks. 
Phosphoinositide 3-kinases (PI3Ks) are a familiy of proteins involved in the 
regulation of cell growth, metabolism, proliferation, glucose homeostasis and vesicle 
trafficking(84). As this pathway is a central integrator of metabolism and 
survival/growth signals, it is not surprising that dysfunctional PI3K cascade would 
lead to metabolic diseases like diabetes and cancer.  
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PI3Ks belong to a conserved family of lipid kinases that phosphorylate the D3 
hydroxil position of the inositol ring of phosphatidylinositol (PI) phospholipids (85). 
These kinases have both lipid and protein activities (86, 87) and are divided in three 
classes. Class I PI3Ks are heterodimers with a catalytic and a regulatory subunit that 
specifically generates the phosphatidylinositol 3,4,5-triphosphate (PIP3) upon 
activation of receptor tyrosine kinase (RTKs) and G-protein-coupled receptors 
(GPCRs) (88, 89). Class I is subdivided in IA or IB. In class IA PI3K, the catalytic 
subunits p110α, p110β or p110δ associate with the regulatory subunits p85α, p85β, 
p55α, p55γ or p50α. Class IB PI3Ks consist only of p110γ catalytic subunit that binds 
the regulatory subunits p101, p84 or p87PIKAP(84). The class II presents three 
isoforms (α, β and γ), which generate 3,4-biphosphate (PIP2) and 3-monophosphate 
of inositol lipids (PI) and do not require a regulatory subunit. Class II PI3Ks are 
involved in membrane trafficking and receptor internalization when activated in 
response to RTKs, integrins and cytokine receptors (84). Finally, the class III PI3K 
(VPs34) can only make phosphatidylinositol 3-monophosphate and is involved in 
vesicle trafficking. Recently, Backer and collegues (90) unraveled a role of class III 
PI3K in the formation of autophagossomes involved in the digestion of intracellular 
components in response to stress and starvation. Furthermore, other studies suggest a 
novel function for VPs34 in amino acid sensing and metabolic processes (91).  
Thus far, only the class IA PI3Ks have been implicated in human cancer. Activating 
mutations in the gene coding for p110α, PIK3CA were identified as a mechanism of 
inducing oncogenic PI3K signaling (92). These mutations are frequent in breast 
(27%), endometrial (23%), colorectal urinary tract (17%) and ovarian (8%) cancers 
(http://www.sanger.ac.uk/genetics/GCP/cosmic) No PIK3CA mutations were found in 
acute myeloid leukemia (AML) (93, 94) and only very recently a few T-ALL cases 
were identified which harbored PIK3CA activating mutations (95). These hot spot 
mutations affect the helical and kinase domains and functionally disrupt the inhibitory 
interaction with the regulatory subunit, improving the kinase domain affinity to the 
substrate (96-98).  
The specific product of class I PI3K, PIP3, interacts with many proteins through their 
pleckstrin homology domain (PH), promoting the transduction of PI3K-mediated 
signals and consequently the involvement of class IA PI3Ks in cancers (99).  
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1.4.3.2. The canonical PI3K/Akt signaling pathway. 
Normally, the axis of PI3K signaling begins with engagement of growth factors by 
RTKs (89) or G-protein-coupled receptors (88), Figure 1 and 3. PI3K is then recruited 
to the plasma membrane-anchored receptors and becomes activated. At the cell 
membrane, PI3K has the ability to phosphorylate phosphatidylinositol 4,5-
biphosphate (PIP2) at the 3-position of the inositol ring, generating PIP3 (100). These 
phospholipids are second messengers and serve as membrane anchors for proteins 
with a pleckstrin homology (PH) domain (84), like the serine-threonine kinase Akt, 
also known as PKB and the 3-phosphoinositide-independent kinase (PDK1) (101). 
The co-localization of Akt and PDK1 at the cell membrane favors Akt 
phosphorylation at threonine 308 (T308) (102) and consequent activation. To become 
fully active Akt has to be phosphorylated at the serine 473 (S473). For many years 
investigators speculated about the kinase responsible for S473 phosphorylation, 
considering that “PDK2” could be tissue and context specific (103). Although this 
possibility cannot be completely excluded, an elegant study (104) provided strong 
evidence that the most prominent, if not only, kinase to phosphorylate Akt at The 
S473 residue is mTOR. Sarbassov and colleagues demonstrated that mTOR associates 
with rapamycin insensitive companion of TOR (RICTOR) protein to form the 
mTORC2 complex and phosphorylate Akt at S473 both in vitro and in vivo. 
Activated Akt triggers a cascade of signals that regulate growth, proliferation, 
survival and motility. 
The tumor suppressors PTEN and SHIP dephosphorylate PIP3, at the 3-position and 
5-position of the inositol ring respectively (105, 106), therefore acting as negative 
regulators of the PI3K/Akt pathway. In addition Akt kinase activity is negatively 
regulated by phosphatase 2A (PP2A) and PHLPP activity (107, 108). 
 
1.4.3.3. Akt family, downstream targets. 
The serine/threonine kinase Akt was identified in 1991 by two independent lines of 
research (109, 110). However, the major interest arose later when Akt was 
demonstrated to be a downstream target of PI3K (100, 111, 112). In mammals there 
have been identified three genes that encode for three AKT isoforms with similar 
structural organization: AKT1/PKBα; AKT2/PKBβ and AKT3/PKBγ (112). As 
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mentioned above the crucial regions to activate Akt kinase are the PH domain and the 
conserved threonine and serine residues (T308 and S473). No major activating 
mutations in AKT were described until Carpten et al identified a somatic mutation in 
human breast, colorectal and ovarian cancers that results in a glutamic acid to lysine 
substitution at amino acid 17 (E17K) in the lipid-binding pocket of Akt1 (113). This 
mutation activates Akt1 by means of pathological localization to the plasma 
membrane, stimulates downstream signaling, transforms cells and induces leukemia 
in mice (113). However, Tibes and colleagues screened a cohort of AML patients and 
found no mutations in Akt1, concluding that this is an unlikely cause of PI3K/Akt 
pathway activation in AML (114) and likely in other hematological cancers. Akt has 
many natural substrates implicated in different cellular processes, such as gene 
transcription, protein synthesis, glucose metabolism, cell cycle and survival. Akt 
phosphorylates and inactivates the glycogen synthase kinase-3α/β (GSK3α/β) at 
Serine 21 (GSK3α) and Serine 9 (GSK3β) (115).Upon GSK3 inhibition, glycogen 
synthesis is activated and transcription factors like NFAT translocate to the nucleus 
and promote gene transcription (50, 116-118). Moreover GSK3 regulates cell cycle by 
targeting cyclin D1 for degradation through phosphorylation, and inhibiting G1/S 
transition (117, 118). Importantly, GSK3 induces apoptosis by phosphorylation of 
MCL-1 at S159, leading to its degradation by the ubiquitin-proteasome pathway, and 
therefore disrupting the balance of anti- and pro-apoptotic proteins at the 
mitochondrial membrane and ultimately cytochrome c release (119). Surprisingly, 
Wang and colleagues demonstrated an oncogenic requirement for GSK3 in the 
maintenance of a specific subtype of poor prognosis human leukemia, genetically 
defined by mutations of the MLL proto-oncogene. In contrast to its previously 
characterized roles in suppression of neoplasia-associated signaling pathways, GSK3 
paradoxically supports MLL leukemia cell proliferation and transformation by a 
mechanism that ultimately involves destabilization of the cyclin-dependent kinase 
inhibitor p27Kip1 (120).   
Gene transcription is controlled by Akt, through regulation of cellular localization of 
different transcription factors. Phosphorylation of members of the Forkhead box O 
family of transcription factors (FOXOs) by Akt promotes their binding to the 
chaperone proteins 14-3-3 and consequent arrest at the cytoplasm (121). Inhibition of 
FOXOs is a major mechanism by which Akt exerts its anti-apoptotic and proliferative 
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functions (122), since FOXOs transcriptionally activate pro-apoptotic molecules (e.g., 
Fas and Bim) and cell cycle inhibitors (p27Kip1 (123)). Not surprisingly, inactivation 
of FOXO proteins is associated with tumorigenesis, including leukemia (122). The 
activation of the NF-κB transcription factor complex by Akt is executed through 
phosphorylation and consequent activation of IKKs (Inhibitor of NF-κB kinases), 
which in turn phosphorylate and thereby target for degradation IκB (inhibitor of NF-
κB) (124). Since NF-κB activity is challenged by IκB, activation of IKKs by Akt 
ultimately leads to NF-κB activation. Interestingly, constitutive NF-κB activation is a 
common characteristic of childhood ALL and strongly suggests a critical role of this 
factor for leukemia cell survival (125). 
In addition, Akt acts as a pro-survival protein by regulating programmed cell death 
either through enhanced expression of antiapoptotic Bcl-2 or reduced activity of pro-
apoptotic proteins. Akt can augment Bcl-2 levels (126) increasing the ratio of pro-
survival proteins at the outer membrane of the mitochondria. Moreover, Akt directly 
phosphorylates the pro-apoptotic protein Bad at serine 136 (S136), contributing to its 
location at the cytoplasm instead of heterodimerizing with Bcl-2 at the mitochondrial 
membrane (127).  
It has been recognized that malignant cells show increased glucose uptake and 
utilization when compared to their non malignant counterparts and the over-uptake of 
glucose might provide extra energy for cancer cell growth (128). This uptake was 
shown to be mediated by the facilitative glucose transporters (GLUTs) and GLUT1 
appears to be the most ubiquitously distributed (129). Akt activation enhances glucose 
uptake by increasing the expression of glucose transporters GLUT1 and GLUT3 and 
the translocation of GLUT4 to the plasma membrane (130, 131). This can have a clear 
impact on cell expansion, since, in a human leukemia cell line, proliferation is 
inhibited using antisense nucleic acids for GLUT1 (132). In addition, cytokine 
stimulation promotes glucose uptake in a PI3K/Akt-dependent manner (130, 133, 
134). Furthermore, Dhar-Mascareno et al. examined the function of PI3K pathway in 
GMCSF-stimulated glucose uptake and identified the early events in the stimulation 
of glucose uptake by GMCSF as involving local H2O2 generation and requiring PI3K 
pathway activation (135). 
Similar to glucose metabolism, Akt also regulates protein synthesis. Akt activates 
mTOR pathway through inhibitory phosphorylation of tuberous sclerosis complex 2 
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(TSC2) and disruption of the heterodimer TSC1/TSC2 that functions as a tumor 
suppressor (136). As a result of this inactivation, the small GTPase Rheb becomes 
available to activate mTORC1 (136), which forms a rapamycin-sensitive complex 
with Raptor (regulatory-associated protein of mTOR). Upon activation, mTORC1 
increases mRNA translation and protein synthesis via activation of S6 kinase (S6K) 
and inhibition of eIF-4E binding protein 1 (4E-BP1) (137). Interestingly, Notch 
aberrant activation, one of the most common events in T-ALL, induces mTOR 
activation in a c-Myc-dependent manner (138), and rapamycin, a specific inhibitor of 
mTOR, stimulates apoptosis of pediatric T-ALL cells (139). Moreover, studies in 
murine Ph+ pre-B ALL cells showed that class IA PI3K and mTOR signaling 
contribute quantitatively to BCR-ABL transformation and are essential for in vivo 
leukemogenesis (140). 
PI3K/Akt pathway is also involved in the upregulation of endogenous reactive oxygen 
species (ROS), usually via activation of a non-phagocytic NADPH oxidase complex 
(141), and different stimuli known to activate the PI3K/Akt axis utilize ROS as part of 
their signal transduction machinery (142). Indeed, ROS are frequently required for 
efficient signal transduction and thus, not surprisingly, are upregulated in many 
cancers (143, 144). The mitochondria and the Nox family of NADPH oxidases have 
emerged as major sources of ROS induction (145, 146). Kim et al suggested that 
elevated levels of ROS in BCR-ABL-transformed cells are secondary to a 
transformation-associated increase in glucose metabolism and is specifically regulated 
by PI3K (147). 
 
1.4.3.4. PTEN, the major negative regulator of PI3K/Akt pathway. 
PI3K/Akt pathway is constitutively activated in various T-ALL cell lines because they 
lack the expression of the tumor suppressor PTEN (Phosphatase and Tensin Homolog 
Deleted from Chromosome 10) (148, 149). PTEN is the second most frequently 
mutated gene in human cancer after p53 (150, 151). PTEN was identified by 
homozygous deletion mapping of the human chromosome 10q23 in cancer (152, 153). 
The germline mutation of PTEN leads to numerous autosomal dominant disorders 
such as Cowden syndrome (154), characterized by the presence of developmental 
defects, hamartomatous overgrowths of various tissues and increased risk of cancer 
(155). In addition, the homozygous deletion of PTEN causes embryonic lethality and 
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the heterozygous loss of PTEN leads to numerous neoplasms in mice (156). These 
evidences together with cellular assays, either with PTEN deficient cells (157, 158) or 
PTEN overexpressing cells (159-162) demonstrate the important role of PTEN to 
suppress cell growth, proliferation, survival and migration.  
The tumor suppressor PTEN is a dual-specificity phosphatase for the lipid second 
messenger PIP3 and for specific protein substrates (105, 163), and a member of the 
protein tyrosine phosphatase family. Many effects of PTEN are associated with its 
lipid phosphatase activity and consequent capacity to negatively regulate PI3K 
pathway by specifically metabolize PIP3 and thereby inhibit Akt (164). Although less 
well studied, it is also known that PTEN can regulate dynamic cell surface 
interactions and inhibit cell migration and invasion through its protein phosphatase 
activity, namely by dephosphorylating focal adhesion kinase (FAK) and p130cas or 
Shc (161). Moreover, it has been demonstrated that PTEN can dephosphorylate the 
platelet–derived growth factor receptor (PDGFR), negatively regulating PDGFR 
activation (165, 166). 
In contrast to PTEN gene alterations affecting the lipid phosphatase activity (e.g., 
G129E), there are no reported PTEN mutations that originate a protein deficient 
exclusively in protein phosphatase activity. In any case, overall phosphatase activity 
is believed to be the most pertinent property of PTEN as a tumor suppressor. 
However, there is evidence that PTEN mutants for lipid phosphatase activity (G129E) 
(155, 165) or both lipid and protein phosphatase activity (C124S) (167) prevent cell 
invasion to the same extent as wild type PTEN, suggesting that at least this particular 
tumor suppressor function is independent of the phosphatase activity (168).  
Different studies correlated genetic instability with PTEN deficiency in human 
cancers (150, 151). In addition PTEN expression and localization is also linked with 
malignancies (169-171). An example of the importance of PTEN sub-cellular 
localization comes from the evidence that PTEN protein concentrates in the 
cytoplasm of primary cutaneous melanoma cells (169). Moreover, a study in thyroid 
tissues demonstrated an accumulation of nuclear PTEN in normal samples compared 
to primary thyroid tumors (171). Recently, Shen and co-workers demonstrated an 
important role for PTEN nuclear localization in maintaining chromosome stability 
and preventing tumorigenesis, which is independent of PTEN phosphatase activity 
(172). PTEN physically interacts with CENP-C a component of the kinetochores at 
the centromeres, and promotes chromosome stability. In addition, PTEN regulates key 
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elements for DNA repair such as CHK1 and Rad51 (172, 173) in a phosphatase-
dependent way. In the nucleus PTEN may be also involved in the regulation of 
transcription of important genes involved in cell-cycle control and DNA repair, such 
as c-Met (174), NF-κB (175), MDM2 (176, 177) and Rad51 (172). 
The structure of PTEN is well known (Figure 2). The N-terminal domain of this 403-
amino-acid protein is constituted by PIP2 binding site (amino-acids 6-14) and catalytic 
phosphatase center (amino-acids 7-185) (178). Interesting studies demonstrated that 
PIP2 and other acidic lipids in membranes recruit PTEN to these surfaces increasing 
access to the lipidic substrate (179, 180) and apparently causing a conformational 
change within the enzyme and consequent allosteric activation (181). As expected, the 
PTEN phosphatase domain is mutated in many cancers and autosomal diseases either 
at the catalytic motif (155, 182) or at the α-helix responsible for the phosphatase 
secondary structure (183). However, the C-terminal domain also has tumor 
suppressive functions, since over 40% of cancer-associated PTEN mutations are in 
this region (184). A C2 domain and a C-tail compose PTEN C-terminus. The C2 
domain is involved in PTEN stability, centromere interactions and recruitment to 
phospholipid membranes (172, 180, 185). Several studies have highlighted the C-tail 
as the major regulatory site of PTEN protein, since the well-described 
phosphorylation sites and the PDZ binding motif control PTEN protein stability and 
protein-protein interactions (186) that are essential for the regulation of PTEN 
activity.  
 
Figure 2 - Structure of the phosphatase PTEN. The N-terminal domain of this 403-amino-acid 
protein is constituted by a PIP2 binding site and the catalytic phosphatase center. The phosphatase 
center has lipid and protein phosphatase activity and is reversibly inactivated through oxidation or 
acetylation. The C2 domain is responsible for lipid binding and membrane association and is involved 
in the regulation of protein stabilization and localiztion by ubiquitination. The C-terminal tail has: the 
PEST domain that is involved in the regulation of protein stabilization, through phosphorylation by 
CK2 and GSK3β; and the PDZ domain where the protein-protein interactions occur. 
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1.4.3.5. PTEN regulatory mechanisms. 
PTEN can be regulated transcriptionally and posttranscriptionally. PTEN gene 
transcription can be dramatically decreased in human cancer due to transcriptional 
repression, promoter silencing by DNA methylation, and micro-RNA-directed mRNA 
degradation(187-190). Recently Palomero and co-workers identified NOTCH1 
mutational activation as responsible for the reduced PTEN gene expression in human 
T-ALL, since the Notch target gene HES1 is a negative regulator of the PTEN 
promoter (59). Pandolfi and colleagues showed that the PTEN expression level 
correlates inversely in a dose-dependent manner with prostate cancer initiation, 
latency and progression (191). However complete PTEN deletion does not have the 
pro-tumorigenic action predicted, for instance in prostate cancer acute PTEN loss 
leads to a strong p53-dependent senescence response that opposes cancer progression 
(192). 
Upon translation PTEN is ubiquitously expressed and stable in the cytoplasm. 
However when active as a lipid phosphatase, PTEN integrates a protein complex, 
establishes dynamic interactions with the cytoplasmatic membrane where it co-
localizes with and dephosphorylates PIP3 (193). PTEN function is regulated by 
multiple modes of posttranslational modification (ubiquitination, acetylation, 
oxidation, phosphorylation) that regulate protein stability, cellular localization and 
activity (Figure 2).  
Regulation of PTEN by phosphorylation is probably the best characterized 
posttranslational modification. The C-terminal tail of PTEN contains a cluster of 
phosphorylation sites (S380/T382/T383/S385) and all appear to be phosphorylated by 
Casein Kinase 2 (CK2) (194-196). In addition, the phosphorylation in these residues 
is decreased upon use of selective inhibitors for CK2 and pull-down experiments 
demonstrate the direct interaction of CK2 and PTEN (194). CK2 is a ubiquitously 
expressed serine/threonine kinase whose activation partners, inhibitors and 
physiological stimuli are still largely undefined. Importantly, the information about 
PTEN phosphorylation sites and crystal structure (178) led to a proposed model in 
which phosphorylated PTEN is arrested at the cytoplasm in a more stable, ‘closed’ 
and inactive conformation, unable to engage in PDZ domain-dependent protein-
protein interactions necessary for plasma membrane localization (197). PTEN 
phosphorylation by CK2 appears to abrogate caspase 3 cleavage of PTEN (198), 
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and/or PTEN ubiquitination and proteosome-mediated degradation, thereby 
increasing PTEN protein stability. In contrast, unphosphorylated PTEN exposes the 
C-terminal regions, allowing translocation of PTEN from the cytoplasm to the plasma 
membrane by integrating protein complexes through protein-protein interactions 
dependent on its PDZ domain. Finally, the C2-domain (and the N-terminal PIP2 
binding motif) can interact with the plasma membrane and allow PTEN activity to 
oppose PI3K-dependent signaling. Although more active, unphosphorylated PTEN 
appears to be more unstable and subject to ubiquitin-mediated proteosomal 
degradation (199, 200). Under this context, it is interesting to note that the 
mechanisms by which PTEN is dephosphorylated remain to be clarified, although 
there is evidence indicating that PTEN can auto-dephosphorylate (201). 
PTEN is phosphorylated at additional residues (S370 and T366) of the C-terminus by 
CK2 and GSK3 respectively (202, 203). Interestingly, T366 phosphorylation can 
promote PTEN degradation (203). PTEN can also be phosphorylated on tyrosine 
residues yet the functional consequences of tyrosine phosphorylation are currently 
unclear. Nonetheless, tyrosine phosphorylation of PTEN might be associated with 
regulation by RhoA and ROCK (204-206). As mentioned above, PTEN establishes 
protein-protein interactions with specific partners through its PDZ binding motif. For 
example, association with MAGI-2 stabilizes and contributes to PTEN activity, since 
this complex translocates PTEN to the plasma membrane (199, 207). In addition, 
interaction of PTEN C-terminus with PICT-1 (protein interacting with the C tail-1) 
promotes both the phosphorylation and stability of PTEN (208). 
Regulation of PTEN protein stability is evidently highly important for the control of 
PTEN activity, particularly given the fact that PTEN appears to be a haploinsufficient 
tumor suppressor (209-211). Treatment of various cell types with proteosome 
inhibitors enhances the levels of PTEN protein (194, 199), indicating that the 
ubiquitin-proteosome system plays an important role in the regulation of PTEN 
expression. A recent study elegantly demonstrated that the E3 ligase NEDD4-1 
regulates PTEN ubiquitination and consequently PTEN protein stability and cellular 
localization (212). Apparently, NEDD4-1 can induce PTEN degradation through 
polyubiquitination or PTEN nuclear translocation through monoubiquitination, and 
these two separate pathways might be differentially regulated in cells (213, 214). 
PTEN presents a major ubiquitination site (K289) for NEDD4-1 activity at the C2 
domain (214). Ubiquitination at this site disrupts the interaction of the C2 domain 
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with the C-tail (215), thereby compromising the stability of PTEN and promoting its 
degradation. Ubiquitination at K289 residue might also compromise the C2 domain-
plasma membrane interaction and thus inhibit the conventional function of PTEN in 
antagonizing membrane PI3K signaling. 
Interestingly, PTEN is acetylated by PCAF in the presence of growth factors. 
Expression of PCAF results in increased acetylation of lysine residues (K125 and 
K128) within the catalytic cleft of PTEN and disrupting the PIP3 specificity (216). 
So far the posttranslational mechanisms highlighted showed the importance of the C-
terminus in PTEN regulation. Additionally, PTEN activity is directly regulated by 
oxidation of its phosphatase center. As a member of the protein tyrosine phosphatase 
family, PTEN requires a reduced active site cysteine nucleophil in its catalytic center.  
Evidently, this implicates that oxidation of this cysteine can significantly impact on 
PTEN catalytic activity. PTEN is inactivated by oxidation upon treatment of cells 
with H2O2, due to the formation of a disulfide bond between C71 and the active site 
C124 (217). In more physiological conditions, LPS/PMA-stimulated macrophages or 
growth factor-stimulated cells elevate endogenous ROS, which consequently 
inactivate PTEN and induce an oxidant-dependent activation of downstream Akt 
signaling (218-220). Interestingly, oxidation of cellular PTEN by S-nitrosothiols also 
inhibits its phosphatase activity in a reversible manner (221). 
 
1.5. Microenvironmental factors and T-ALL 
Cells crosstalk and interact with their microenvironment. Cancer cells do not 
constitute an exception, and signals provided by the microenvironment modulate the 
overall behavior of the tumor cells (222, 223). Extracellular matrix, adhesion 
molecules, chemokines, cytokines and growth factors present in the local 
microenvironment might, for example, promote a differential response to the 
engagement of the specific receptors on normal versus leukemic cells, therefore 
resulting in a competitive advantage favoring the malignant cells. External signals 
may also provide the time and support necessary for pre-leukemic cells to become 
fully malignant. 
Because T-ALL lymphoblasts proliferate in the BM, the marrow microenvironment 
has been studied as a source of external factors that allows neoplastic cells to expand 
and/or evade the effects of chemotherapy (224-226). In order to understand T-ALL 
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lymphoblast interactions with BM stromal cells, different groups have studied cell-
cell adhesion as an early event preceding intracellular signaling. T-ALL cells express 
integrins such as LFA-1 and VLA-4 (227). Moreover LFA-1/ICAM-1-mediated 
interactions regulate T-ALL survival in the BM microenvironment (228), whereas 
VLA-4 plays the primary role in regulating cytoadhesion of precursor B-ALL cells 
co-cultured with BM stroma (226, 229). Based on this evidence, Winter and 
colleagues developed a test where stroma-supported leukemic cell recovery served as 
basis for assigning risk-adjusted therapy (230). In contrast to B-ALL, T-ALL cells 
that receive positive stroma-mediated signals to maintain normal growth control are 
less aggressive and correlate with better patient survival (230). As mentioned before, 
constitutive activation of NF-κB was detected in all major subtypes of ALL (125). 
Interestingly, it was recently shown that the NF-κB subunit RelB expressed in mouse 
BM stromal cells can favor leukemia onset and increase disease severity by as yet 
unidentified mechanisms (231). Also noteworthy is the fact that the escape of T-ALL 
cells from dormancy is associated with delta ligand 4 (Dll4) expression in the tumor 
microenvironment and increased Notch3 signaling in tumor cells (232). 
The importance of microenvironmental cues in leukemogenesis is not restricted to 
cell-cell interactions. Chemokine receptors are present on many different cell types, 
including leukocytes, and are defined by their ability to induce directional migration 
of cells toward a gradient of a chemotactic cytokine (chemotaxis). Chemokines are 
small-secreted proteins, and their interaction with the respective receptor participates 
in the coordination of the trafficking and distribution of cells within various tissue 
compartments (233, 234). Only in a minority of cases T-ALL cells remain confined to 
the thymus (33), and the BM is the ubiquitous site for leukemic cell metastasis since it 
might provide a favorable environment for circulating tumor homing and growth. It is 
known that mesenchymal or marrow-derived stromal cells constitute a large 
proportion of the non-neoplastic cells within the tumor microenvironment. These cells 
constitutively secrete the chemokine stromal-cell derived factor-1 (SDF-1/CXCL12) 
(235). Sipkins et al demonstrated that SDF-1/CXCR4 (and E-selectin) is important for 
pre-B-ALL cells retention in the marrow matrix (236). Recently, the same group 
showed that leukemic cell proliferation in the BM alters the stromal 
microenvironment, increasing the levels of stem cell factor (SCF), and creating 
malignant niches that outcompete normal hematopoietic progenitor cell niches (237). 
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Intervention at these microdomains can potentially provide new treatments of 
metastatic disease and improve the outcome of BM transplantation. In addition, there 
is increasing evidence for the role of SDF-1/CXCR4 in T-ALL disease progression, 
since it regulates the gene expression of cytokines IL-8 (CXCL8) and IL-6, which 
might function as chemotactic and pro-angiogenic factors (238). Other chemokines, 
such as PARC, are highly expressed in the serum of T-ALL patients, however their 
functional role is still unknown. So far PARC levels can only be used as leukemia 
marker and possibly reflecting tumor/host cell interactions in the circulation (239). 
Importantly, it has been described that T-ALL cells express high levels of some 
chemokine receptors, such as CCR9 and CXCR5. Activation of CCR9/CCL25 and/or 
CXCR5/CXCL13 axis in T-ALL cells contribute to resistance to apoptosis, 
proliferation and extra-medullary organ infiltration (240-243). 
Another group of soluble proteins are cytokines that act as key regulators of 
hematopoietic homeostasis. Cytokines bind to their specific receptors expressed on 
the cell surface, leading to receptor oligomerization and activation of intracellular 
cascades of signaling molecules. The cytokine/cytokine receptor interaction can act as 
an autocrine or paracrine loop in lymphopoiesis and potentially support malignant cell 
growth and survival(244). ALL samples express cytokines and cytokines receptors 
responsible for the control of immune modulation (TGFβ, IL-10 and IL-10R1) and 
tumor neovascularization (VEGF and Flt1) (207). Not yet well known is the role of 
the common γ chain (γC) cytokine family in T-ALL. This cytokine family includes 
interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15 and IL-21. All of them share the γC 
receptor and play some role in normal T-cell development, survival, proliferation, 
differentiation and homeostasis. Signaling mediated by all γC cytokines can promote 
proliferation of T-ALL cells in vitro (245). IL-2 might act in an autocrine loop, since 
some T-ALL cases secrete functional IL-2 and express the receptors for IL-2 (246, 
247). Apparently, the proliferative effect of IL-4 and IL-9 is dependent on the 
maturation stage of the T-ALL cells (245). Interestingly, proliferation in response to 
IL-4 increases consistently from the most immature to the most differentiated T-ALL 
samples (245) and is dependent of mTOR activation (248). Furthermore, the 
proliferative responses promoted by IL-9 appear to be significantly less robust in 
cortical T-ALL specimens. Finally, IL-7 consistently promoted T-ALL cell 
proliferation and survival in vitro both in cell suspension cultures and in co-cultures 
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with stromal cells (245, 249, 250). In contrast to IL-2, IL-7 does not appear to act in 
an autocrine fashion, since T-ALL cells do not express IL-7 (251). 
 
1.5.1. IL-7/IL-7R complex. 
The gene for human IL-7 is located on chromosome 8q12-13 (252) and codes for a 25 
amino-acid signal peptide (253) that depends on glycosylation to be active (254). IL-7 
was initially identified by its ability to stimulate the proliferation of pre-B cells (254, 
255). However, Morissey et al showed that IL-7 could function as a co-stimulator for 
the proliferation of T cells by inducing the production of IL-2 (256, 257). Although 
there is 81% homology between the human and the murine IL-7 coding sequence, the 
protein has just 65% amino-acid sequence identity (257). Human IL-7 has activity in 
murine cells(258). Conversely, murine IL-7 was reported to be unable of stimulating 
human pre-B cells (259). while apparently stimulating human T lymphocytes (260, 
261). Recently, our group clearly demonstrated that murine IL-7 can stimulate human 
T cells and act also upon human B cell precursor cell lines (251). 
Production of IL-7 has been detected from multiple stromal origins, including 
epithelial cells in thymus and BM (262, 263). Although IL-7 is a soluble factor, it has 
been shown to bind extensively to the extracellular matrix-associated 
glycosaminoglycan, heparan sulfate, and to fibronectin — a feature that is likely to 
play an important role in the regulation of local tissue availability of IL-7 and IL-7–
induced signaling within the microenvironment (264-266).  
The IL-7 receptor (IL-7R) is constituted not only by the γC but also by the IL-7R 
alpha chain (IL-7Rα; CD127) (267-269). IL-7Rα is also used by thymic stromal-
derived lymphopoietin (TSLP) (270). Direct binding of IL-7 to IL-7Rα induces 
heterodimerization with γC, which is sufficient for activation of intracellular signaling 
events (271). Nevertheless, recruitment of kinases is required for signal transduction 
because the intracellular portion of IL-7Rα does not contain intrinsic tyrosine kinase 
activity. Therefore IL-7 signaling involves a number of tyrosine kinases that associate 
with the cytoplasmic tail of the receptor, including JAK (272), PI3K (259) and Src 
(273). Heterodimerization of IL-7R chains at the cell membrane triggers the 
activation of the receptor associated tyrosine kinases JAK1 and JAK3 (274). 
Activated JAK3 phosphorylates the IL-7Rα chain at residue Y449, creating docking 
sites for both STAT5 (275) and PI3K (276). STAT5 and PI3K have different binding 
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kinetics to this docking site, thereby yielding a potential mechanism for regulating the 
extent and timing of these two pathways and thus influencing the downstream 
integration of these survival signals (277). Once STAT5 is activated, it dimerizes and 
translocates to the nucleus where it modulates the expression of a multitude of pro-
survival and cell proliferation genes, including BCL-XL, MYC, cyclin D1, and PIM-1 
(278). JAK3 activation is also associated with triggering of PI3K/Akt pathway in IL-
7-mediated signaling (279).  
IL-7 is a pleiotropic cytokine with central roles in modulating T- and B-cell 
development and T-cell homeostasis (280). IL-7 null mice showed that IL-7 is a 
nonredundant cytokine for murine T and B lymphopoiesis (281, 282). Patients with 
severe combined immunodeficiency (SCID) present mutations in γC and IL-7Rα, 
confirming that IL-7 is indispensable for T-cell development in humans (283). 
However, the presence of B cells in these individuals suggests important differences 
regarding the role of IL-7 in murine and human lymphocyte development (284). 
Interestingly, IL-7Rα null mice present a more severe impairment of T and B cell 
development than IL-7 KO mice, which might be a consequence of TSLP signaling 
impairment (283).  
The IL-7R is tightly regulated through T-cell differentiation. In the mouse, the earliest 
T-lineage cell to proliferate in response to IL-7 is the TN (CD3- CD4- CD8-) 
CD44+CD25+. IL-7Rα chain is expressed throughout the TN and DN (CD4-CD8-) 
stage, contributing to proliferation, survival, and TCR rearrangement (at least for the 
δ locus). Rearrangement of the TCR α component and positive selection occur during 
the DP (CD4+ CD8+) stage, resulting in the death of most thymocytes and in self-
MHC restriction. IL-7Rα expression is downregulated during this stage. Clonal 
deletion of thymocytes expressing self-reactive TCRs begins toward the end of the 
DP stage and probably continues through the early SP stage. IL-7Rα chain is re-
expressed at the SP stage and remains, at some level, throughout the life of a mature T 
cells (285). 
 
1.5.2. IL-7/IL-7R axis in leukemogenesis 
Despite the important role in normal T-cell function and development, there is 
evidence that IL-7 can contribute to the pathogenesis of T-cell leukemia(223). In the 
first IL-7 transgenic mouse line reported, only mild effects on T cell and thymocyte 
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development were seen (286). However, in two subsequent reports, effects were more 
dramatic with profound perturbation of thymocyte subpopulations and the generation 
of T cell tumours (287, 288). Other studies demonstrated that transgenic mice with 
IL-7 transgene controlled by the SRα promoter, constitutively expressed in many 
tissues including lymphoid cells, developed cutaneous lymphomas with high 
frequency (289). Moreover, IL-7Rα overexpression in mouse thymocytes has led to 
similar observations. AKR/J mice spontaneously develop T-cell lymphomas and the 
proliferative and tumorigenic cell population has high levels of IL-7Rα (290). This 
suggests that overexpression of IL-7Rα may confer a survival advantage to early 
thymocytes in the normal thymic environment. In contrast, other reports where IL-
7Rα is constitutively expressed show normal numbers of T cells or hypoplasia(291, 
292). Recently, Buenke and colleagues generated an IL-7R KO mouse with a 
tetracycline-inducible IL-7Rα transgene under control of human CD2 promoter, 
which is a valuable tool to study T cell development in vivo and to analyze the 
possible role of IL-7Rα in tumorigenesis (293).  
Interestingly, various studies have provided evidence associating the role of IL-7/IL-
7R signaling with the expansion of T-ALL (Figure 3). In a comparative microarray 
gene expression study, Golub and collaborators found that IL-7R expression is 
increased in ALL as compared to other leukemias (294). Other studies have shown 
that T-ALL samples express IL-7Rα (279, 295, 296). Functional studies blocking the 
IL-7Rα and IL-7 in co-cultures with thymic epithelial cells (TECs) showed a decrease 
in viability and proliferation of T-ALL cells (250, 297). Similar to IL-7, the thymic 
stromal-derived lymphopoietin (TSLP) influences the proliferation and survival of 
ALL cells by signaling through the IL-7Rα (298, 299). In the past years, our group 
has contributed significantly to the understanding of IL-7-mediated signaling in T-
ALL cells. Barata et al showed that IL-7 downregulates p27Kip1 in T-ALL cells, and 
this promotes clonal expansion of the malignant cells (133, 300). Moreover, survival 
and proliferation of T–ALL cells in response to IL-7 was largely attributed to 
PI3K/Akt pathway activation (133). Furthermore, PI3K/Akt activation is crucial for 
IL-7-mediated cell growth and glucose uptake of T-ALL cells in vitro (133, 245), as 
shown in Figure 3. 
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Figure 3 – IL-7-mediated signaling pathways. Upon IL-7 binding, IL-7Rα and γC heterodimerize 
and lead to the activation of Jak3 and Jak1, and subsequent recruitment of downstream signaling 
pathways, including JAK/STAT, MEK/Erk and PI3K/Akt. STATs are recruited to the receptor and 
tyrosine phosphorylated by the Jaks, inducing STAT dissociation from the receptor and dimerization. 
The STAT dimers enter the nucleus, bind DNA consensus sequences and mediate trancription of target 
genes. In malignant T cells, MEK phosphorylates and activates Erk, which phosphorylates several 
targets in the cytoplasm. Subsequently, Erk translocates to the nucleus, where it modulates the activity 
of several transcription factors. IL-7-activated PI3K mediates the phosphorylation of PI-4,5-P into PI-
3,4,5-P, thereby recruiting PDK and Akt to the membrane, and inducing Akt activation by PDK. The 
effect of PI3K is opposed mainly by the phosphatase PTEN. Akt phosphorylates and thus modulates 
the activity of numerous targets that are directly or indirectly involved in the regulation of protein 
synthesis (mTOR), cell cycle progression(GSK3, p27Kip1), metabolism (GLUTs) and viability (NFκB, 
FOXOs, Bcl-2). The PI3K/Akt pathway downstream targets analysed in this work are represented in 
black. Adapted from (223). 
 
1.6. Aims and strategies 
The aim of this research project is to contribute towards the understanding of T-ALL 
pathophysiology, more specifically the contribuition of cell-autonomous mechanisms 
and microenvironmental factors involved in leukemia progression. To achieve this 
aim, we used not only T-ALL cell lines but also, and mostly, primary leukemia 
samples collected at diagnosis, since we believe these are more significant 
representatives of actual disease. To characterize the contribution of IL-7 for 
leukemogenesis in vivo, we used a human-mouse T-ALL xenograft model that 
involved the comparison between IL-7KO/γCKO/Rag2KO and γCKO/Rag2KO mice. 
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Finally, to better understand the importance of IL-7Rα in T-cell leukemia we used an 
IL-7Rα-inducible mouse model in an IL-7R KO background (293).  
To this end, this project first focused on the basal activation status of PI3K/Akt 
pathway in T-ALL. We analyzed the phosphorylation levels of Akt and its 
downstream targets (GSK3 and FOXOs) by western blot, in order to determine the 
activation status of PI3K/Akt pathway. In parallel, we detected PIP3 levels by 
confocal microscopy and flow cytometry. We compared the results to thymocytes, the 
normal counterparts of T-ALL cells. Next, we characterized the expression levels 
(mRNA and protein) and the function (mutation analysis and activity) of the 
PI3K/Akt pathway negative regulator PTEN. The results obtained prompted us to 
study PTEN posttranslational regulation by phosphorylation and oxidation in T-ALL. 
To test the therapeutic potential of our observations, our strategy included the 
inhibition of PI3K/Akt pathway activity by the use of PI3K pharmacological 
inhibitors and/or inhibitors of other molecules that indirectly activate the pathway. 
Results obtained in this part of the work are described in Chapter 2. 
Next, we evaluated whether the reported capacity of IL-7 to further upregulate 
PI3K/Akt signaling in T-ALL cells could be associated with the regulation of 
intracellular ROS. We analyzed the ability of IL-7 to upregulate ROS in T-ALL using 
the redox-sensitive dye DCF-DA and subsequently evaluated the involvement of ROS 
in PI3K/Akt activation IL-7-dependent cellular effects. Chapter 3 describes the results 
obtained. 
Our in vitro data indicating the importance of IL-7 for T-ALL viability and 
proliferation, together with the in vivo evidence from mouse studies indicating that 
IL-7 can act as an oncogene, prompted us to try and analyze the potential role of IL-7 
for human T-ALL progression in vivo. First, we demonstrated that murine IL-7 is 
active upon human T-ALL cells. Then, we generated a human T-ALL xenograft 
mouse model that enabled us to evaluate the functional impact of the presence or 
absence of IL-7. To this end, we transplanted primary T-ALL cells or cell lines into 
IL-7 wild type (γCKO/Rag2KO) and deficient (IL-7KO/γCKO/Rag2KO) mice. We 
followed animal survival rate or culled the animals at established time points, to 
compare the infiltration of malignant blasts in different organs. We also used a whole 
body in vivo bioimaging system to follow leukemia development longitudinally. 
Importantly, we determined survival and proliferation ex vivo and evaluated the 
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levels of p27kip1 and Bcl-2. Results were compared in IL-7 WT versus IL-7 KO mice, 
and are presented in Chapter 4. 
Of particular relevance to the understanding of the molecular mechanisms that 
regulate leukemogenesis, was the characterization of IL-7Rα involvement in 
leukemia progression. To this end, we used an engineered polyclonal (OTII-) and 
monoclonal (F5 and OTII+) TreIL-7Rα mouse model. We continuously fed the 
animals with doxycycline (dox) food to induce long-term expression of the IL-7Rα 
and determine leukemogenic potential and animal survival rate. We characterized 
molecular and cellular features of tumor cells. We further set up adoptive transfers of 
tumor cells to Rag1 KO mice in order to determine their capacity to induce 
malignancy and the requirement of IL-7Rα. These results are presented in Chapter 5. 
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2.1. Abstract  
 
PTEN mutations leading to PTEN protein deletion and subsequent activation of 
PI3K/Akt pathway are common in cancer. Here, we show that PTEN inactivation in 
tumor cells is not always synonymous with PTEN gene lesions and diminished protein 
expression. We report that diagnostic T-cell acute lymphoblastic leukemia (T-ALL) 
patient samples very frequently show constitutive hyperactivation of PI3K/Akt signaling 
pathway. In contrast to immortalized cell lines, most primary T-ALL cells do not harbor 
PTEN gene alterations, display normal mRNA levels and express higher protein levels 
than normal T-cell precursors. However, PTEN overexpression is associated with 
decreased PTEN lipid phosphatase activity, resulting from CK2 overexpression and 
hyperactivation. In addition, T-ALL cells present constitutively high levels of reactive 
oxygen species (ROS), which can also downmodulate PTEN activity. Accordingly, both 
CK2 inhibitors and ROS scavengers activate PTEN and impair PI3K/Akt signaling in T-
ALL cells. Strikingly, inhibition of PI3K and/or CK2 promotes leukemia cell death 
without affecting normal T-cell precursors. Overall, our data indicate that leukemia cells 
inactivate PTEN not only by canonical mechanisms but mostly in a non-deletional, 
posttranslational manner. Pharmacological manipulation of these mechanisms may open 
new avenues for T-ALL treatment.  
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2.2. Introduction 
Phosphoinositide 3-kinase (PI3K) catalyzes the production of the second messenger 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), thereby recruiting and activating several 
downstream kinases. PI3K and its most prominent effector Akt regulate cell viability, 
metabolism, motility and proliferation and are extensively implicated in tumorigenesis 
(1-3). Constitutive activation of PI3K/Akt pathway in hematological malignancies 
including myeloid leukemia, multiple myeloma and T-cell large granular lymphocytic 
leukemia has been shown to support tumor cell proliferation and viability in vitro (4-6). 
The main negative regulator of PI3K/Akt pathway, the lipid phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN), is frequently inactivated in human cancer 
as result of various genetic lesions (7, 8), which ultimately result in decreased or absent 
PTEN protein expression and activity. PTEN deficiency in mice replicates the tumor 
spectrum observed in humans, including T-cell malignancies (9, 10), and T-cell-specific 
deletion of PTEN results in lymphoma-induced death (11). Importantly, PTEN is 
critically involved in maintaining hematopoietic stem cells and preventing 
leukemogenesis (12, 13). Several human T-cell acute lymphoblastic leukemia (T-ALL) 
cell lines lack PTEN as a result of deletions or mutations in the gene, consequently 
having constitutive hyperactivation of PI3K/Akt pathway (14, 15). Enforced expression 
of PTEN in these cell lines induces apoptosis by inhibiting PI3K/Akt (16), suggesting this 
pathway may be important in T-ALL. However, most T-ALL cell lines were established 
from relapsed patients, have been in culture for long and likely accumulated genomic 
alterations not associated with the primary disease. Hence, it is unclear whether PTEN 
mutations and PI3K/Akt hyperactivation are common events in T-ALL patient cells, and 
whether these putative alterations originate relevant functional consequences. 
PTEN inactivation and consequent PI3K/Akt pathway aberrant activation may arise from 
mechanisms other than those targeting PTEN gene integrity (17). Although not directly 
implicated in cancer, downregulation of PTEN activity by mechanisms such as 
phosphorylation and oxidation has been recognized for several years (18-21). PTEN C-
terminal phosphorylation appears to stabilize the protein by preventing its ubiquitination 
and proteasome degradation while decreasing PTEN phosphatase activity (20-23). The 
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serine/threonine protein kinase CK2 has been linked to PTEN phosphorylation (21, 22). 
Interestingly, CK2 overexpression is observed in human solid tumors (24-26), and is 
essential for multiple myeloma cell survival (27). Moreover, transgenic mice with 
targeted expression of CK2 in T-cells develop lymphomas (28). In addition, reactive 
oxygen species (ROS), which are commonly upregulated in cancer cells and proposed to 
contribute to transformation (29-31), were shown to oxidize PTEN C124 in the active site 
to form a disulfide bond with C71, thereby inactivating PTEN (18, 19, 32). However, 
there is no direct evidence linking CK2 or ROS and PTEN phosphorylation or oxidation 
to downregulation of PTEN function in patient tumor cells, and the actual implications of 
these mechanisms to cancer cell function remain undetermined.  
Here, we show that constitutive activation of PI3K/Akt signaling pathway is a very 
common event in primary T-ALL and is critical for leukemia cell viability. PI3K/Akt 
pathway hyperactivation appears to result not only from canonical mechanisms involving 
PTEN gene alterations leading to protein deletion, but most frequently from PTEN 
protein stabilization and inactivation by high CK2 activity and elevated intracellular 
ROS. Constitutive hyperactivation of PI3K/Akt pathway occurs not only in PTEN-null 
but also in most PTEN-expressing leukemias, and dependence on PI3K/Akt-mediated 
signaling can be used to selectively target leukemic cells. In addition, our data suggest 
that PI3K/Akt activation status, which integrates cues arising from both genetic and 
posttranslational inactivation of PTEN, could serve as a biomarker for the identification 
of candidate patients for treatment with inhibitors of PI3K and/or of its downstream 
targets. 
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2.3. Methods 
Primary samples and T-ALL cell lines. T-ALL cells were obtained from the peripheral 
blood and/or the bone marrow of patients with high leukemia involvement (85-100%). 
Samples were enriched by density centrifugation over Ficoll-Paque (GE Healthcare), 
washed twice in culture medium (RPMI-1640 supplemented with 10% FBS), subjected to 
immunophenotypic analysis by flow cytometry, and classified according to their 
maturation stage (Table 1). Normal thymocytes were isolated from thymic tissue obtained 
from children undergoing cardiac surgery. The tissue was gently minced in medium, the 
resulting cell suspension was filtered through a cell strainer, and thymocytes were 
enriched by density centrifugation to >95% purity. Informed consent and institutional 
review board approval were obtained for all primary leukemia and thymic sample 
collections. The PTEN-positive T-ALL cell line TAIL7 shares significant similarities 
with primary leukemia samples (41). The cell lines Jurkat, Molt4 and CEM (PTEN-
negative), and HPB-ALL (PTEN-positive) have been extensively described.  
Immunoblotting. Cell lysates were resolved by 10% SDS-PAGE, transferred onto 
nitrocellulose membranes, and immunoblotted with the following antibodies: ZAP70, p-
PTEN (S370), p-PTEN (S380/T382/T383/S385) (Upstate), actin, CK2α, CKβ  (Santa 
Cruz Biotechnology), Akt, p-Akt (S473), p-GSK3β (S9), p-FOXO3a (T32), PTEN and p-
PTEN (S380) (Cell Signaling Technology). When indicated densitometry analysis was 
performed using Image Quant 5.2 software. Each band was analyzed with a constant 
frame and normalized to the respective loading control.  
Detection of PIP3 levels. Cells were washed in PBS and fixed in 2% paraformaldehyde, 
blocked with 5% normal goat serum in PBS, and incubated overnight at 4°C with mouse 
anti-PIP3 monoclonal antibody (Echelon) at 1:10 dilution. Primary antibody was detected 
with Alexa488-conjugated goat anti-mouse antibody (Molecular Probes). Samples were 
split and: 1) imaged by confocal microscopy using a Zeiss LSM 510 Meta microscope, 
using identical acquisition parameters in one imaging session; 2) analyzed by flow 
cytometry to quantify mean fluorescence intensity using FACSCanto flow cytometer 
(Becton-Dickinson) and FlowJo (Tree Star) software. When measuring PIP3 levels in 
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thymocytes cells were washed in PBS and fixed in 1% paraformaldehyde, blocked with 
10% normal goat serum in PBS, and stained for PIP3 as described. Samples were washed 
and surface stained with anti-CD3 APC-Alexa Fluor 750, anti-CD4PE and anti-CD8 APC 
antibodies. Samples were acquired on a FACSCanto flow cytometer and analyzed with 
FlowJo software. 
RT-PCR and Q-PCR. Total RNA (1µg) was reverse transcribed using the ImProm II 
Reverse Transcriptase enzyme (Promega) and random hexamers. PTEN expression was 
evaluated by RT-PCR using CCAAGTCCAGAGCCATTTC (forward), and 
GTGGGTCCTGAATTGGAGG (reverse) primers. The quantitative assessment of PTEN 
transcripts was made by Q-PCR on an ABI PRISM 7500 (Applied Biosystems) with the 
following primers: ABL, TGGAGATAACACTCTAAGCATAACTAAAGGT and 
GATGTAGTTGCTTGGGACCCA; and PTEN, GCTACCTGTTAAAGAATCATCTGG 
and CATGAACTTGTCTTCCCGT. PTEN primers were designed to provide the most 
possible difference to the PTEN pseudogene transcript. PCR products were cloned into 
the pGEM-T Easy vector (Promega), and standard curves were obtained by serial 
dilutions of uncut plasmid. PTEN transcript values were normalized with respect to the 
number of ABL transcripts.  
PTEN sequencing and mutational analysis. The entire PTEN coding and flanking 
intronic sequences were amplified by PCR. Primers used are indicated in Supplemental 
Table 1. PCR reactions were done using 100ng of DNA and 0.5U of TripleMaster 
Polymerase (Eppendorf). The PCR products were sequenced directly, on both strands, 
using the BigDye kit (Applied Biosystems). Sequences were evaluated using Chromas 
Lite 2.0 (Technelysium Pty Ltd) and Mutation Explorer 2.6.1 (SoftGenetics LLC) 
software. All mutations were confirmed by sequencing a newly amplified product. When 
necessary, PCR amplicons were cloned into pGEM-T vetor (Promega) and several 
individual clones were sequenced. 
Endogenous PTEN in vitro lipid phosphatase assay. Immunoprecipitations were 
carried out with an anti-PTEN antibody (Santa Cruz) overnight and a secondary agarose-
conjugate antibody for 3h at 4ºC. Immunoprecipitated protein was washed, ressuspended 
in enzyme reaction buffer (50mM Tris pH 8, 50mM NaCl, 10mM DTT, 10mM MgCl2), 
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incubated with 10µM PIP3 (Echelon) for 30 minutes at 37ºC, and phosphatase reaction 
was stopped with 100µl malachite green reagent (Echelon). Free phosphate levels were 
measured in an ELISA plate reader at 620nm. Absorbance was converted into pmol of 
phosphate, using a phosphate standard curve. 
PTEN intracellular staining. Cells were fixed in 1% paraformaldehyde, permeabilized 
in 0.05% saponin and incubated 30 minutes at 4°C with a mouse anti-PTEN monoclonal 
antibody (Santa Cruz Biotechnolgy) at 1:100 dilution. Primary antibody was detected 
with Alexa488-conjugated donkey anti-mouse antibody (Molecular Probes). Thymocyte 
samples were surface stained with anti-CD4PE and anti-CD8 APC (Ebioscience) 
conjugated antibodies. Samples were analyzed by flow cytometry to quantify mean 
fluorescence intensity using FACSCanto flow cytometer (Becton-Dickinson) and FlowJo 
(Tree Star) software. 
Detection of PTEN oxidized form. Cells were treated with or without 1mM H2O2 in 
PBS for 30 minutes at 37oC with 5%CO2. Whole cell lysates were prepared in non-
reducing lysis buffer (100mM Tris-Hcl pH6.8, 2% SDS, 50mM Iodoacetamide) and 
ultracentrifuged at 55000 rpm for 10 minutes at 4oC. Lysates were split and incubated 
with or without 100mM DTT (Sigma) for 5 minutes at room temperature. Protein was 
analyzed in denaturating, non-reducing conditions by SDS-PAGE, transferred onto 
nitrocellulose membranes, and immunoblotted. 
Assay of PTEN redox state and activity. To measure PTEN activity modulation by 
oxidation the indirect method relying upon the oxidative protection from alkylation was 
performed as described (19).  
Intracellular ROS levels. Cell samples were washed in PBS, incubated with 10µM 
DCF-DA (Sigma-Aldrich) for 30 minutes in PBS at 37ºC, washed, acquired on a 
FACSCalibur flow cytometer (Becton-Dickinson) and analyzed with FlowJo software. 
When measuring ROS in thymic populations cells were stained with DCF-DA, washed 
and surface stained with anti-CD3 APC-Alexa Fluor 750, anti-CD4 PE-Cy7 
(Ebioscience), and anti-CD8 APC antibodies. Samples were acquired on a FACSCanto 
flow cytometer and analyzed with FlowJo software. 
PTEN AND PI3K/Akt PATHWAY REGULATE T-ALL VIABILITY 
 55 
Endogenous CK2 kinase activity assay. CK2 activity in cell lysates was measured 
using an appropriate kit from Usptate Biotechnology following the manufacturer’s 
instructions.  
Assessment of cell viability. Cells were cultured in 24-well plates as 2x106 cells/ml at 
37ºC with 5% CO2 in control medium, or with the indicated concentrations of LY294002 
(Calbiochem), TBB, DRB, β-ME, NAC (Sigma) or combinations thereof. At 24, 48 
and/or 72h cells were harvested and quantitative determination of viability was 
performed using an Annexin V-based apoptosis detection kit (R&D Systems), as 
previously described (3). Alternatively, viability was assessed by FSC x SSC flow 
cytometry analysis. Viability index was calculated as the ratio of experimental to control 
conditions. 
Fluorescence-activated cell sorting of thymic subpopulations. Normal thymocytes 
(108 cells) were surface stained with anti-CD3 APC-Alexa Fluor 750 (Ebioscience), anti-
CD4 PE (Pharmingen), and anti-CD8 FITC (Pharmingen) conjugated antibodies at a 1:50 
dilution. Cells were washed in PBS and CD8+CD3+ (SP8), CD8+CD4+CD3+ (TP), CD3+ 
and CD3- thymocyte subpopulations were isolated using a FACSAria cell sorter (Becton-
Dickinson). Sorted populations with purities ranging from 83% to 99% were immediately 
lysed or used for culture experiments. 
Statistical analysis. Differences between populations were calculated using unpaired 2-
tailed Student’s t-test or Mann-Whitney test, as appropriate. Differences were considered 
significant for p<0.05. 
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2.4. Results 
2.4.1. PI3K/Akt pathway is constitutively hyperactivated in primary T-ALL cells. 
Based on evidence from T-ALL cell lines, it has been hypothesized that PI3K/Akt 
signaling may be hyperactivated in primary disease. To establish how frequently 
PI3K/Akt constitutive activation actually occurs, we evaluated the integrity of PTEN-
PI3K-Akt axis in T-ALL patient samples collected at diagnosis. Constitutive 
hyperactivation of PI3K/Akt signaling pathway was detected in most T-ALL specimens 
(87.5%; 21 of 24), as evaluated by increased phosphorylation of Akt and/or at least one 
of its downstream targets GSK-3β and FOXO3a in comparison to normal T-cell 
precursors (Figure 1A,B, Table 1, and data not shown). Hyperactivation of PI3K/Akt 
pathway was not associated with overexpression of total Akt (Supplemental Figure 1; 
Supplemental Data at the end of this Chapter) and was consistently observed 
independently of the stage of developmental arrest of the leukemia samples (Table 1). 
Moreover, primary T-ALL cells presented higher phosphatidylinositol 3,4,5-triphosphate 
(PIP3) levels in the plasma membrane, as determined by both confocal microscopy and 
flow cytometry analysis (Figure 1C-E). Consistent with previous reports (15, 33) we also 
observed PI3K/Akt hyperactivation in leukemia T-cell lines (Supplemental Figure 2).  
Each T-ALL sample is essentially constituted by a clonal population of leukemia blasts 
arrested a particular stage of thymic T-cell development (34, 35), whereas normal 
thymocytes are immunophenotypically and functionally heterogeneous, comprising the 
spectrum of distinct developmental subpopulations. To ensure that our data were not 
biased by the prevalence of one particular subpopulation in the normal control samples, 
we next analyzed patient specimens arrested at two particular stages of T-cell 
development and compared them with their purified normal equivalents. We selected 
patients with CD3+CD4+CD8+ (triple positive, TP) and CD3+CD4-CD8+ (CD8 single 
positive, SP8) immunophenotypes because they represent the most prevalent amongst 
primary T-ALL samples (Table 1 and Supplemental Figure 3A). Additionally, normal TP 
and SP8 thymocytes represent two very distinct subpopulations: TP cells are mostly 
quiescent, whereas SP8 cells are actively proliferating or have recently done so (36). 
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Figure 1. PI3K/Akt signaling pathway is constitutively hyperactivated in primary T-ALL cells. (A) 
Cell lysates of normal human thymocytes or primary T-ALL cells collected at diagnosis and 
immunoblotted with the indicated phospho-specific antibodies or actin as loading control. (B) Levels of 
phosphorylated Akt (S473) in thymocyte (n=8) and T-ALL (n=15) samples were quantified by 
densitometry analysis, P<0.0001. Mean ± sem are indicated in parenthesis. (C) Surface expression of PIP3 
was determined by confocal microscopy after staining with anti-PIP3 antibody. White bar indicates 50µm. 
Inlays (20 x 20 µm) of one representative cell of each sample are shown. (D) Same samples were analyzed 
by flow cytometry. Values in each histogram indicate PIP3 mean intensity of fluorescence. Grey histogram 
represents negative isotypic control. Vertical lines indicate peak value in T-ALL samples. (E) Mean 
intensity of fluorescence was quantified by flow cytometry and compared in thymocyte (n=4) and T-ALL 
(n=4) samples, P<0.05. Columns and error bars represent mean ± sem. 
 
Both TP and SP8 T-ALL cells revealed clearly higher levels of P-Akt than their normal 
immunophenotypic counterparts (Supplemental Figure 3B). Likewise, both CD3-negative 
and CD3-positive T-ALLs displayed hyperphosphorylation of Akt as compared with 
immunophenotype-matched normal thymocytes (data not shown). Also, PIP3 levels were 
similar amongst the different normal thymic subsets and significantly and consistently 
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lower than those of primary T-ALL cells (Supplemental Figure 4). Our data indicate that 
constitutive hyperactivation of PI3K/Akt pathway is a very common event in T-ALL, not 
only in immortalized cell lines but more importantly in primary tumors. 
 
2.4.2. PTEN gene alterations are relatively infrequent, whereas protein expression is 
commonly deregulated in primary T-ALL. 
PTEN dephosphorylates PIP3 and is the main negative regulator of PI3K/Akt pathway. 
Thus, we next analyzed the expression of PTEN mRNA and protein in primary leukemia 
samples. Whereas all samples analyzed (n=23) expressed PTEN mRNA, a minority of the 
cases (20%, 6 of 30) lacked PTEN protein (Figure 2A and Table 1). Notably, not only the 
PTEN protein-negative (n=5) but also most PTEN protein-positive samples (84.2%; 16 of 
19) showed PI3K/Akt pathway hyperactivation (Table 1). Since point mutations may 
render PTEN protein inactive with unnoticeable effects on protein expression, we 
performed mutation analysis of all PTEN exons and flanking introns. Interestingly, all 3 
PTEN protein-null samples analyzed showed PTEN gene alterations involving exon 7 
(Figure 2C and Table 2), which is mutated in Jurkat cells and is essential for PTEN 
protein stability (15, 37). One of the samples was also affected in exon 1, which appears 
to be involved in PTEN-membrane binding and activation (38). None of the 15 PTEN 
protein-positive T-ALLs analyzed presented PTEN mutations in exons 1-9 or in the 
flanking intronic splice site sequences. Our data indicate that relatively few primary T-
ALL samples harbor PTEN gene alterations, in accordance with recent reports indicating 
that PTEN mutations are fairly rare in primary T-cell leukemia specimens (33, 39). In 
addition, despite some heterogeneity, average PTEN mRNA expression in primary T-
ALL cells was comparable to that in normal T-cell precursors, as assessed by quantitative 
RT-PCR (Figure 2B). This suggests that PTEN transcription is largely normal in T-ALL, 
arguing against the possibility that PTEN promoter hypermethylation (40) or Notch-
dependent PTEN transcriptional repression (39) play a broad role in primary disease. 
Finally, we assessed whether hyperactivation of PI3K/Akt pathway in PTEN-positive 
leukemia cells could be due to decreased PTEN protein abundance. Unexpectedly, we 
found that PTEN-positive T-ALL samples expressed even higher levels of PTEN protein  
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Figure 2. PTEN gene alterations and protein expression deregulation in primary T-ALL cells. (A) 
Expression of PTEN mRNA (upper panel) and protein (lower panel) in normal thymocytes, T-ALL primary 
samples and cell lines was assessed by RT-PCR and immunoblotting, respectively. (B) PTEN mRNA 
levels in thymocyte (n=12) and T-ALL (n=18) samples were evaluated by quantitative RT-PCR, P=0.98. 
Mean ± sem are indicated. (C) None of 15 PTEN-expressing T-ALL patients present PTEN gene 
alterations, whereas all PTEN-negative leukemia samples analyzed (n=3) harbor mutations in exons 1 
and/or 7. (D) PTEN protein levels in thymocyte (n=6) and T-ALL (n=8) samples were evaluated by 
densitometry analysis after immunoblotting, P<0.001. Mean ± sem are indicated. Representative of 4 
independent analyses involving a total of 9 thymocyte samples and 15 PTEN-expressing T-ALL 
specimens.sequences, in 3 PTEN protein-negative and 15 PTEN-positive T-ALL cases. 
 
than normal controls (Figure 2D), despite displaying constitutive activation of the 
PI3K/Akt pathway. Similar results were found for PTEN-positive T-ALL cell lines 
(Supplemental Figure 2). Importantly, analysis of PTEN protein expression by flow 
cytometry revealed no significant differences between the four major normal thymic 
subpopulations (Supplemental Figure 5A-C). Furthermore, each subpopulation had lower 
PTEN levels than the T-ALL cell line TAIL7 (41), which is a good representative of 
PTEN-positive primary leukemia T-cells (Supplemental Figure 5D-F and Figure 2A). In 
addition, immunoblot analysis of TP and SP8 T-ALL cells and FACS-isolated normal 
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thymocytes showed once again that the leukemia cells express higher PTEN protein 
levels than their normal counterparts (Supplemental Figure 5G). 
 
2.4.3. CK2 regulates PTEN expression and activity in PTEN protein-positive T-ALL 
cells. 
The apparent contradiction between PTEN protein abundance and PI3K/Akt pathway 
activation in leukemia samples prompted us to analyze PTEN phosphatase activity. We 
found that high PTEN expression was not associated with increased activity but rather 
with PTEN inactivation, since T-ALL samples showed diminished PTEN in vitro lipid 
phosphatase activity as compared with normal thymocytes (Figure 3A). Furthermore, 
most malignant specimens showed higher PTEN phosphorylation at different residues in 
the C-terminal tail (S380, S370, and the cluster including T382/T383/S385) than normal 
controls (Table 1, Figures 3B, 5D,E and data not shown). Thus, most leukemia cells 
expressed both higher PTEN (Figure 2A) and phospho-PTEN (Figure 3B) levels. 
Importantly, the ratio of phosphorylated PTEN over total PTEN was significantly higher 
in phospho-PTEN-high T-ALL cases than in normal thymocytes (Supplemental Figure 
6). This indicates that the higher amounts of phosphorylated PTEN in leukemic T-cells 
are not simply due to increased PTEN protein availability. Since CK2-mediated 
phosphorylation of PTEN at the C-terminal tail was proposed to downmodulate PTEN 
activity while increasing its stability (20, 21), we then examined expression and 
activation of CK2. T-ALL cells expressed higher levels of both the catalytic CK2α and 
regulatory CK2β subunits compared to normal thymocytes (Table 1, Figure 3C-E and 
Supplemental Figure 7), and showed clearly increased constitutive CK2 kinase activity 
(Figure 3F). Treatment of TAIL7, HPB-ALL or primary T-ALL cells with the CK2-
specific inhibitor TBB resulted in abrogation of C-terminal phosphorylation of PTEN, 
downregulation of PTEN expression, and simultaneous inhibition of Akt and GSK-3β 
phosphorylation (Figure 3G). These results suggest that PTEN phosphorylation, leading 
to PTEN protein stabilization and inactivation, and consequent PI3K/Akt pathway 
hyperactivation, might be secondary to constitutive increase of CK2 activity in T-ALL 
cells. Because it was shown that CK2 may stimulate. 
PTEN AND PI3K/Akt PATHWAY REGULATE T-ALL VIABILITY 
 61 
 
 
Figure 3. PTEN expression and activity are regulated by CK2 in PTEN-positive T-ALL. (A) PTEN in 
vitro lipid phosphatase activity was determined after immunoprecipitation of endogenous PTEN from 
normal thymocytes (n=5) and PTEN-positive primary leukemia cells (n=4), P<0.005. PTEN activity was 
normalized to the levels of immunoprecipitated PTEN in each sample. (B) PTEN phosphorylation at S380 
was determined by immunoblotting. Results shown are from two independent analyses representative of a 
total of 8 thymocyte samples and 14 PTEN-positive T-ALL specimens. T-ALL#14 (in red) shows no 
PI3K/Akt basal hyperactivation (Table 1). (C) Immunoblot analysis of CK2α and β expression. (D,E) CK2 
levels in normal thymocytes (n=3), and T-ALL primary cells (n=4) were quantified by densitometry 
analysis regarding CK2α (D), P<0.005, and CK2β (E), P<0.05. Expression of CK2 in a total of 12 cases 
analyzed is detailed in Table 1. (F) CK2 kinase activity in thymocyte (n=6) and T-ALL (n=5) sample 
lysates was measured in vitro, P<0.05. (G) TAIL7, HPB-ALL or primary T-ALL cells were treated for 
2h30min with DMSO vehicle control or 25µM  TBB and levels of expression and phosphorylation of 
indicated proteins were analyzed by immunobloting. P-PTEN (sev) indicates phosphorylation of PTEN at 
the cluster S380/T382/T383/S385. (H) TAIL7 cells treated for 2h30min with DMSO vehicle control 
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(untreated) or 25µM TBB were lysed, and in vitro lipid phosphatase activity of immunoprecipitated PTEN 
was assessed in triplicate, P<0.0001. Columns and error bars in A, D, E, F, H represent mean ± sem. 
 
Akt activity directly (42), we next analyzed the effect of TBB on phosphorylation of Akt 
in PTEN-null Jurkat T-ALL cells stably expressing PTEN in a Tet-inducible manner 
(16). CK2 inhibition clearly diminished the levels of Akt S473 phosphorylation in Jurkat 
cells that expressed PTEN upon doxycycline treatment, whereas it induced only a minor 
downregulation of Akt phosphorylation in Jurkat cells that did not express PTEN 
(Supplemental Figure 8). These data argue that the effect of CK2 on PI3K/Akt signaling 
pathway activity in T-ALL cells is largely dependent on the ability of CK2 to regulate 
PTEN activity. To confirm this, we analyzed the effect of TBB directly on PTEN 
phosphatase activity. CK2 inhibition dramatically upregulated PTEN activity in TAIL7 
(Figure 3H) and HPB-ALL cells (data not shown), suggesting that constitutive aberrant 
CK2 activity contributed to PI3K/Akt pathway activation at least in part by non-
deletional posttranslational inactivation of PTEN. Consistent with this hypothesis, patient 
samples without PI3K/Akt pathway hyperactivation displayed levels of PTEN 
phosphorylation similar to normal thymocytes (T-ALL#14, Figure 3B; and T-ALL#08, 
Figure 5E; indicated in red in each figure). Moreover, high CK2 expression in PTEN-
positive leukemia samples associated with increased phospho-PTEN (Supplemental 
Figure 9 and Table 1).  
 
2.4.4. High ROS levels downregulate PTEN activity in PTEN protein-positive T-
ALL cells 
Cancer cells frequently express high levels of ROS, including superoxide anion (30) and 
hydrogen peroxide (H2O2) (29). By using the redox-sensitive dye DCF-DA we found that 
the majority of primary T-ALL cells had higher intracellular ROS levels than normal 
thymocytes (Table 1, Figure 4A,B and Supplemental Figure 10). Since H2O2 was shown 
to oxidize and thereby inactivate PTEN (18, 19, 32), we checked whether diminished 
PTEN activity in T-ALL cells might be also associated with increased ROS. Although 
most PTEN present in TAIL7 cells was in the reduced form, there were constitutively 
detectable levels of oxidized PTEN, which were further upregulated by addition of 
exogenous H2O2, and abrogated by in vitro treatment with the reducing agent DTT 
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(Figure 4C). Treatment of PTEN-positive T-ALL cells with another antioxidant, β-ME, 
downregulated constitutive phosphorylation of Akt and GSK-3β  (Figure 4D and 
Supplemental Figure 11A), whereas H2O2 induced the opposite effect (Figure 4E and 
Supplemental Figure 11B). In contrast, Akt and GSK-3β phospho-levels were not 
significantly affected by modulation of ROS in PTEN-null T-ALL Jurkat cells (Figure 
4D,E), suggesting that oxidation-dependent activation of PI3K/Akt signaling pathway 
largely relied on regulation of PTEN. In accordance, the PI3K-specific chemical inhibitor 
LY294002 abrogated not only constitutive but also H2O2-promoted Akt phosphorylation, 
indicating that ROS upregulated phosho-Akt in a PTEN/PI3K/PIP3-dependent manner 
and not via alternative mechanisms acting directly on Akt (Figure 4F). To further support 
the evidence that PTEN activity contributed to ROS-mediated activation of PI3K/Akt 
signaling pathway, we performed an indirect PTEN redox assay (19),in which lysis 
buffers alkylate reduced cysteine residues thereby irreversibly inactivating PTEN. 
Oxidized cysteine residues are protected from alkylation and, because oxidation is 
reversible, they can be recovered afterwards by treatment with a reducing agent for 
assessment of PTEN activity. The resultant in vitro phosphatase activity reflects the 
proportion of PTEN that was oxidized and inactivated at the time of lysis. Using this 
approach, we determined that β-ME (Figure 4G) and H2O2 (Figure 4H) modulated 
endogenous PTEN redox state and activity in opposite directions. Importantly, addition 
of β-ME to T-ALL cells reverted constitutive oxidation-induced inactivation of PTEN. 
These data suggest that high levels of intracellular ROS contributed to PTEN inactivation 
by oxidation with subsequent PI3K/Akt pathway hyperactivation. Furthermore, 
combination of low doses of the antioxidant NAC and the CK2 inhibitor TBB acted 
synergistically in inhibiting PI3K/Akt pathway (Supplemental Figure 12). This effect did 
not appear to result from possible upregulation of CK2 by increased ROS levels in T-
ALL cells, since treatment of TAIL7 and HPB-ALL cell lines with β-ME did not affect 
significantly the expression of CK2α/β (Supplemental Figure 13).   
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Figure 4. PTEN activity is downregulated by ROS in T-ALL. (A) Intracellular H2O2 levels were 
assessed by flow cytometry after incubation with the redox-sensitive fluorescent dye DCF-DA. One 
representative patient sample and one representative normal control are shown. (B) Mean intensity of DCF-
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DA fluorescence was compared between normal thymocytes (n=7) and T-ALL (n=5), P<0.0001. Data are 
representative of most T-ALL samples (listed in Table 1) analyzed in four independent experiments. (C) 
TAIL7 cells previously treated with or without 1 mM H2O2 for 30min. were lysed in non-reducing 
conditions and analyzed for expression of PTEN oxidized and reduced bands. DTT was added where 
indicated to demonstrate the specificity of the lower, oxidized band.  (D,E) PTEN-positive TAIL7, HPB-
ALL or primary T-ALL cells and PTEN-null Jurkat cells were treated for 2h with 0.5 mM β‐ME (D) or 30 
min. with 1 mM H2O2 (E) and levels of Akt and GSK-3β phosphorylation were determined by immunoblot. 
(F) TAIL7 and HPB-ALL cells were pretreated for 1h with 25µM LY294002 or with DMSO vehicle 
control, stimulated with 1 mM H2O2 for 30min., and analyzed for Akt phosphorylation by immunoblot. 
(G,H) Effects of β‐ME (G), P<0.01, or H2O2 (H), P<0.0005, on PTEN activity were measured by using the 
indirect PTEN redox assay, as described (19). More PTEN activity in the assay (“Post-alkylation PTEN 
Relative Activity”) reflects less PTEN activity in the cell. Data from two independent experiments were 
normalized to the highest value in the control conditions. Columns and error bars in B, G, H represent mean 
± sem. 
 
2.4.5. Targeting PI3K/Akt pathway hyperactivation in T-ALL.  
Malignant cell lines lacking PTEN activity due to PTEN gene and protein deletion are 
particularly sensitive to PI3K/Akt pathway inhibition (43). Our present data demonstrated 
that although generally expressing PTEN, primary T-ALL cells frequently show 
functional inactivation of PTEN phosphatase activity and constitutive activation of 
PI3K/Akt pathway. Hence, we next analyzed the effect of the PI3K inhibitor LY294002 
on the viability of T-ALL cells. In contrast to normal thymocytes, primary leukemia cells 
underwent significant death upon LY294002 treatment in vitro (Figure 5A,B and 
Supplemental Figure 14). The effect of LY294002 on T-ALL cells did not appear to be 
solely dependent on the expression of PTEN, since it affected not only PTEN-negative 
but also PTEN-positive patient samples (Figure 5C) and cell lines (Supplemental Figure 
15). Moreover, PTEN-positive patient samples with hyperactivation of PI3K/Akt 
pathway (e.g. T-ALL#19; Figure 5D) were clearly sensitive to PI3K inhibition (Figure 
5F,G). In contrast, PTEN-positive samples without constitutive activation of PI3K/Akt 
signaling pathway (e.g. T-ALL#08; Figure 5E) were unresponsive to LY294002 
treatment (Figure 5F,G). As expected, the latter showed low levels of PTEN 
phosphorylation (e.g. T-ALL#08, Figure 5E, and T-ALL#14, Figure3B, in red), 
indicative of normal PTEN activity, in contrast to the samples with hyperactivation of 
PI3K/Akt pathway (e.g. T-ALL# 4, 19 and 22, Figure 5D,E) that displayed 
hyperphosphorylation of PTEN. 
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Figure 5. Inhibition of PI3K induces selective cell death of T-ALL cells displaying hyperactivation of 
PI3K/Akt pathway and does not affect normal T-cell precursors. (A) Normal thymocytes (n=10) and 
primary leukemia cells (n= 15) were treated with 10 or 25 µM LY294002 (LY) for 48h. Viability index to 
control untreated samples is shown. *** P<0.0001. (B) Annexin V-FITC / PI dot plots of representative 
cases and respective percent viable cells are shown. (C) PTEN-negative (T-ALL#01) and PTEN-positive 
(T-ALL#05) patient samples were analyzed for viability by FSC x SSC distribution. Values indicate 
percent viable cells. (D,E) T-ALL patients were reevaluated for PI3K/Akt pathway activation by western 
blot analysis of phosphorylated Akt, GSK-3β and PTEN. One T-ALL patient with (D; T-ALL#19) and one 
without (E; T-ALL#08) basal PI3K/Akt hyperactivation were cultured with two different doses of LY and 
analyzed for viability after 24h (F). One thymocyte sample is shown as a control for unresponsiveness to 
C 
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LY treatment. Values indicate percent viable cells for each condition. (G) Responsiveness to LY treatment 
at 24h of culture of T-ALL samples without PI3K/Akt constitutive activation (PI3K/Akt activation 
negative) and with hyperactivation of the pathway (PI3K/Akt activation positive). Results are 
representative of two independent experiments. (H) Primary leukemia cells (n=12 for TBB and n=9 for 
DRB) were cultured for 48h in the presence of each one of two unrelated CK2-specific inhibitors TBB 
(40µM), P=0.0005 or DRB (12.5µM), P=0.0003. TBB and DRB showed no significant effect on viability 
of normal thymocytes (n=7) treated similarly. In all panels ‘Medium’ represents culture medium with 
vehicle control (DMSO).  
These results suggest that the sensitivity of T-ALL cells to PI3K inhibition is determined 
by PTEN functional integrity, and consequent activation status of PI3K/Akt pathway, 
rather than the levels of PTEN expression per se. Because abrogation of CK2 activity 
leads to PTEN activation and PI3K/Akt pathway inhibition we next treated T-ALL cells 
with two distinct CK2 inhibitors to assess their impact on viability of leukemia cells. 
Both TBB and DRB induced significant cell death in primary T-ALL cells but not in 
normal thymocytes (Figure 5H). Since we showed that CK2-mediated activation of 
PI3K/Akt signaling pathway was largely dependent on regulation of PTEN activity, we 
next compared the effect of CK2 inhibition on the viability of PTEN-expressing versus 
PTEN-negative Jurkat T-ALL cells. Although TBB and DRB promoted death in PTEN-
null leukemia cells, the effect of both CK2 inhibitors was significantly higher in the cells 
that expressed PTEN (Supplemental Figure 16). This suggests that PTEN-positive T-
ALL cells with hyperactivation of PI3K/Akt pathway may especially benefit from 
therapies that include pharmacological inhibitors of CK2. Similarly, viability of PTEN-
expressing Jurkat cells was strikingly diminished upon treatment with β-ME, whereas 
PTEN-null Jurkat cells were insensitive to the reducing agent (Supplemental Figure 16).  
Finally, to evaluate potential cooperative anti-leukemia effects, we performed 
experiments combining CK2 inhibition with ROS scavenging. CK2 blockade by TBB 
cooperated with the antioxidants β-ME (Figure 6A) and NAC (Figure 6B) to markedly 
decrease leukemia T-cell viability, with more than 95% cell death. We then used each 
one of these agents together with the PI3K antagonist LY294002. Addition of LY294002 
markedly increased the anti-leukemia activity of both CK2 inhibitors TBB (Figure 6C) 
and DRB (Figure 6D). Finally, PI3K blockade also potentiated the inhibitory effects of 
ROS scavenging by either β-ME (Figure 6E) or NAC (Figure 6F). Similar cooperative 
effects were observed using HPB-ALL (Supplemental Figure 17) and primary 
(Supplemental Figure 18) T-ALL cells. Together, these data suggest that combinatorial 
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strategies targeting multiple elements related to PTEN regulation and PI3K/Akt 
activation are promising therapeutic approaches in T-cell leukemia. 
 
Figure 6. Cooperative effects of combinatorial treatment of T-ALL cells with pharmacological 
antagonists of PI3K, CK2 and ROS. (A,B) Inhibition of CK2 and ROS scavenging cooperate in inducing 
T-ALL cell death. TAIL7 cells were cultured with the indicated concentrations of TBB and b-ME (A), 
TBB and NAC (B) or their combination and viability was assessed at 72h. (C-F) Inhibition of PI3K 
signaling cooperates with inhibition of CK2 and ROS scavenging in inducing T-ALL cell death. TAIL7 
cells were cultured with the indicated concentrations of LY294002 (LY) and TBB (C), LY and DRB (D), 
LY and  β‐ME (E), LY and NAC (F) or their combination and viability was assessed at 72h. Percent 
viability relative to untreated control (vehicle alone) is indicated for each condition. Similar results were 
obtained using HPB-ALL and primary T-ALL cells (Supplemental Figures 17 and 18, respectively).  
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2.5. Discussion 
PTEN gene alterations occur frequently in human cancers and mainly associate with 
PTEN protein “deletion”. However, many so-called PTEN-null malignant cells actually 
express low levels of PTEN protein (44). One possible explanation for this observation is 
that complete PTEN depletion may be detrimental for tumor function. Indeed, complete 
loss of PTEN can lead to p53-dependent cellular senescence that antagonizes 
tumorigenesis (45). Moreover, PTEN was shown to be haploinsufficient for tumor 
suppression (46), and many human cancers retain a wild-type copy of PTEN (8). Hence, 
PTEN does not appear to conform necessarily to the canonical definition of a tumor 
suppressor that requires inactivation of both alleles. Under this context, it is tempting to 
speculate that posttranslational inactivation of PTEN may result in levels of activity 
similar to those seen in cells carrying PTEN heterozygous mutations. Accordingly, 
aberrant PTEN polyubiquitination and proteasome-dependent degradation were recently 
shown to potentiate transformation (47). Hence, diminished but detectable PTEN activity 
likely provides an optimum intracellular context for cancer development. Our data further 
indicate that decreased PTEN activity, and subsequent activation of PI3K/Akt pathway, 
can be uncoupled from PTEN gene lesions and from PTEN protein 
downregulation/deletion in primary leukemia cells. 
Previous studies conducted in cell lines or in a very small number of patient samples 
suggested that PI3K/Akt pathway is constitutively activated in T-ALL (33, 48), but did 
not assess how frequently primary leukemia specimens display PI3K/Akt pathway 
hyperactivation. Here, we demonstrated that the majority of T-ALL primary samples 
(87.5%) show hyperactivation of PI3K/Akt pathway, suggesting that PI3K-mediated 
signaling is critical for the biology of this malignancy in patients. PTEN expression 
inversely correlates with phosphorylation of Akt in some T-ALL (14, 33) and many 
leukemia/lymphoma cell lines (49). Similarly, we found that some T-ALL patient 
samples present alterations in PTEN gene coding sequence, lack PTEN protein 
expression, and show constitutive activation of PI3K/Akt signaling pathway. PTEN 
inactivating mutations predicted to cause protein truncation were recently reported in 
5.2% (33) and 8% (39) primary T-ALL samples, a low frequency event confirmed in our 
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studies. However, the vast majority of primary leukemias show simultaneously high 
expression of unmutated PTEN protein and hyperactivation of PI3K/Akt pathway. We 
propose two posttranslational mechanisms to solve this apparent paradox: CK2-mediated 
phosphorylation and ROS-dependent oxidation of PTEN in leukemia cells downregulate 
PTEN activity and consequently promote PI3K/Akt constitutive hyperactivation without 
decreasing PTEN expression (Figure 7).  
Previous studies showed that CK2 and PTEN can physically interact (22), and CK2-
mediated phosphorylation of PTEN affects its activity and stabilizes the protein by 
preventing proteasome-mediated degradation (20, 21). We demonstrate here, for the first 
time, that CK2 is overexpressed and hyperactivated in primary T-ALL cells and suggest 
that CK2-mediated phosphorylation of PTEN stabilizes PTEN expression and inhibit its 
activity, ultimately leading to PI3K/Akt pathway constitutive activation. The biological 
impact of these observations was addressed by using two distinct pharmacological 
inhibitors of CK2, both of which promoted leukemia cell death without affecting the 
viability of normal T-cell precursors, similarly to the PI3K-specific inhibitor LY294002. 
Our present work indicates that increased CK2 expression in leukemia T-cells is likely 
not a consequence of PI3K/Akt hyperactivation itself. Future studies to identify why CK2 
is overexpressed and activated in T-ALL are warranted. Interestingly, PTEN 
phosphorylation on the CK2 target residues Ser380/Thr382/Thr383 was observed in some 
AML patients and shown to correlate with increased phosphorylation of Akt and 
decreased overall patient survival (50). These observations suggest that CK2-mediated 
posttranslational inactivation of PTEN could have important implications in other 
hematological malignancies besides T-ALL. In addition, PTEN-expressing breast cancer 
cell lines with hyperactivation of PI3K/Akt have concomitant phosphorylation of PTEN, 
and both can be inhibited by the anti-tumor agent tetracarcin A (51). Finally, a recent 
report demonstrated the co-existence of high PTEN protein levels and increased Akt 
activation in some cases of renal cell carcinoma (52). These studies raise the question of 
whether the mechanism described herein may extend to solid tumors (17). 
We further reported that the intracellular levels of H2O2 are significantly upregulated in 
primary T-ALL cells and presented evidence indicating that high ROS levels can lead to 
constitutive oxidation and inactivation of a PTEN pool in leukemia T-cells. Although 
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PTEN oxidation is known to be reversible, it appears to significantly contribute to T-ALL 
cell viability, since the use of β-ME that reverted endogenous oxidation/inactivation of 
PTEN also promoted leukemia cell death. This is in accord with previous observations 
that minor alterations in the pool of oxidized PTEN can significantly impact cellular 
function (53). Future studies should identify the origin of high ROS in T-ALL. Genes 
involved in redox regulation, including thioxiredoxin, peroredoxin and manganese 
superoxide dismutase affect ROS levels and may thereby regulate PTEN (18, 32) but 
their status in T-cell leukemia is unknown. The Akt substrates FOXO transcription 
factors were shown to downregulate ROS levels (54, 55), and FOXO1/3/4 full knockout 
mice develop thymic lymphomas (56). These findings may suggest the existence of a 
positive feedback loop involving ROS and PI3K/Akt activation in T-ALL. However, we 
did not find evidence that inhibition of PI3K-mediated signaling affected ROS levels in 
T-ALL cells (Supplemental Figure 19). Hence, the genetic source of high ROS affecting 
PTEN function in T-ALL remains to be identified. Overall, our data suggest that ROS-
dependent oxidation and CK2-mediated phosphorylation of PTEN contribute to 
PI3K/Akt pathway hyperactivation and viability of T-ALL cells. Evidently, although we 
provide clear evidence that high ROS levels and CK2 expression and activity act upon 
PI3K/Akt signaling pathway largely by regulating PTEN, we cannot exclude that in some 
T-ALL cases they may also act via PTEN-independent mechanisms (Figure 7). 
Moreover, although PI3K/Akt pathway hyperactivation in the majority of the PTEN-
positive specimens analyzed can be explained by at least one of the mechanisms we 
reported (Supplementary Figure 20), it is conceivable that other posttranslational PTEN 
modifications, orchestrated by different regulators, may contribute to inactivation of 
PTEN in T-ALL. 
Genetic lesions could be implicated in hyperactivation of PI3K/Akt without PTEN 
deletion in T-ALL. For instance PTEN gene alterations could occur, leading to functional 
inactivation without affecting protein stability. This possibility is highly improbable, 
since no PTEN mutations were found in any of the PTEN-expressing samples analyzed. 
PI3K amplifications and mutations in hematopoietic/lymphoid cancers are very rare (33, 
57), and thus unlikely to justify the very high frequency of PI3K pathway activation that 
we found in T-ALL. In contrast, Notch1 activating mutations are common, occurring in 
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roughly 50% of T-ALL cases (58). Notch1 ectopic expression in Jurkat cells upregulates 
PI3K and Akt activity (59), suggesting a possible link between the two pathways in T-
cell leukemia. In agreement, a recent study using T-ALL cell lines showed that 
mutational deletion of PTEN induces resistance to Notch1 inhibition and that Notch 
signaling via Hes1 mediates repression of PTEN transcription (39). However, most 
primary T-ALL samples express abundant, unmutated PTEN. One possible explanation 
for this discrepancy is that the Notch target gene MYC, which was shown to 
transcriptionally upregulate PTEN (39), may counterbalance the effect of Hes1 in 
primary leukemia cells while not being able to do so in cell lines. Alternatively, Notch-
mediated transcriptional downregulation of PTEN may be complemented at the protein 
level by CK2-mediated PTEN stabilization. In any case, a higher level of complexity 
appears to exist in the integration of signals regulating PTEN in primary leukemia cells 
compared to T-ALL cell lines. Regardless of the underlying mechanism, we showed that 
dependence on PI3K/Akt pathway hyperactivation could be used to selectively target the 
malignant cells without affecting their normal counterparts (Supplemental Figure 21). 
Strikingly, T-ALL samples with normal levels of PTEN expression, phosphorylation and 
PI3K/Akt activation were insensitive to LY294002 treatment, whereas all the remaining 
PTEN-expressing samples tested that showed PI3K/Akt pathway hyperactivation were 
clearly affected. We propose that evaluation of the activation status of PI3K/Akt 
signaling pathway at diagnosis could be used to determine the end-point of different 
mechanisms that affect PTEN function, which are not restricted to gene mutations and 
deletions affecting PTEN expression. This could be easily performed by flow cytometry 
analysis of Akt and GSK3 phosphorylation in patient samples, against a panel of known 
PI3K/Akt activation-negative cell lines. Such simple evaluation should allow for a more 
accurate assessment of the clinical impact of constitutive PI3K/Akt activation on disease 
prognosis, treatment response and patient survival. 
Overall, we showed that PTEN inactivation is not necessarily synonymous with PTEN 
deletion in tumor cells. Primary T-cell leukemias frequently present high levels of 
PI3K/Akt activation as a result of posttranslational, non-deletional, inactivation of PTEN 
by CK2-mediated phosphorylation and ROS-dependent oxidation. Importantly, our 
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studies indicate that combinations of PI3K pathway inhibitors with CK2 antagonists or 
ROS scavengers may be therapeutically beneficial in T-ALL.  
 
 
 
Figure 7. Model for CK2 and ROS-mediated activation of PI3K/Akt signaling pathway in primary T-
ALL. By as yet unknown mechanisms CK2 is overexpressed and hyperactivated in T-ALL cells. Likewise, 
ROS intracellular levels are clearly elevated. These two phenomena lead to posttranslational, non-
deletional, inactivation of PTEN thereby contributing to constitutive hyperactivation of PI3K/Akt signaling 
pathway in leukemia cells. Previous studies suggest that CK2 and ROS may also mediate PTEN-
independent activation of PI3K/Akt in T-ALL cell lines.  
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Table 1. Immunophenotype, classification according to the stage of differentiation, PTEN-PI3K/Akt status, and CK2 and ROS levels of T-ALL patient samples. 
Surface markers 
 
Stage of differentiation / 
Classification  
PTEN and PI3K/Akt status 
 
CK2 and ROS 
levels T-ALL 
# CD1 
CD2 CD5 CD7 CD3   CD4 CD8   Uckun et al.:   EGIL:   PI3K/Akt 
activation 
PTEN protein PTEN mRNA PTEN mutations 
PTEN 
phosphorylation   CK2  ROS 
01 - + + + + + +  III Mature TL  IV Mature T-ALL  + - + n.d. n.a.  + + 
02 + + + + + - -  III Mature TL  III Cortical T-ALL  + + + n.d. +  n.d. - 
03 + + + + - + +  II Immature TL  III Cortical T-ALL  + + + n.d. +  n.d. n.d. 
04 - + + + + - +  III Mature TL  IV Mature T-ALL  + + + n.d. +  + + 
05 - + + + - + -  II Immature TL  II Pre-T-ALL  + + + n.d. -  - + 
06 + + + + + - +  III Mature TL  III Cortical T-ALL  + - + n.d. n.a.  n.d. n.d. 
07 + + + + + - -  III Mature TL  III Cortical T-ALL  - + n.d. n.d. +  n.d. + 
08 + - + + - + -  II Immature TL  III Cortical T-ALL  - + n.d. n.d. -  n.d. n.d. 
09 + + + + - - +  II Immature TL  III Cortical T-ALL  n.d. + n.d. n.d. n.d.  n.d. + 
10 + + + + - + +  II Immature TL  III Cortical T-ALL  + + + wt +  + + 
11 n.d. + + + + n.d. n.d.  III Mature TL  III or IV n.d  + + + wt n.d.  n.d. n.d. 
12 + + + + - + -  II Immature TL  II or III Cortical T-ALL  + + + wt +  + - 
13 n.d. + + + + n.d. n.d.  III Mature TL  III or IV n.d  + - + mutated n.a.  n.d. n.d. 
14 n.d. + + + + n.d. n.d.  III Mature TL  III or IV n.d  - + + wt -  n.d. n.d. 
15 + + + + - + +  II Immature TL  III Cortical T-ALL  + + + wt n.d.  n.d. + 
16 n.d. - - + - n.d. n.d.  I Pro-TL  I or III n.d  n.d. + + wt n.d.  n.d. n.d. 
17 n.d. + + + + n.d. n.d.  III Mature TL  III or IV n.d  + + + wt +  n.d. n.d. 
18 - + + + - + +  II Immature TL  II Pre-T-ALL  + + + wt +  n.d. + 
19 + + + + + + +  III Mature TL  III Cortical T-ALL  + + + wt +  + + 
20 n.d. + + + + n.d. n.d.  III Mature TL  III or IV n.d  n.d. - + mutated n.a.  + + 
21 - + + + + + +  III Mature TL  IV Mature T-ALL  n.d. + n.d. wt n.d.  n.d. n.d. 
22 + + + + + + +  III Mature TL  III Cortical T-ALL  + + + wt +  n.d. - 
23 - + + + + - +  III Mature TL  IV Mature T-ALL  + + n.d. n.d. n.d.  + + 
24 - + + + + + -  III Mature TL  IV Mature T-ALL  n.d. + + wt n.d.  n.d. n.d. 
25 - + + + - + -  II Immature TL  II Pre-T-ALL  + + + wt n.d.  + + 
26 - + + + + - +  III Mature TL  IV Mature T-ALL  + + + wt +  + n.d. 
27 - + + + + - +  III Mature TL  IV Mature T-ALL  + - n.d. mutated n.a.  + n.d. 
28 + + + + + + +  III Mature TL  III Cortical T-ALL  n.d. + + wt n.d.  n.d. n.d. 
29 + + + + - - +  II Immature TL  III Cortical T-ALL  + - + n.d. n.a.  n.d. n.d. 
30 + - + + + + +  III Mature TL  III Cortical T-ALL  + + n.d. n.d. n.d.  + + 
               
21/24 
 (87.5%) + 
24/30 
(80.0%) + 
23/23 
(100%) + 
15/18  
 (83.3%) wt 
11/14  
(78.6%) +  
11/12 
 (91.7%) + 
13/16 
(81.3%) + 
                              
3/24 
 (12.5%) - 
6/30 
 (20.0%) - 
0/23   
(0%) - 
3/18 
 (16.7%) mut 
3/14     
(21.4%) -   
1/12  
(8.3%) - 
3/16 
(18.7%) - 
 
 Table 1. Immunophenotype, classification according to the stage of differentiation, PTEN-PI3K/Akt status, and CK2 and ROS levels of T-ALL 
patient samples. 
 
T-ALL maturation stages were defined as described by Uckun et al. (60): Stage I (Pro-TL): CD7+ CD2- CD3-; stage II (Immature TL): CD7+ (CD2 and/or 
CD5)+; Stage III (mature TL): CD7+ CD2+ CD5+ CD3+; and by the EGIL (61): Stage I (pro-T-ALL): CD7+ only; Stage II (pre-T-ALL): CD7+ (CD2 
and/or CD5 and/or CD8)+; Stage III (cortical T-ALL): CD1a+; Stage IV (mature T-ALL): CD3+ CD1a-. Patients were considered positive for a marker if > 
30% of the blasts were positive as compared to an irrelevant isotypic control. PI3K/Akt signaling pathway activation status was considered positive when at 
least one pathway member (Akt, GSK-3β and FOXO3α) showed increased levels of phosphorylation by immunoblot analysis as compared to a panel of at 
least two normal thymocyte samples. PTEN and CK2 protein expression, and PTEN phosphorylation were determined by immunoblot. PTEN mRNA 
expression was determined by semi-quantitative RT-PCR and/or quantitative real-time PCR. ROS levels were determined by flow cytometry after staining 
with DCF-DA. Leukemia samples were denoted as positive for PTEN phosphorylation, CK2 expression and ROS when presenting levels above the panel of 
normal control thymocytes. n.d. – not determined. n.a. – not applicable.  
  
Table 2. Alterations in PTEN gene coding sequence of PTEN protein-negative patients.  
T-ALL# PTEN protein 
PTEN 
mRNA Exon Nucleotide change Predicted protein change 
      
755-87 hom_del (ATATCAAAGTAGAGTTCTTCCACAAACAGAACA) 252-63 del (DIKVEFFHKQNK) 
13 - + 7 
755-60 hom_ins (CGAAAG) 252-4 ins (AKE) 
      
2-13 het_del (TGACAGCCATCA) 
20 - + 1 
2-15 het_ins (GGTTCTTTGGGCTG) 
1-34 del (MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIA) 
Frameshift, stop at 242 
   7 697 het_ins (A) 
233-41 ins (TTGRQVHVL) 
      
Frameshift, stop at 260 
27 - n.d. 7 700-710 hom_ins (ACCTTACCTTC) 
234-59 ins (SPLPSGKTSSCTLSSLSRYLCVVISK) 
            
      
 
hom_del, homozygous deletion; hom_ins, homozygous insertion; het_del, heterozygous deletion; het_ins, heterozygous insertion; 
ins, insertion; del, deletion. 
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2.6. Supplementary data 
 
(Supplementary Table; Supplementary Figures and legends S1-S21) 
 
Table S1. Primers used for PTEN amplification and sequencing 
 
 
 
 
 
 
 
 
Forward and reverse primers used for PCR amplification and sequencing of each indicated PTEN exon. 
One additional primer for sequence analysis of the reverse strand of exon 8 was also synthesized: 
AACTTGTCAAGCAAGTTCTTC. 
 
 
 
Figure S1. Akt levels are similar in primary T-ALL samples with or without activation of PI3K/Akt 
signaling pathway and in normal thymocytes. (A) Primary T-ALL cells and thymocytes were analyzed 
for Akt expression by immunoblot. Patient samples indicated in red (T-ALL#07 and T-ALL#08) display 
low levels of  PI3K/Akt signaling pathway activation, comparable to those of normal thymocytes (Figure 
5E and Table 1), whereas samples in black (T-ALL#01 and T-ALL#04) show PI3K/Akt pathway 
hyperactivation (Figure 1A). 
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Figure S2. Hyperactivation of PI3K/Akt pathway in T-ALL cell lines. Cell lysates of normal human 
thymocytes or PTEN-positive (TAIL7, HPB-ALL) and PTEN-negative (MOLT4, Jurkat) T-ALL cell 
lines were analyzed by immunoblotting with the indicated antibodies. 
 
 
Figure S3. Isolated normal T-cell precursor subpopulations display lower levels of PI3K/Akt 
signaling pathway activation than their malignant immunophenotypical equivalents. (A) Simplified 
scheme of normal T-cell development in humans and total number and percentage of primary T-ALL 
cases analyzed with corresponding immunophenotype. The most common T-ALL phenotypes are 
indicated in bold (TP and SP8). (B) Normal thymocytes were stained for CD3, CD4 and CD8, and 
CD3+CD4+CD8+ (TP), and CD3+CD4-CD8+ (SP8) subpopulations were isolated by FACS (TP: >83%; 
SP8: >96% purity) and immediately lysed for immunoblot analysis of phosphorylated Akt and GSK3β. 
Primary T-ALL samples with equivalent immunophenotype were subjected to the same procedure.  
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Figure S4. Major normal T-cell precursor subpopulations exhibit similar PIP3 levels that are lower 
than those of primary T-ALL cells. (A) Normal thymocytes were stained for CD3, CD4 and CD8 and 
subsequently assessed for PIP3 levels using an anti-PIP3-specific antibody by flow cytometry analysis 
within the gated subpopulations: TN, CD3-CD4-CD8-; ISP, CD3-CD4+CD8-; DP, CD3-CD4+CD8+; 
TP, CD3+CD4+CD8+; SP4, CD3+CD4+CD8-; SP8, CD3+CD4-CD8+. One representative thymus out of 
six analyzed is shown. Values indicate PIP3 mean intensity of fluorescence for each subpopulation. (B) 
Four primary T-ALL samples were subjected to the same procedure and analyzed at the same time. T-
ALL were ISP (n=2), TP (n=1) and SP8 (n=1). Columns indicate average PIP3 MIF ± sem for each 
thymic subpopulation (n=5) and T-ALL cells (n=4). One-way ANOVA statistical analysis with 
Bonferroni’s correction showed that none of the thymic subpopulations differed from each other (P>0.05 
for all comparisons), but each and every normal thymic subset was significantly different from the T-ALL 
group (P<0.001 for DN, ISP or SP8 vs T-ALL; P<0.01 for DP, TP or SP4 vs T-ALL).  
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Figure S5. Normal T-cell precursor subpopulations express similar PTEN protein levels. (A,B) Flow 
cytometry analysis of PTEN expression was initially calibrated using two T-ALL cell lines whose PTEN 
expression levels were already known: Jurkat (A) are PTEN-null, whereas TAIL7 (B) display PTEN 
levels similar to most primary T-ALL cells (panel E in this figure, Figure 2A, and data not shown). 
Values indicate PTEN mean intensity of fluorescence (MIF). (C) Normal thymocytes were stained for 
CD4 and CD8 and the four major thymic T-cell precursor subpopulations evaluated for PTEN protein 
expression by flow cytometry analysis. PTEN expression within gated CD4-CD8- (DN), CD4+CD8+ 
(DP), CD4+CD8- (SP4) and CD4-CD8+ (SP8) subpopulations is indicated by different histogram colors. 
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Corresponding negative controls (secondary antibody only) are denoted by the same colors (lighter 
histograms). Values indicate PTEN MIF within each subpopulation. One representative thymus 
(THY#24) is shown out of three analyzed. (D) PTEN expression within each subpopulation was analyzed 
in three different thymic samples. Differences are not statistically significant (P=0.57; One-way 
ANOVA). TAIL7 and Jurkat PTEN levels are represented as references. (E) To ensure that TAIL7 cells 
are representative of PTEN-positive primary T-ALL samples, PTEN expression was evaluated by 
densitometry analysis after immunoblotting in T-ALL primary cells and cell lines, including TAIL7. 
Black columns: PTEN-negative T-ALL cells; Red columns: PTEN-positive T-ALL cells. (F) A second 
thymic sample (THY#26) is depicted to further illustrate that each thymic subpopulation has higher 
PTEN levels than PTEN-null Jurkat T-ALL cells and lower levels than PTEN-positive TAIL7 T-ALL 
cells. Values indicate PTEN MIF in each thymocyte subpopulation. Jurkat and TAIL7 histograms are the 
same as in panels A and B, respectively, and are overlaid with each thymocyte subpopulation to simplify 
visual comparison. (G) Immunoblot analysis of PTEN expression in CD3+CD4+CD8+ TP and 
CD3+CD4-CD8+ SP8 T-ALL cells and sorted thymocytes. Actin was used as a loading control.  
 
 
 
 
Figure S6. T-ALL cells displaying high levels of phosphorylated PTEN have increased phospho-
PTEN / total PTEN ratio as compared to normal thymocytes. Levels of phosphorylated PTEN (S380) 
and total PTEN were assessed by immunoblot and quantified by densitometry analysis in normal 
thymocytes (n=8), T-ALL primary cells displaying high phospho-PTEN (P-PTEN+, n=10) and T-ALL 
primary cells displaying normal levels of phospho-PTEN (P-PTEN-, n=2). Columns and error bars 
indicate the mean ± sem ratio of phosphorylated PTEN over total PTEN (P-PTEN / PTEN). One-way 
ANOVA statistical analysis with Bonferroni’s correction showed that P-PTEN+ T-ALL cells presented P-
PTEN/PTEN ratios that were significantly higher than those of normal thymocytes (P<0.001) or P-PTEN- 
T-ALL cells (P<0.05). In contrast, P-PTEN/PTEN ratios did not differ significantly in normal thymocytes 
versus P-PTEN- T-ALL cells (P>0.05).  
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Figure S7. Isolated normal T-cell precursor subpopulations express lower CK2 protein levels than 
their malignant immunophenotypical equivalents. Normal thymocytes were stained for CD3, CD4 and 
CD8, and CD3+CD4+CD8+ (TP), and CD3+CD4-CD8+ (SP8) subpopulations were isolated by FACS 
(TP: 83%; SP8: 97% purity) and immediately lysed for immunoblot analysis of CK2α.  Primary T-ALL 
samples with equivalent immunophenotype were subjected to the same procedure.    
 
Figure S8. Downregulation of Akt phosphorylation upon CK2 inhibition using TBB is largely 
dependent on PTEN expression. PTEN-negative T-ALL Jurkat cells stably transfected with either 
PTEN or the empty vector containing a tetracycline response element were cultured with or without 
doxycycline for 24h and subsequently incubated for 2h30 in the presence or absence of 25µM TBB. Cells 
were then lysed and assessed for phospho-Akt, phospho-PTEN and PTEN by immunoblot.    
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Figure S9. PTEN phosphorylation correlates with CK2 expression in PTEN-positive primary T-
ALL cells. (A) Expression of CK2α and phosphorylated PTEN (S380) was analyzed by immunoblot in 
two T-ALL cases with high phospho-PTEN levels (T-ALL#12 and #26) and one with phospho-PTEN 
levels similar to normal thymocytes (T-ALL#05). The two primary T-ALL cases with high phospho-
PTEN levels overexpressed CK2, whereas T-ALL#05 displayed CK2 levels that are similar to normal 
controls. Blots concerning T-ALL#26 are from the same analysis presented in Figure S7. (B) Immunoblot 
analysis of CK2α and phospho-PTEN (S380) in T-ALL was quantified by densitometry, normalized to 
actin loading control and expressed as fold-increase in expression as compared to normal control 
thymocytes. T-ALLs# 04, 10, 12, 19 and 26 presented fold increases ranging from 1.79 to 3.09 (CK2a) 
and from 2.92 to 6.06 (P-PTEN); whereas T-ALL#05 showed similar levels to normal thymocytes (<1.5 
fold increase): 1.28 (CK2α) and from 1.38 (P-PTEN).     
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Figure S10. Normal T-cell precursor subpopulations exhibit lower ROS levels than primary T-ALL 
cells with equivalent immunophenotype. Normal thymocytes were stained for CD3, CD4 and CD8 and 
subsequently assessed for ROS levels with DCF-DA by flow cytometry analysis within gated (A) 
CD3+CD4+CD8+ (TP), (B) CD3+CD4-CD8+ (SP8), (C) CD3-negative, or (D) CD3-positive 
subpopulations. Primary T-ALL cells with the equivalent immunophenotypes were subjected to the same 
procedure and analyzed at the same time. Columns indicate average DCF-DA MIF ± sem for each thymic 
subpopulation and corresponding T-ALL cells.       
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Figure S11. Analysis of modulation of PI3K/Akt signaling by ROS manipulation in additional 
primary T-ALL samples. PTEN-positive primary T-ALL cells were treated for 2h with 0.5 mM β-ME 
(A) or 30 min. with 1 mM H2O2 (B) and levels of phospho-Akt were determined by immunoblot.     
Figure S12. Combination of low doses of the CK2 inhibitor TBB and the antioxidant NAC 
cooperate in inhibiting PI3K/Akt pathway activation. TAIL7 cells were treated for 2h30min with 
12.5 µM TBB, 4mM NAC, or a combination of the two (T+N), and analyzed by immunoblotting.  
 
 
 
 
Figure S13. ROS scavenging using β-ME does not significantly affect CK2 levels in T-ALL cells. T-
ALL cell lines TAIL7 and HPB-ALL were treated with 1mM β-ME for 24h. Expression of CK2α and 
CK2β was evaluated by immunoblot. 
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Figure S14. Isolated normal T-cell precursor subpopulations are not sensitive to PI3K 
pharmacological inhibition, in contrast to their malignant immunophenotypical equivalents. 
Normal thymocytes were stained for CD3, CD4 and CD8, and (A,B) CD3+CD4+CD8+ (TP), (C,D) 
CD3+CD4-CD8+ (SP8) subpopulations were isolated by FACS (TP: >83%; SP8: >90% purity) and 
cultured for 24h in medium alone or with 25µM LY294002 (LY). Primary T-ALL samples with the 
corresponding immunophenotype were cultured under the same conditions. (A,C) Mean (± sem) viability 
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index to control untreated cells. (B,D) Representative AnnexinV / PI dot plots. Values indicate percent 
live cells. Similar results were obtained after 48h of culture and also using 10mM LY294002 (not shown). 
(E,F) Normal CD3- and CD3+ thymocytes were isolated by FACS (both populations: >98% purity) and 
cultured for 24h in medium alone or with 25µM LY294002. Primary CD3-negative and CD3-positive T-
ALL samples (immature and mature T-ALL specimens, respectively, according to the classification by 
Uckun et al. – see Table 1) were cultured under the same conditions. Mean (± sem) viability index of 
CD3-negative (E) and CD3-positive (F) LY-treated to control untreated cells is indicated.  
 
Figure S15. Inhibition of PI3K induces cell death of both PTEN-negative and PTEN-positive T-
ALL cell lines. T-ALL cell lines were cultured for 48h (TAIL7; PTEN-positive) or 24h (MOLT4, CEM; 
PTEN-negative) in the presence or absence of LY (50µM) and percent viability was determined by flow 
cytometry analysis. Columns and error bars indicate mean ± sem of triplicates.  
 
 
Figure S16. Effect of CK2 inhibition or ROS scavenging on viability of T-ALL cells is largely 
dependent on PTEN expression. PTEN-negative T-ALL Jurkat cells stably transfected with a vector 
containing a tetracycline response element driving the expression of PTEN were cultured with (PTEN +) 
or without (PTEN -) doxycycline for 24h and subsequently cultured in medium or with 40µM TBB, 
25µM DRB or 0.1mM b-ME for 48h. Empty vector Tet-on T-ALL Jurkat cells responded to TBB, DRB 
and ROS similarly to PTEN – cells and independently of being treated with or without doxycycline (not 
shown). 
PTEN AND PI3K/Akt REGULATE T-ALL VIABILITY 
 89 
 
 
 
Figure S17. Cooperative effects of combinatorial treatment of HPB-ALL cells with pharmacological 
antagonists of PI3K, CK2 and ROS. (A,B) Inhibition of CK2 and ROS scavenging cooperate in 
inducing T-ALL cell death. HPB-ALL cells were cultured with the indicated concentrations of TBB and 
b-ME (A), TBB and NAC (B) or their combination and viability was assessed at 24h. (C-F) Inhibition of 
PI3K signaling cooperates with inhibition of CK2 and ROS scavenging in inducing T-ALL cell death. 
HPB-ALL cells were cultured with the indicated concentrations of LY294002 (LY) and TBB (C), LY and 
DRB (D), LY and b-ME (E), LY and NAC (F) or their combination and viability was assessed at 24h. 
Percent viability relative to untreated control (vehicle alone) is indicated for each condition (average ± 
sem of duplicates). 
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Figure S18. Cooperative effects of combinatorial treatment of primary T-ALL cells with 
pharmacological antagonists of PI3K, CK2 and ROS. (A,B) Inhibition of CK2 and ROS scavenging 
cooperate in inducing T-ALL cell death. Primary leukemia cells were cultured with the indicated 
concentrations of TBB and b-ME (A), TBB and NAC (B) or their combination and viability was assessed 
at 48h. (C-F) Inhibition of PI3K signaling cooperates with inhibition of CK2 and ROS scavenging in 
inducing T-ALL cell death. Primary leukemia cells were cultured with the indicated concentrations of 
LY294002 (LY) and TBB (C), LY and NAC (D) or their combination and viability was assessed at 48h. 
Percent viability relative to untreated control (vehicle alone) is indicated for each condition. 
Representative results out of six patients analyzed are shown. (E) Summary of results from all patients 
evaluated. Frequency refers to the percentage of primary samples for which cooperative effects were 
observed. Median and Range refer to the 'fold increase' in inhibitory effect of combination in relation the 
most effective single agent. 
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Figure S19. PI3K inhibition does not affect ROS levels in T-ALL cells. T-ALL cell lines TAIL7 (A) 
and HPB-ALL (B), and three different primary T-ALL patient samples (C) were treated with 25µM 
LY294002 (LY) for the indicated time points and intracellular H2O2 levels were analyzed by flow 
cytometry using the ROS-sensitive dye DCF-DA. (D) A proportion of HPB-ALL cells from the same 
experimental setting were lysed and phosphorylation of Akt (P-Akt) was determined by immunoblot to 
confirm that LY was effectively inhibiting PI3K. Cells lines were also treated with 50µM LY with similar 
results (not shown).   
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Figure S20. Percentage of PTEN-expressing PI3K/Akt pathway-‘hyperactivated’ primary T-ALL 
cases concomitantly overexpressing CK2/P-PTEN and/or ROS. (A) Percentage of T-ALL specimens 
with PI3K/Akt pathway hyperactivation was calculated from a total of 24 cases. Percentage of PTEN-
positive T-ALL cases was calculated within those that were classified as displaying PI3K/Akt pathway 
hyperactivation (n=21). In turn, percentage of cases with overexpression of CK2/P-PTEN and/or ROS 
was calculated within those that expressed PTEN (n=16). (B) Detailed distribution of overexpression of 
CK2/P-PTEN and/or ROS within PTEN-expressing PI3K/Akt pathway-‘hyperactivated’ primary T-ALL 
cases. + denotes high levels; - denotes normal levels; n.d. – not determined. Approximate percentages are 
indicated.  
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Figure S21. Summary of conclusions. (A) A minority of primary T-ALL cells lack PTEN protein 
expression as a consequence of PTEN gene alterations, whereas most specimens actually show increased 
PTEN expression that associates with PTEN phosphorylation and inactivation. Oxidation further 
promotes functional downregulation of PTEN activity. PTEN inactivation in leukemia cells contributes to 
constitutive hyperactivation of PI3K/Akt signaling pathway. (B) In contrast to their normal counterparts, 
T-ALL cells are clearly sensitive to inhibition of PI3K, upstream regulators and downstream effectors. 
Hence, specific small molecule inhibitors of PI3K/Akt signaling pathway may be valuable therapeutic 
tools for T-cell leukemia. 
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3.1. Abstract 
Interleukin-7 (IL-7) might play a role in leukemogenesis. IL-7 activates PI3K/Akt 
pathway, thereby mediating viability, proliferation, and growth of T-cell acute 
lymphoblastic leukemia (T-ALL) cells. Reactive oxygen species (ROS) can be 
upregulated by growth factors and are known to regulate proliferation and viability. In 
the present study, we explored the possible involvement of ROS in IL-7-mediated 
viability in T-ALL. We found that IL-7 consistently upregulates ROS levels in a 
PI3K-dependent manner in both primary T-ALL cells and in the T-ALL cell line 
TAIL7. Activation of PI3K/Akt pathway by IL-7 has been shown to induce the 
upregulation of the glucose transporter Glut1 and to augment glucose use in T-ALL 
cells. In turn, high glucose metabolism is associated with increased ROS production. 
Using Phloretin to inhibit Glut function, we demonstrate that IL-7-mediated ROS 
upregulation in T-ALL cells also relies on glucose uptake, suggesting that IL-7 
stimulation ultimately leads to an increase in ROS via PI3K activation and consequent 
increase in glucose metabolism. Importantly, we show that ROS are essential for IL-
7-mediated viability of T-ALL cells. In contrast, exogenous addition of H2O2 does not 
mimic IL-7 and is markedly pro-apoptotic. Although H2O2 leads to JNK 
phosphorylation, H2O2-generated apoptosis is not dependent on JNK activation but 
rather on lysosomal disruption. It is likely that, in contrast to IL-7-induced ROS 
upregulation, non-physiological addition of exogenous H2O2 overcomes a ROS 
threshold above which cell death is induced. Nonetheless, both IL-7 and H2O2 
activate PI3K/Akt pathway. Moreover, pre-treatment with β-mercaptoethanol (βME) 
showed that IL-7-mediated activation of PI3K/Akt signaling pathway is dependent on 
ROS generation, suggesting the existence of a positive feedback loop in which PI3K 
is critical for upregulation of ROS by IL-7 and, in turn, elevated ROS contribute to 
PI3K/Akt activity. Overall, our studies indicate that generation of ROS within the 
context of IL-7-mediated signaling ultimately promotes leukemia T-cell survival and 
suggest that the use of antioxidants may have therapeutic value in T-ALL.  
ROS ARE ESSENTIAL FOR IL-7 MEDIATED VIABILITY IN T-ALL 
100 
3.2. Introduction 
Despite an increasing awareness of the potential importance of exogenous, 
microenvironmental factors for the initiation and progression of hematological 
malignancies, the actual relevance for and regulation of tumorigenesis by particular 
factors remains largely undefined. Nonetheless, several lines of evidence indicate that 
the cytokine IL-7 plays a significant role in T-cell leukemia (1). For instance, in vitro 
studies have shown that IL-7 promotes survival and proliferation of leukemia T-cells 
(2-4) and IL-7 transgenic mice develop lymphoid malignancies (5).  
The phosphoinositide 3-kinase (PI3K) signaling pathway plays a pivotal role in 
controlling key biological processes (including cellular survival, proliferation, growth 
and motility) and is deregulated in numerous human cancers. The pathway is 
characterized by the stimulated production of the second messenger, 
phosphatidylinositol triphosphate (PIP3) by class I PI3K enzymes. PIP3 activates 
downstream signaling through proteins that specifically recognize and bind this lipid 
(6). PI3K/Akt pathway hyperactivation can occur constitutively in BCR-ABL-
expressing cells in CML (7) and in 50% of AML patients independently of N-RAS/K-
RAS and FLT3-ITD mutations (8) or due to PTEN deregulation in T-ALL (9). 
Moreover, PI3K can be activated in response to external stimuli such as insulin, 
growth factors or cytokines (10, 11). Previously, we demonstrated that PI3K 
activation is critical for IL-7-mediated proliferation and viability of T-ALL cells and 
that PI3K is also critical for IL-7-dependent T-ALL cell growth, since it regulates 
Glut1 expression and glucose uptake (3, 4).   
ROS contribute to diverse cellular functions, including proliferation and apoptosis, 
and ultimately are implicated in malignant transformation (12). Primary tumor 
samples of CML (13) and T-ALL (9) display elevated levels of ROS even in the 
absence of external stimuli. Upon ligand binding, a wide variety of receptors (e.g., IL-
3, IL-4, PDGF, TPO, SF, GM-CSF) induce the generation of intracellular ROS such 
as hydrogen peroxide (H2O2) and superoxide (O2-) (14, 15). Importantly, ROS can 
function as second messengers by regulating the expression levels of FOXO (16) and 
NFκB (17) transcription factors or by regulating the activity of many signaling 
molecules, in particular redox-sensitive kinases and phosphatases (18, 19). 
Furthermore, PI3K can be activated upon ROS generation and PTEN is highly 
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sensitive to oxidation (19-21) due to a critical thiol group in the active site of the 
phosphatase (22).  
In this study, we have investigated the potential role of ROS in IL-7-mediated signal 
transduction in T-ALL cells. We observed that ROS levels in T-ALL cells were 
upregulated by IL-7 stimulation, and that IL-7 signaling promoted mitochondrial 
homeostasis and sustained viability in a ROS-dependent manner. Furthermore, ROS 
were critical for IL-7-mediated PI3K activation. Reciprocally, the PI3K/Akt/Glut axis 
was mandatory for IL-7-mediated ROS upregulation in T-ALL cells.  
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3.3. Methods 
Primary samples and T-ALL cell lines. T-ALL cells were obtained from the 
peripheral blood and/or the bone marrow of patients with high leukemia involvement 
(85-100%). Samples were enriched by density centrifugation over Ficoll-Paque (GE 
Healthcare) at 2100 rpm for 15 minutes, washed twice at 1600 rpm for 7 minutes in 
RPMI-1640 (Gibco, Invitrogen Corporation, CA) supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Gibco invitrogen), 1% (v/v) Hepes buffer (Gibco Invitrogen) 
and 1% (v/v) penicillin-streptomycin (Gibco Invitrogen). Informed consent and 
Institutional Review Board approval were obtained for all primary leukemia sample 
collections. The T-ALL cell line TAIL7 shares significant similarities with primary 
leukemia samples (23).  
In vitro culture. Primary T-ALL or TAIL7 cells were cultured in 24-well plates as 
2x106 cells/ml at 37ºC with 5% CO2 in RPMI-1640 supplemented with 1% (v/v) FBS 
(RPMI-1) and: 1) vehicle (control medium); 2) 10ng/ml IL-7 (Peprotech); 3) IL-7 
plus 10µM PI3K-specific inhibitor LY294002 (Calbiochem, San Diego, CA); 4) IL-7 
plus increasing concentrations of βME (Sigma-Aldrich, St Louis, MO, USA); 5) IL-7 
plus increasing concentrations of the glucose transporter specific inhibitor Phloretin 
(Calbiochem); 6) H2O2 (Merck, NJ, USA) increasing doses; 7) 50µM H2O2 plus 
10µM JNK-specific inhibitor SP600125 (Calbiochem); or 7) 100µM or 500µM H2O2 
plus 1mM Deferoxamine (DFO; Sigma-Aldrich). At the indicated time points, cells 
were harvested and processed as indicated below for assessment of viability, 
activation, intracellular ROS levels and mitochondrial membrane potential. TAIL7 
cells were previously starved in RPMI-1 without IL-7 for 3 days. 
Assessment of cell viability. Quantitative determination of viability of the cells after 
culture under different conditions was performed by using an Annexin V-based 
apoptosis detection kit and the manufacturer’s protocol (R&D systems, Flanders, NJ), 
or assessed by cell size (FSC) versus cell complexity (SSC) flow cytometry analysis, 
as described in material and methods of chapter 2. Because activated cells have 
increased size and complexity, activation status was assessed by measuring changes 
in these physical parameters through analysis of FSC versus SSC flow cytometry 
plots gated on the live population. Samples were analyzed using FACSCalibur flow 
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cytometer (Becton-Dickinson, San Jose, CA, USA) and FlowJo (Tree Star, Ashland, 
OR, USA) software. Results were expressed as the percentage of live and activated 
cells.  
Intracellular signaling experiments. For the initial experiments, IL-7-deprived 
TAIL7 cells were washed twice with 1x PBS and incubated for the indicated periods 
at 37ºC with pre-warmed 1x PBS alone (unstimulated), with 50ng/ml of IL-7 or with 
1mM H2O2. In defined experiments, the cells were preincubated in RPMI with 0.5mM 
βME or the corresponding volume of vehicle (H2O) for 2h30, washed and incubated 
for 15minutes at 37ºC with pre-warmed 1x PBS alone or with 50ng/ml IL-7. 
Reactions were stopped by placing samples on ice and adding ice-cold 1x PBS. Cells 
were washed twice with cold 1x PBS and lysed for immunoblotting.  
Immunoblotting. Following the indicated conditions and time intervals, cell lysates 
were prepared in Nonidet P-40 (NP-40) lysis buffer [50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 5 mM EDTA, 1% (v/v) NP-40, 1 mM Na3VO4, 10 mM NaF, 10 mM 
NaPyroph, 1 mM 4-(2-aminoethyl) benzenesulfonyl (AEBSF), 10 µg/ml leupeptin, 10 
µg/ml aprotinin, 1 µg/ml Pepstatin] (chemical reagents were purchased from Sigma-
Adrich), mixed sorely, incubated 15 minutes on ice and centrifuged at 13000 rpm for 
15 minutes at 4°C. After determination of protein concentration with the Bradford 
assay (Bio-Rad) performed according to the manufacturer, equal amounts of protein 
(50µg/sample) were boiled for 5 minutes at 100ºC with sample buffer [187.5mM Tris-
HCl pH6.8; 6% (w/v) SDS; 30% (v/v) glycerol; 150mM DTT; 0.03% (w/v) 
bromophenol blue] diluted to 1x. Proteins were analyzed by 10% sodium-dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were 
transferred by the wet-transfer method to a nitrocellulose membrane (Bio-Rad), and 
immunoblotted with relevant antibodies following standard procedures and antibody-
manufacturer recommendations. Briefly, all western blots were performed in Tris-
buffered saline (TBS; 1x TBS containing 10 mM Tris-HCl pH 8.0, 150 mM NaCl)-
based solutions as follows: upon transference, membranes were washed in 1x TBS, 
blocked for 1 hr at room temperature in 1x TBS/ 0.1% (v/v) Tween-20 (TBS-T)/ 3% 
(w/v) dry-milk, washed twice for 5 minutes and once more for 15 minutes in TBS-T, 
and incubated with each indicated antibody diluted in TBS-T/ 0.2% (w/v) sodium 
azide (NaN3). Antibodies used at dilution 1:1000, were raised against: ZAP70 
(Upstate Biotechnology, Lake Placid, NY), actin (Santa Cruz Biotechnology, Santa 
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Cruz, CA, I-19), P-Akt (S473), P-GSK3β (S9), P-FOXO3a (T32) (Cell Signaling 
Technology, Beverly, MA). Immune complexes were detected with appropriate 
horseradish peroxidase-conjugated secondary antibodies (Promega, Madison, WI) 
anti-rabbit (diluted 1:10000), anti-mouse (1:5000) and anti–goat (1:5000), in 1x TBS-
T/ 3% dry-milk and ECL western blotting detection reagents (Amersham Pharmacia 
Biotech, Piscataway, NJ, USA), as described by the manufacturer. For probing 
different proteins the membrane was either cut according with the specific proteins 
molecular weights (estimated with the resolved full range rainbow marker, Amersham 
Biosciences) or the same membrane was probed once, stripped by incubating with a 
stripping solution [2% (w/v) SDS, 62.5 mM Tris-HCl pH 6.8 and 100mM β-
mercaptoethanol] for 1 hr at 56°C, and reprobed. When indicated, densitometry 
analysis was performed using Image Quant 5.2 software. Each band was analyzed 
with a constant frame and normalized to the respective loading control.  
Intracellular ROS levels. To determine basal ROS levels, cells were washed in 1x 
PBS, incubated with 10µM dichlorofluorescein diacetate (DCF-DA) (Sigma-Aldrich) 
for 30 minutes at 37ºC, washed again, and samples were analyzed by flow cytometry. 
Results were expressed as mean intensity of fluorescence (MIF). 
Mitochondrial membrane potential. To determine mitochondrial membrane 
potential, TAIL7 cells were harvested, incubated with 100nM tetramethylrhodamine, 
ethyl ester, perchlorate (TMRE) (Sigma-Aldrich) for 15 minutes at 37ºC, and 
analyzed by flow cytometry. Results were expressed as MIF. 
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3.4. Results 
3.4.1. IL-7 upregulates ROS levels in T-ALL cells. 
Elevated levels of ROS, and down-regulation of ROS scavengers and antioxidant 
enzymes were reported to be associated with cancer (24). As reported in Chapter 2, 
we found that primary T-ALL cells had higher intracellular ROS levels than normal 
thymocytes. Moreover, our results indicated that elevated ROS are important for 
leukemia maintenance. Since we had previously demonstrated that IL-7 is critical for 
expansion and viability of T-ALL cells in vitro (4), we asked whether ROS levels 
could be regulated in malignant cells through IL-7 receptor activation. We cultured 
the IL-7-dependent T-ALL cell line, TAIL7 with IL-7 (10ng/ml) or in medium alone 
for 72h and observed that IL-7-mediated signaling can further upregulate the levels of 
intracellular ROS (Figure 1A). To demonstrate that IL-7 signals specifically via the 
IL-7R to induce the upregulation of ROS in T-ALL cells, we cultured primary T-ALL 
samples with or without IL-7Rα expression in medium alone or with IL-7. We 
observed that, IL-7Rα (+) samples (e.g., T-ALL#64) increased endogenous ROS 
levels in the presence of IL-7 while primary T-ALL samples (e.g., T-ALL#ANP) 
lacking IL-7Rα expression did not alter the levels of intracellular ROS upon IL-7 
culture (Figure 1B and data not shown). This suggests that IL-7 upregulates 
endogenous ROS levels in T-ALL cells through IL-7Rα activation. 
 
Figure 1. IL-7 upregulates ROS levels in T-ALL cells. IL-7-deprived TAIL7 cells (A), IL-7Rα(+) 
and IL-7Rα(-) primary T-ALL samples (B) were cultured for 72h in medium alone (Med) or with IL-7 
(10ng/ml) and then analyzed by flow cytometry within the live cell population, for intracellular ROS 
levels with DCF-DA staining. Results from flow cytometry analysis were expressed as MIF of viable 
cells. Results from primary T-ALL samples are from one representative experiment of four done. 
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3.4.2. Endogenous upregulation of ROS is essential for IL-7-mediated increase in 
mitochondrial membrane potential and viability of TAIL7 cells. 
We next investigated the role of ROS in the modulation of IL-7-mediated functions 
using the ROS scavenger βME. As shown in Figure 2A, the increase in ROS levels 
observed after 72h of culture with IL-7 was completely abrogated by addition of 
βME. We therefore examined whether IL-7-mediated mitochondrial homeostasis and 
viability of T-ALL cells could be dependent on ROS generation. Mitochondrial 
homeostasis can be evaluated by measuring mitochondrial membrane potential using 
the potentiometric dye TMRE. Analysis of the whole cell population of TAIL7 cells 
by flow cytometry demonstrated that βME completely abrogated IL-7-mediated 
upregulation of mitochondrial membrane potential (Figure 2B). Because 
mitochondrial homeostasis is an early event in IL-7-mediated regulation of viability 
of T-ALL cells (4), we next investigated whether ROS upregulation could also 
contribute to the viability effect of IL-7 in the leukemic T cells. We observed that 
βME completely inhibited the viability of IL-7-cultured TAIL7 cells (Figure 2C). 
These results show that upregulation of intracellular ROS plays is critical for IL-7-
mediated mitochondrial homeostasis, and viability of TAIL7 cells. 
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Figure 2. Endogenous upregulation of ROS is essential for IL-7-mediated increase in 
mitochondrial membrane potential and viability of TAIL7 cells. IL-7-deprived TAIL7 cells were 
cultured in medium alone or in the presence of 10ng/ml IL-7, with or without 0.5mM βME, and 
analyzed at 72h of culture. (A) Cells were stained with the redox sensitive dye DCF-DA for 15 minutes 
at 37ºC, and intracellular ROS were determined by flow cytometry analysis within the live population. 
Results were expressed as MIF. (B) Cells were stained with 100nM TMRE for 15 minutes at 37ºC and 
mitochondrial membrane potential was determined by flow cytometry analysis. Results were expressed 
as the MIF of total population. (C) Cell viability was analyzed by flow cytometry analysis, using FSC 
and SSC discrimination. Results were expressed as the percentage of viable cells. Results represent at 
least 3 independent experiments. 
 
3.4.3. Exogenous H2O2 stimulation induces apoptosis of TAIL7 in a 
concentration-dependent manner. 
The results obtained from the analysis of DCF-DA oxidation (Figure 1 and 2A) 
suggested that hydrogen peroxide (H2O2) or some derivative thereof are upregulated 
upon IL-7 stimulation and crucial for T-ALL cells viability. Thus, we evaluated 
whether exogenous H2O2 stimulation could mimic IL-7 functional effects in T-ALL 
cells. We stimulated TAIL7 cells with increasing doses of H2O2 and assessed viability 
at 72h of culture by Annexin V-FITC and propidium iodide staining followed by flow 
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cytometry analysis. Our data revealed that high concentrations of H2O2 induced 
apoptosis whereas low doses of H2O2 showed no effect (Figure 3). This suggests that 
either H2O2 is not the oxidative species responsible for the effect promoted by IL-7 in 
T-ALL cells or that the bolus delivery of exogenous H2O2 might not accurately 
reproduce the upregulation in H2O2 under physiological conditions of growth factor 
stimulation. 
 
 
Figure 3. Exogenous H2O2 stimulation induces apoptosis of TAIL7 cells in a concentration 
dependent manner. TAIL7 cells were cultured either alone or with increasing concentrations of H2O2 
as indicated. After 72h of culture, cells were stained with Annexin V-FITC and propidium iodide (PI) 
and viability was determined by flow cytometry. Results were expressed as the percentage of viable 
cells (Annexin V negative and PI negative population). Results represent three independent 
experiments. 
 
3.4.4. IL-7 and H2O2 induce the activation of partially overlapping signaling 
pathways in TAIL7 cells. 
Recently, several studies have reported H2O2 as a second messenger molecule in T-
cell signaling (25). To understand the discrepancy between H2O2 and IL-7 treatment 
on T-ALL cell viability, we investigated which signaling pathways are activated by 
H2O2 in T-ALL cells. We stimulated cytokine-deprived TAIL7 cells with 1mM H2O2 
for 15 and 30 minutes and compared with IL-7 (50ng/ml) stimulation. Protein 
phosphorylation was assessed by western blot. As shown in Figure 4, phosphorylation 
of Akt at S473, necessary for Akt kinase full activation, occurred within 15 minutes 
both with H2O2 and IL-7 stimulation. GSK3 and FOXOs, which are direct Akt 
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downstream targets, were phosphorylated by both stimuli with similar kinetics. These 
results suggest that H2O2, similarly to IL-7, induced PI3K pathway activation with 
phosphorylation of Akt and consequent inhibitory phosphorylation of GSK3β and 
FOXO3a. STAT5 phosphorylation and consequent activation has been previously 
demonstrated upon IL-7 stimulation in both normal and malignant T cells (23, 26, 
27). We confirmed these observations in our present study, since IL-7 induced clear 
phosphorylation of STAT5 (Figure 4). In contrast, although H2O2 has been reported to 
activate members of the STAT family of transcription factors (28), it failed to activate 
STAT5a/b in TAIL7 cells (Figure 4). H2O2 has been described as an activator of 
stress-activated MAPK signaling pathways. In accordance, we observed the ability of 
H2O2, but not IL-7, to phosphorylate and activate JNK in TAIL7 cells when exposed 
to lethal concentrations of this oxidative species (1mM H2O2). Our results suggest that 
IL-7-mediated signals activate specifically pro-survival pathways whereas exogenous 
H2O2 triggers both pro-survival and pro-apoptotic pathways.  
 
Figure 4. IL-7 and H2O2 induce the activation of partially overlapping signaling pathways. IL-7-
deprived TAIL7 cells were stimulated with 50ng/ml of IL-7 or 1mM H2O2 for the indicated periods. 
Cell lysates were resolved with 10% SDS-PAGE and immunoblotted with the indicated antibodies. 
Levels of phosphorylated Akt, GSK-3β, Foxo3a and JNK were analyzed by using antibodies that 
specifically recognize S473-phosphorylated Akt (p-Akt), S9-phosphorylated GSK3β (p-GSK3β, S256-
phosphorylated FOXO1/FOXO3a (p-FOXO1/FOXO3a), and T183/Y185-phosphorylated JNK (p-
JNK), respectively. Levels of phosphorylated STAT5 were detected with an antibody that reacts with 
Y694/Y699-dual-phosphorylated STAT5a and STAT5b (p-STAT5a/b). Blots were reprobed with actin 
to confirm even protein loading. Results representative of three independent experiments are shown. 
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3.4.5. H2O2 stimulation induces cell death of TAIL7 cells independently of JNK 
pathway, but dependent on lysossomal disruption. 
Since H2O2 specifically activates the pro-apoptotic JNK pathway and bolus addition 
induces apoptosis of TAIL7 cells, we next determined whether H2O2-induced cell 
death depended on JNK pathway activation. We specifically abrogated JNK pathway 
with the small molecule inhibitor SP600125. Surprisingly, the JNK inhibitor 
potentiated H2O2-induced cell death rather then reverting it (Figure 5A and data not 
shown). Since the dose used (10µM) has not been reported to significantly associate 
with unspecific effects on other kinases, this suggests that JNK activation might be 
involved in diminishing apoptosis of T-ALL cells induced by exogenous H2O2. 
Although uncommon, a pro-survival role for JNK is not unprecedented (29). 
Similarly, blockade of PI3K pathway using LY294002 further increased death of 
H2O2-treated cells, suggesting that H2O2-mediated PI3K pathway activation 
contributes to cell viability (Figure 5A). It has been demonstrated that H2O2 
stimulation induces apoptosis of Jurkat cells via lysosomal disruption (30). Based on 
this evidence, we investigated whether lysosome disruption could be involved in cell 
death mediated by H2O2 in our T-ALL cell line. For this purposed, we prevented 
lysosomal disruption using deferoxamine (DFO), and found that DFO significantly 
reverted H2O2-induced death of TAIL7 cells (Figure 5B). Our data indicate that 
lysosomal disruption, rather than the stress-activated JNK pathway, is involved in 
promoting T-ALL cell death upon bolus H2O2 stimulation. 
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Figure 5. H2O2 stimulation induces cell death of TAIL7 cells independently of JNK pathway, but 
dependent on lysossomal disruption. (A) TAIL7 cells were cultured in medium alone or with 50µM 
H2O2, either alone or in the presence of 10µM SP600125 (H2O2+SP) or 10µM LY294002 (H2O2+LY) 
and analyzed at 72h of culture. Cell viability was analyzed by flow cytometry using FSC and SSC 
discrimination. Results were expressed as the percentage of viable cells. Results represent three 
independent experiments. (B) TAIL7 cells were pretreated with 1mM DFO for 30 minutes at 37ºC. 
Cells were washed and incubated for 1 hour at 37ºC with 100µM H2O2 or 500µM H2O2, either alone or 
in the presence of 1mM DFO (H2O2+DFO). We next washed out the stimuli and inhibitors and 
analyzed at 48h of culture. Viability was analyzed by FACS using FSC and SSC discrimination. 
Results were expressed as the percentage of viable cells. Results represent three independent 
experiments. 
 
3.4.6. IL-7-mediated upregulation of ROS is PI3K-dependent and necessary for 
Akt phosphorylation. 
Further analysis of the requirement of ROS for IL-7–stimulated signal transduction 
focused upon the PI3K pathway, which we showed to be activated by both exogenous 
(Figure 4) and endogenously generated (Chapter 2) ROS. We pre-treated IL-7-
deprived TAIL7 cells with 0.5mM βME for 2h30 prior to IL-7 stimulation. As shown 
in Figure 6A, βME abrogated IL-7-dependent phosphorylation of Akt, without 
affecting STAT5a/b phosphorylation. Thus, IL-7–stimulated Akt phosphorylation 
appears to selectively require the participation of ROS in T-ALL cells.  
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Figure 6 IL-7-mediated upregulation of ROS is PI3K-dependent and necessary for Akt 
phosphorylation. (A) IL-7-deprived TAIL7 cells were pre-treated for 2h30 with 0.5mM βME or with 
vehicle and stimulated for 15 minutes without or with 50ng/ml of IL-7. Cell lysates were resolved with 
10% SDS-PAGE and immunoblotted with the indicated antibodies. Levels of phosphorylated Akt, 
were analyzed by using antibodies that specifically recognize S473-phosphorylated Akt (P-Akt) and 
levels of phosphorylated STAT5 were detected with an antibody that reacts with Y694/Y699 dual-
phosphorylated STAT5a and STAT5b (P-STAT5a/b). Blots were reprobed with actin to confirm even 
protein loading. (B) IL-7-deprived TAIL7 cells were cultured in medium alone or with 10ng/ml of IL-
7, either alone or in the presence of 10µM LY294002 (IL-7+LY) for 72h. Intracellular ROS were 
determined by FACS analysis. Results were expressed as the MIF and represent at least 3 independent 
experiments. 
Previous studies demonstrated that constitutive activation of PI3K/Akt pathway in 
leukemia cells can lead to the upregulation of endogenous ROS (7). Hence, we next 
asked whether IL-7-mediated PI3K activation could also contribute to ROS 
upregulation in T-ALL cells. TAIL7 cells were cultured for 72h in the presence or 
absence of IL-7, with or without the PI3K specific inhibitor LY294002. PI3K 
pathway inhibition completely abrogated IL-7-mediated elevation of intracellular 
ROS levels (Figure 6B). These results suggest the existence of a positive interplay 
between ROS and PI3K/Akt pathway within the context of IL-7-mediated signaling in 
T-ALL, in which ROS are essential for full activation of PI3K/Akt pathway and, in 
turn, PI3K/Akt pathway activity is critical for the upregulation of ROS.  
 
3.4.7. Glucose transporter inhibition abrogates IL-7-mediated upregulation of 
intracellular ROS and viability in TAIL7 cells. 
We next sought to dissect how increased IL-7-mediated PI3K/Akt pathway activation 
might lead to upregulation of ROS in T-ALL cells. It has been extensively described 
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that intracellular ROS are a consequence of augmented cellular metabolism (7), 
including glucose metabolism. IL-7 increases the expression of the glucose 
transporter Glut1, providing the machinery for nutrient use by T cells, in a PI3K-
dependent manner (4, 7, 31). We therefore asked whether glucose transporter activity 
would regulate IL-7-mediated increase in intracellular ROS. TAIL7 cells were 
analyzed for ROS levels and viability by flow cytometry after 72h of culture with IL-
7 and 50µM of the glucose transporter specific inhibitor, Phloretin. We observed that 
abrogation of Glut function prevented IL-7-mediated increase in intracellular ROS 
(Figure 7A) and in the percentage of viable cells (Figure 7B). These results suggest 
that increased metabolism due to augmented glucose transport is a mechanism critical 
for IL-7-mediated upregulation of intracellular ROS levels in T-ALL cells.  
 
 
Figure 7. Glucose transporter inhibition abrogates IL-7-mediated upregulation of intracellular 
ROS and viability in TAIL7 cells. IL-7-deprived TAIL7 cells were cultured in medium alone or with 
10ng/ml of IL-7, either alone or in the presence of 50µM Phloretin (IL-7 + Pht) and analyzed at 72h of 
culture. (A) Cells were stained with the redox-sensitive dye DCF-DA and intracellular ROS were 
determined by flow cytometry analysis within the live population. Results were expressed as MIF. (B) 
Cell viability was determined by FACS analysis of FSC and SSC. Results were expressed as the 
percentage of viable cells. Results represent at least three independent experiments. 
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3.5. Discussion 
Despite the increasing awareness of the importance of studying the complexity of 
tumors, including the interplay between the cancer cell and the full spectrum of 
elements that constitute the malignant milieu, the current knowledge about the 
contribution of microenvironmental factors to tumor formation and progression is still 
far from complete. Others and we have been focusing our attenation on the role of γC 
cytokines in T-cell leukemia, since these are present in the leukemogenic milieu and 
induce the activation of pro-survival and proliferative mechanisms. IL-7 plays a 
critical role in T-ALL biology in vitro by inducing the activation of pro-survival 
molecules such as PI3K. Here, we further explored how IL-7 contributes to T-ALL 
survival in vitro. Although we have previously shown that primary T-ALL cells 
display high levels of ROS, we now demonstrate that IL-7 can further up-regulate 
ROS levels. Most interesting and somewhat surprising is the observation that 
increased intracellular ROS are not associated with cell death. On the contrary, our 
data indicate that ROS are actually mandatory for IL-7-mediated viability of T-ALL 
cells. The use of antioxidants abrogated PI3K activation in T-ALL cells, suggesting 
that ROS contribute, at least partially, to IL-7-mediated signal transduction in T-ALL 
cells. Finally, we showed that PI3K pathway and glucose transporters are critical for 
IL-7 mediated ROS upregulation in T-ALL cells. The identity of the glucose 
transporter(s) involved was not addressed in the present study, although our previous 
work (4) suggests that Glut1 is a likely candidate to participate in IL-7-mediated ROS 
upregulation. A model for the interplay between ROS and PI3K pathway within the 
context of IL-7-mediated signalling in T-ALL is depicted in Figure 8. 
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Figure 8. Model of IL-7-mediated ROS upregulation and PI3K/Akt pathway activation in T-ALL 
cells. In the context of IL-7 signaling in T-ALL, ROS upregulation appears to occur in a PI3K/Akt/Glut 
dependent manner. Elevated ROS may contribute to PI3K/Akt activity in a positive feedback loop, 
indirectly due to PTEN inactivation or through direct activation of PI3K.  
 
ROS levels can be upregulated in malignant cells as a consequence of cell-
autonomous alterations, such as aberrant tyrosine kinase constitutive activation (7) or 
over-expression of oxidases (32). ROS can also be formed in normal and malignant 
cells after a variety of stimuli, including UV-irradiation (33), or cytokines and growth 
factors such as IL-3 (7), PDGF (15), GM-CSF, TPO or SF (14). In this study, we 
showed that the pro-survival cytokine IL-7 induces upregulation of ROS in T-ALL 
cells via binding to IL-7Rα. ROS levels were detected by DCF-DA, which 
preferentially detects H2O2, suggesting that IL-7 upregulates at least this species in T-
ALL. To better understand the significance and origin of high ROS levels in T-ALL 
upon IL-7 signaling further work should include the identification of specific ROS 
involved in IL-7 signaling and the determination of the levels of enzymes that 
metabolize these oxidants. 
Interestingly, high oxidative state in hematopoietic cells can promote apoptosis (34, 
35) or viability (14). Importantly, inhibition of ROS with the antioxidant βME, a 
monothiol reducing agent, affected IL-7-mediated mitochondrial homeostasis and 
viability, indicating that these events occur in a ROS-dependent manner in T-ALL 
cells. However, the pro-survival effects of IL-7 were not mimicked by treatment with 
ROS ARE ESSENTIAL FOR IL-7 MEDIATED VIABILITY IN T-ALL 
116 
H2O2. In our hands, exogenous H2O2 stimulation did not prevent spontaneous 
apoptosis of T-ALL cells. There are at least two possible, non mutually exclusive, 
explanations for this discrepancy. First, it is likely that the bolus addition of high 
concentrations of H2O2 may originate transient but very high doses of intracellular 
ROS that are detrimental to the cell, whereas low concentrations of H2O2 are rapidly 
metabolized and thus insufficient to induce a pro-survival effect. This technical 
limitation may be overcome by ‘steady-state’ addition of H2O2 (36). Despite some 
variability, our preliminary data using this approach suggest that low doses of ‘steady-
state’ administered H2O2 can have an anti-apoptotic effect similar to IL-7 (data not 
shown). Second, because H2O2 is a small and diffusible molecule, it is conceivable 
that its exogenous administration will affect the overall cellular redox state and 
activate multiple signaling pathways (37, 38). In contrast, ROS generated through 
receptor activation will likely alter the redox state locally within specific cellular 
regions (34, 39), therefore acting as second messengers in signaling pathways by 
influencing the redox state and activation of neighbouring proteins (12, 40). 
Irrespectively of the cause, different studies using exogenous H2O2 administration on 
leukemic T cells, have concluded that ROS are effectors of T cell apoptosis (36, 41). 
One of the upstream kinases in the JNK and p38 MAPK cascades is the apoptosis 
signal regulating kinase-1 (ASK-1) that is maintained in an inactive state by binding 
reduced thioredoxin (42). Oxidation of thioredoxin by ROS releases ASK-1, 
permitting its activation and consequent downstream signaling. However, we 
discarded the stress-activating pathway JNK and p38 activation (not shown) as the 
cause of H2O2-induced apoptosis of T-ALL cells, since treatment with specific 
inhibitors of these kinases failed to abrogate apoptosis. On the contrary, our data 
surprisingly suggest that JNK activation by H2O2 constitutes a compensatory 
protective mechanism against ROS-induced apoptosis. Instead, our results using 
TAIL7 T-ALL cells are in accordance with those of Zhao and collaborators, who 
showed that exogenous oxidant-induced apoptosis of Jurkat cells involves relocation 
of lysosomal enzymes to the cytosol and lysosome rupture (30).  
Despite its pro-apoptotic effects, we found that exogenous H2O2 mimics IL-7 in 
inducing the activation of PI3K/Akt pathway. H2O2-induced PI3K activation might 
result from a direct effect of ROS in PI3K activity, since we demonstrated that H2O2-
induced Akt phosphorylation in TAIL7 and HPB-ALL cell lines can be blocked by 
LY294002, a PI3K inhibitor that has a global effect on all PI3K classes and isoforms 
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(9). Other evidences were shown in Qin studies (43) where they report that 
wortmannin inhibited by 75% H2O2-induced PI3K activity. They further suggested 
that at least one of the PI3K p110 catalytic subunits can be activated in a redox 
dependent manner since the studied cells (DT40 cells) lack PTEN. In addition, PI3K 
activation resulted from H2O2-stimulated membrane recruitment of PI3K subunits and 
was independent of H2O2-induced tyrosine phosphorylation of the p110 catalytic 
subunit (43). How H2O2 triggers PI3K membrane recruitment remains unclear. 
Moreover, it has been shown that NO generated ROS species can lead to the 
recruitment of PI3K subunits to the plasma membrane, therefore increasing PI3K 
activity (44). Interestingly PI3K catalytic subunits demonstrate an isoform-specific 
sensitivity to ROS, where p110β and δ induce a ROS-dependent Akt activation versus 
a ROS-independent Akt activation by p110α (44). Therefore, use of p110 isoforms 
specific inhibitors would be necessary to unravel which isoform is critical for H2O2-
induced Akt activation.  
Moreover other studies indicated that an important function of ROS may be to 
modulate the function of phosphatases. Phosphatases contain a critical cysteine 
residue in their active site that is a potential target for redox regulation, and this 
residue must be in the reduced state for full phosphatase activity (45). Lee et al (22) 
proposed that H2O2 production would inactivate the PI3K/Akt pathway negative 
regulator PTEN by oxidation and formation of a disulfide bond between C71 and the 
active site C124. Other studies described that growth factors increase PIP3 levels, not 
only by increasing PI3K activation but also by inactivating a fraction of PTEN 
through endogenous production of cellular oxidants (21, 46). Recently, a similar 
mechanism of intracellular ROS-induced phosphatase, PTP1B, inactivation was 
demonstrated upon IL-4 signaling (39). Future studies are warranted to examine 
whether IL-7-mediated ROS upregulation can induce the oxidation of PTEN and 
thereby affect significantly PTEN activity in T-ALL cells. 
The identity and sub-cellular localization of the molecular machinery responsible for 
IL-7-mediated ROS generation in T-ALL cells remains to be investigated. One 
possible candidate is the NADPH oxidase complex (NADPH/NADP+), which can be 
activated by PIP3-dependent signals (47). In this regard, it is interesting to note that 
PI3K was shown to regulate the phosphorylation of the NADPH oxidase component 
p47phox and the subsequent activation of NADPH oxidase complex (48). Moreover, 
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receptor tyrosine kinase-mediated activation of PI3K results in the recruitment of 
p47phox to the plasma membrane and consequent production of reactive oxygen 
species (49). The involvement of the NADPH oxidase complex in IL-7-induced ROS 
production is all the more interesting because it would implicate the potential co-
localization of PTEN with an oxidant-producing complex, which could result in the 
localized inhibition of PTEN and consequent protection of the PIP3 pool. However, it 
should be taken into account that mitochondrial respiration is the major cellular 
process that produces ROS. Under normal conditions, it is estimated that 
approximately 1–2% of the electrons leak out of mitochondrial electron transport 
chain, forming ROS (50). Kim et al suggested that sustained ROS associated with 
BCR-ABL transformation were linked to the mitochondrial electron transport chain 
(7). We found that IL-7 upregulated ROS levels in TAIL7 cells at late time points 
(e.g. 72h) but did not find evidence of very early ROS upregulation by IL-7 (not 
shown). These observations made us consider the possibility that ROS production was 
a result of increased mitochondrial metabolism associated with IL-7-promoted cell 
growth (4). Glucose metabolism is regulated by glucose uptake, and in hematopoietic 
cells Glut1 is the primary source for intracellular glucose (51). Moreover, we 
previously reported that IL-7 induces glucose uptake and Glut1 upregulation in a 
PI3K-dependent manner in T-ALL cells (4). In the present study, we found that the 
glucose transporter inhibitor, Phloretin, led to a reduction of IL-7 generated ROS 
similar to that observed in cells treated with the PI3K inhibitor, LY294002. This 
suggests that the IL-7-dependent generation of ROS relies mainly on the supply of 
energy in the form of glucose or pyruvate, mediated by a PI3K/Akt/Glut axis. 
Interestingly, it has been shown that the activity of TXNIP, an inhibitory protein of 
thioredoxin, is highly regulated by glucose in a breast cancer cell line (52). It is 
tempting to speculate that TXNIP could play a role in translating increased glucose 
uptake and metabolism into ROS upregulation in IL-7 stimulated T-ALL cells. 
Finally, one relatively direct and simple putative explanation for increased IL-7-
mediated ROS in T-ALL relates to the fact that Akt phosphorylates and inhibits 
FOXO transcription factors. FOXOs are critical negative regulators of oxidative stress 
(53) via transcriptional upregulation of catalase and MnSOD, two enzymes involved 
in the detoxification of ROS (54, 55). When phosphorylated by Akt, FOXOs are 
arrested at the cytoplasm thereby possibly contributing to ROS upregulation in the 
presence of IL-7.  
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A further question that remains to be answered is whether IL-7 induces a rapid and 
transient wave of ROS upon receptor binding. As stated above, we did not detect an 
increase in ROS levels at very early time points of IL-7 treatment (up to one hour; 
data not shown). This may be due to membrane technical limitations of using DCF-
DA and flow cytometry, which perhaps is not sensitive enough to detect minor but 
biologically significant changes in ROS levels, or because localized rather than 
general changes in the overall cellular content of ROS occur upon IL-7 early 
signaling. Alternatively, IL-7 may somehow promote the rapid recruitment of ROS 
already present in the cell for the early activation of PI3K/Akt pathway. 
Taken together, our results indicate that PI3K/Akt pathway and ROS significantly 
crosstalk upon IL-7 signaling in T-ALL cells in vitro. This crosstalk might be relevant 
for expansion of malignant T cells in vivo and may represent an appealing target for 
pharmacological intervention in T-ALL. 
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4.1. Abstract 
Interleukin (IL)-7 is essential for T-cell development. Since IL-7 has a central role in 
promoting cell survival and cell division within the lymphoid lineage, it is not 
surprising that it has also been suggested to be implicated in the pathophysiology of a 
variety of hematological tumors. We have previously demonstrated that IL-7 
promotes viability and proliferation of T-cell acute lymphoblastic leukemia (T-ALL) 
cells in vitro. Here, we addressed whether IL-7 contributes to T-ALL expansion in 
vivo. Because the biological effects of murine IL-7 on human cells remained 
controversial, we first demonstrate that murine IL-7 mimics the function of human IL-
7 in normal and malignant human lymphoid cells. Importantly, TAIL7 cells expand 
specifically in response to endogenous IL-7 produced in a chimeric human-mouse 
fetal thymic organ culture. Then, we transplanted intravenously human IL-7-
responsive (HPB-ALL) and IL-7-dependent (TAIL7) T-ALL cell lines, into 
γCKO/Rag2KO (IL7 WT) and IL-7KO/γCKO/Rag2KO (IL7 KO) mice. IL-7 does not 
affect the engraftment and homing of transplanted cells to the bone marrow (BM), as 
determined by quantification of CFSE-stained TAIL7 cells 6 hours posttransplant. 
However, at later stages, absence of IL-7 clearly slows down leukemia expansion in 
the BM. Moreover, leukemia-associated death is significantly delayed in the absence 
of IL-7. In addition, infiltration of different organs (e.g., spleen, liver, kidney) by T-
ALL cells was more heterogeneous and generally less efficient in IL-7 KO animals. 
Similarly, xenotransplant of primary T-ALL cells induced leukemia more rapidly in 
IL-7 WT than IL-7 KO mice. Leukemia progression in vivo positively correlated with 
Bcl-2 expression and increased viability, as well as with downregulation of p27Kip1 
and augmented cell cycle progression in primary T-ALL cells analyzed ex vivo. 
These results suggest that IL-7 contributes significantly to the progression of human 
T-cell leukemia in vivo, and is a potential target for therapeutic intervention in T-
ALL.  
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4.2. Introduction 
As a pleiotropic cytokine, IL-7 induces trophic and anti-apoptotic responses on 
hematopoietic tissues, particularly lymphocytes (1). On the other hand, there is 
evidence that IL-7 may also partake in leukemia development (2). For example, in 
vitro studies suggest that IL-7 may be an important microenvironmental factor 
supporting T-ALL, since IL-7 promotes survival and proliferation of in vitro cultured 
leukemia T-cells by signaling through PI3K/Akt and JAK-STAT pathways and 
regulating the expression of pro-survival proteins (eg. Bcl-2) and cell cycle inhibitors 
(eg. p27Kip1) (2, 3). In vivo, loss of IL-7 or IL-7R causes immunodeficiency (1), 
whereas overexpression of IL-7 can result in neoplasia. Mouse models with 
transgenic expression of IL-7 show phenotypes ranging from increased levels of T 
and B cells to lymphoproliferation and lymphomas, in addition to dermal lymphoid 
infiltration. (4-6) 
In the present study, we sought to determine the role of IL-7 in the progression of 
human T-cell leukemia in vivo. We first showed that recombinant murine IL-7 (mIL-
7) promoted in vitro survival and proliferation of human T-ALL cells, to the same 
extent as recombinant human IL-7 (hIL-7), thereby contradicting early reports that 
indicated that mIL-7 did not have bioactivity in human lymphoid cells (7). Moreover, 
an anti-mIL-7 blocking antibody abrogated the proliferation of TAIL7 cells in 
chimeric fetal thymic organ cultures (FTOCs). These experiments indicated that 
manipulation of IL-7 using xenotransplant models of human leukemia could be a 
useful tool for the analysis of the role of IL-7 in human leukemia progression in vivo. 
Therefore, we next induced leukemia in immunodeficient IL-7 WT and IL-7 KO mice 
by xenotransplanting T-ALL cell lines, either dependent (TAIL7) or responsive 
(HPB-ALL) to IL-7 and primary T-ALL cells. In all cases, IL-7 WT animals 
developed leukemia symptoms earlier than the IL-7 KO mice. Overall, our data 
indicate that IL-7 accelerated the progression of human leukemia in vivo, and suggest 
that therapeutic approaches abrogating IL-7 function may be efficient in the treatment 
of T-ALL. 
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4.3. Methods 
Cell culture. The IL-7–dependent T-cell line TAIL7 (8, 9) was starved for IL-7, for 
24 hours before the onset of experiments. T-ALL cells were cultured at 37ºC with 5% 
CO2 in RPMI-1640 (Gibco, Invitrogen Corporation, CA) supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Gibco Invitrogen), 1% (v/v) Hepes buffer (Gibco 
Invitrogen) and 1% (v/v) penicillin-streptomycin (Gibco Invitrogen) (RPMI-10), with 
or without 10 ng/mL hIL-7 (R&D Systems, Minneapolis, MN, USA) or 10 ng/mL 
mIL-7 (Peprotech EC, London, UK), for the indicated time points. Where indicated, 
10 µg/mL rabbit anti-mIL-7 or control antiserum (Peprotech EC), was added.  
Proliferation assays. Cells were cultured in flat-bottom 96-well plates as 2x106 
cells/ml at 37ºC with 5% CO2 in RPMI-10 without any cytokine (control condition), 
with 10ng/ml hIL-7 or with 10ng/ml mIL-7 for the indicated time points. Cells were 
incubated with 3H-Thymidine (1µCi/well) for 16 hours prior to harvest. DNA 
synthesis, as measured by 3H-Thymidine incorporation was assessed using a gas 
scintillation counter. Results were expressed as thymidine incorporation in each 
condition in counts per minute (CPM).   
Assessment of viability and activation. Cell viability was examined using an 
apoptosis detection kit, following the manufacturer’s protocol (R&D Systems). 
Briefly, cells were stained with fluorescein isothiocyanate (FITC)-conjugated 
Annexin V and propidium iodide (PI) at room temperature for 15 minutes in the 
appropriate binding buffer and subsequently analyzed by flow cytometry. When 
indicated, cells were surface stained with anti-human CD5-FITC prior to annexin V-
phycoerythrin (PE) staining. Cell activation was measured by flow cytometry based 
on the increased cell size and cell complexity (FSC versus SSC). Percentage of 
‘‘activated’’ cells was calculated by defining a threshold gate that excluded most of 
the bulk, small-sized fraction of live cells. Samples were analyzed using a 
FACSCalibur flow cytometer and CellQuest (Becton-Dickinson, San Jose, CA, USA) 
or FlowJo (Tree Star, Ashland, OR, USA) software. 
Immunoblotting. Equal amounts of protein (50 µg/sample) were analyzed by 10% 
SDS-PAGE, transferred onto nitrocellulose membranes, and immunoblotted with the 
antibodies (all diluted 1:1000): ZAP-70 and p-STAT5 (Upstate, Charlottesville, VA, 
USA); p-Akt (S473) (Cell Signaling Technology, Danvers, MA, USA), p-JAK1/JAK3 
(Y1022/Y1023) (Sigma-Aldrich, St Louis, MO, USA) and p-ERK 1/2 and p27Kip1 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunodetection was performed 
by incubation with horseradish peroxidise-conjugated anti-mouse (1:5000) or anti-
rabbit IgG (1:10,000) (Promega, Madison, WI, USA) and developed by enhanced 
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chemiluminescence (Amersham-Pharmacia, Piscataway, NJ, USA). Blots were 
stripped and reprobed as described in Chapter 2. 
Chimeric fetal thymic organ culture (FTOC). Thymic lobes extracted from d15 
embryos of C57BL/6 mice were depleted of endogenous thymocytes by irradiation 
(3000 rads) and cultured with 105 TAIL7 cells in hanging drops in Terasaki wells. 
After 48 hours, thymic lobes were gently washed and placed on top of 0.8 mm filters 
(Millipore, Billerica, MA, USA) in medium with or without 10 µg/ml rabbit anti-
murine IL-7 antibody (Peprotech EC) or control antibody concentration (day 0 of 
culture). Several lobes were minced at this point to evaluate the number of TAIL7 
cells at the beginning of the FTOC. An average of 1.3x104 cells entered each lobe. 
After 5 days of culture, lobes were minced, and TAIL7 cell viability and number were 
analyzed by flow cytometry. TAIL7 cells were identified using an anti-human CD8 
mAb (BD-Pharmingen, San Jose, CA, USA). 
Mice and xenograft transplants. γCKO/Rag2KO (IL-7 WT) and IL-
7KO/γCKO/Rag2KO (IL-7 KO) mice were originally obtained from the Jackson 
Laboratory (Bar Harbor, Maine, USA) and were subsequently bred, in  a specific 
pathogen-free facility at the National Institute for Medical Research. Mice have a 
mixed background but H-2b MHC haplotype. All animal work was done in 
accordance with the Home Office regulation and local guidelines. All experimental 
mice were used at 6-8 weeks of age at the start of experiments. Mice in each 
experiment were age and sex matched. To assess the role of IL-7 in T-ALL cells in 
vivo, viable TAIL7, HPB-ALL and primary T-ALL cells [0.5-1 x 107 cells/ 250µl of 
IMDM/ 2%(w/v) BSA (IMDM/ BSA)] were injected via the tail vein. Animals were 
monitored daily and sacrificed in a CO2 chamber when moribund or at the indicated 
time points. Bones, spleen, liver and kidneys were collected for flow cytometry and 
histological analysis. We followed the clinical definition of human leukemia, more 
than 20% of malignant cells in the bone marrow, to classify the mice as leukemic 
(10). 
In vivo luciferase assays. For luciferase imaging, mice were injected 
intraperitoneally with luciferin, with the manufacturer's recommended dose of 150 μg 
luciferin g–1 (Caliper Life Sciences, Hopkinton, MA, USA). Mice were anaesthetized 
with 10µl/g (animal body weigh) of 0.012% ketamine (Imalgen; Merial) and 0.16% 
xylazine (Rompun; Bayer, Leverkusen, Germany), then scanned with an IVIS Lumina 
(Caliper Life Sciences). Mice were routinely imaged 7 minutes after luciferin 
injection with 3 minutes exposure and medium binning. For quantitative comparisons, 
we used Living Image software (Caliper Life Sciences) to obtain the total flux 
(photons s–1) over each region of interest – total animal. 
IL-7  ACCELERATES T-ALL IN VIVO  
129 
Blood and organ analysis. Blood was collected at the indicated time points via facial 
vein puncture or cutting the tail edge. All bloods were submitted to red blood cell 
lysis buffer (BD Pharmingen) during 10 minutes at room temperature. Bone marrow 
was extracted by flushing off long bones (tibia and femurs). Small representative 
portions of the collected organs (spleen, liver, kidney) and at least one complete 
femur were preserved in formalin at 4ºC for 24-48h for histological analysis with 
hematoxilin/eosin staining. Spleen, liver and kidneys were mechanically disintegrated 
into single cell suspension. Cell suspensions were stained with PE conjugated mAb 
for human CD2 (Becton Dickson; diluted 1:50) and analyzed using a FACSCalibur 
flow cytometer (Becton Dickinson) and Flowjo (Tree Star) software.  
CFSE labeling. TAIL7 cells were washed and ressuspended in 1x PBS at 
10x106cells/ml. A pre-warmed solution of carboxyfluorescein diacetate succinimidyl 
ester (CFSE) (Sigma-Aldrich) was added to the cell suspension to a final 
concentration of 2µM and incubated for 10 minutes at 37ºC. Cells were washed three 
times in RPMI-10. Finally cells were ressupended at 10x106cells/250µl in IMDM/ 
BSA and injected i.v. into mice. 
Immunophenotype. Cells were immunophenotyped by standard methodology, as 
described in Chapter 2. Briefly, ex vivo cells recovered from FTOCs or bone marrows 
were washed in 1x PBS and incubated with indicated PE or FITC conjugated mAbs, 
for 20-30 minutes at 4ºC. Irrelevant isotype-matched antibodies were used as negative 
controls. Samples were analyzed using a FACSCalibur (Becton-Dickinson) flow 
cytometer and Flowjo (Tree Star) software. 
 
Phosphoprotein staining. Akt and STAT5a/b protein phosphorylation were assessed 
in TAIL7 cells present in bone marrow cell suspensions from both mouse strains by 
intracellular phospho-staining. Cells were either stimulated without or with 50ng/ml 
IL-7 for 15 minutes at 37ºC to evaluate IL-7 capacity to stimulate signaling pathways 
in TAIL7 cells ex vivo; or immediately fixed upon flushing off the bones to evaluate 
the basal levels of Akt and STAT5 phosphorylation. Cells were fixed in 2% (w/v) 
paraformaldehyde for 10 minutes at 37ºC, placed on ice, centrifuged, and 
permeabilized with 1ml of 90% (v/v) ice-cold methanol (Merck, NJ, USA) for 30 
minutes on ice. Fixative and permeabilizing solutions (Ebioscience, San Diego, CA, 
USA) were added to cells while vortexing at medium speed. Cells were washed three 
times in 1x PBS and stained with p-Akt (Cell Signaling; diluted 1: 5) or p-STAT5 a/b 
(Cell Signaling; diluted 1:20) for 1h at room temperature in the dark. Samples were 
washed and acquired on a FACSCalibur flow cytometer (Becton-Dickinson) and 
analyzed with FlowJo (Tree Star) software. Results were expressed as specific mean 
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intensity of fluorescence (MIF), defined as the ratio of MIF of the specific antibody 
stain over the MIF of negative control antibody. 
Intracellular staining. Bcl-2 and Ki-67 protein expression were assessed by 
intracellular staining in primary T-ALL cells collected from bone marrow cell 
suspensions from IL-7 WT and IL-7 KO mice. Cells were immunophenotyped as 
described above using anti-human CD2-PE or CD5-FITC. Cells were fixed in 1x 
Fix/Perm solution (Ebioscience) for 30 minutes at 4ºC, washed in 1x PBS, and 
ressuspended in 1x Permeabilization buffer (Ebioscience) for 10 minutes at 4ºC. 
Samples were divided in two tubes. In the first tube cells were incubated for 30 
minutes at 4ºC either with mouse monoclonal FITC-conjugated anti-Bcl-2 antibody 
(Dako, Glostrup,Denmark; diluted 1:5) or mouse monoclonal PE-conjugated anti-Ki-
67 antibody (Becton-Dickinson; diluted 1:5). In the second tube cells were incubated 
with an irrelevant isotype-matched antibody (diluted 1:100). Samples were washed 
and analyzed by flow cytometry. Results were expressed as the percentage of positive 
cells in comparison to the negative control, and as specific mean intensity of 
fluorescence (MIF). 
Statistical analysis. Log-Rank test and Student’s t-test were used to compare data (p 
< 0.05 was considered significant). 
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4.4. Results 
4.4.1. Murine IL-7 mimics the molecular and functional effects of human IL-7 on 
TAIL7 cells. 
We sought to determine whether mIL-7 has cross-species activity on human cells. We 
first compared the molecular effects of mIL-7 and hIL-7 stimulation in leukemic 
human T cells. The IL-7-dependent pre-T-cell leukemia cell line TAIL7 was 
stimulated with 50ng/mL mIL-7 and hIL-7 for up to 30 minutes and the 
phosphorylation status of critical targets of IL-7 signaling was assessed. Both 
orthologs were equally effective in engaging PI3K-Akt and JAK-STAT pathways and 
in activating mitogen–activated protein kinase kinase/extracellular regulated kinase 
(MEK/ERK) in leukemia T-cells (Figure 1A). This shows that mIL-7 has an identical 
ability to activate the canonical signaling pathways engaged by hIL-7 on human T-
cells. We next compared the activity of mIL-7 to that of hIL-7 on critical functions of 
human T-cells – viability, growth and proliferation. We observed that the orthologs 
have equivalent effects in promoting the survival (Figure 1B) and growth (Figure 1C) 
of TAIL7 cells (Figure 1B). Finally, mIL-7 promoted cell proliferation (Figure 1D), 
even at doses as low as 0.5 ng/ml (data not shown), demonstrating that mIL-7 is 
mitogenic to TAIL7 cells with a potency equivalent that of hIL-7. These studies show 
that the capacity of mIL-7 to engage critical signaling events in human lymphocytes is 
effectively translated into functional effects. 
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Figure 1. Murine IL-7 mimics the molecular and functional effects of human IL-7 on TAIL7 
cells. (A) TAIL7 cells were stimulated with 50ng/mL hIL-7or mIL-7 at 37ºC for the indicated periods. 
Cell lysates were resolved with 10% SDS-page gel electrophoresis and immunoblotted with the 
indicated phosphospecific antibodies. ZAP-70 antibody was used as a load control. Results are 
representative of two independent experiments. (B) Cells were cultured for 96h, stained with Annexin 
V-FITC and propidium iodide, and cell viability was determined by flow cytometry. Boxes display the 
percentage of viable cells for each condition. (C) Cells were evaluated for changes in cell size at 96h, 
as determined by forward (FSC) and side scatter (SSC) flow cytometry analysis of the viable cell 
population. Percentage of “activated” cells was calculated by defining a treshold gate that excluded 
most of the bulk, small-sized population of medium-cultured cells. Results are representative of at least 
three independent experiments. (D) Proliferation was determined at 96h by assessment of 3H-thymidine 
incorporation. Mean + standard error of mean of triplicates are represented. 
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To ascertain the specificity of the activity of mIL-7 on human cells, experiments were 
performed in TAIL7 cells using a neutralizing antibody specific for mIL-7. Anti-mIL-
7, but not the IgG control, inhibited mIL-7-mediated protein phosphorylation (Figure 
2A). Moreover, anti-mIL-7 abolished mIL-7-mediated cell viability while not 
affecting TAIL7 cells cultured in medium alone or, more importantly, the effects of 
hIL-7 (Figure 2B). The thymus is the major IL-7-producing site in the mouse (11) and 
others have shown that human T cell precursors differentiate in murine FTOC (12). 
Hence, mIL-7 endogenously produced by murine stromal cells in the FTOC may also 
affect human T cells. To test this hypothesis, we cultured TAIL7 cells in FTOC with 
or without anti-mIL-7 antibody or irrelevant IgG control. Fetal thymuses from 
C57BL/6 mice were used, because they express high levels of IL-7 (13). To exclude 
possible effects on putative residual murine thymocytes not depleted upon radiation, 
we used an anti-human CD8 mAb, which does not cross-react with mouse CD8, to 
exclusively gate on and analyze the human T-ALL cells. TAIL7 cells cultured for 5 
days in the thymic milieu expanded from an average of 1.3x104 cells to 5.5x104 per 
lobe (Figure 2C). This expansion was inhibited by mIL-7 neutralization, because the 
number of TAIL7 in FTOC treated with anti-mIL-7 antibody was not statistically 
different from the cell number at the beginning of the culture (p=0.11; Student’s t-
test), but it was significantly lower than control antibody-treated cultures (p<0.05). 
Control antibody-treated cultures showed no significant difference as compared to 
medium alone (p=0.19). These data effectively demonstrate that mIL-7 endogenously 
produced in the thymic environment can functionally stimulate human T-ALL cells. 
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Figure 2. Molecular and functional effects of murine IL-7 are specific. (A) Human IL-7-dependent 
TAIL7 cells were pretreated with 10µg/mL anti-mIL-7 or control irrelevant antibody (+IgG) for 30 
minutes and subsequently stimulated with 50ng/mL mIL-7 for 15 minutes. Immunoblot analysis was 
performed with the indicated phosphospecific antibodies and ZAP-70 as load control. (B) TAIL7 cells 
were cultured with or without 10ng/mL hIL-7 or mIL-7, with or without 10µg/mL anti-mIL-7 antibody 
and viability was determined at 72h. Mean + standard error of mean (SEM) are represented, from four 
independent experiments. (C) Chimeric FTOC was performed as described in Material and Methods. 
Total number of viable human cells (TAIL7), identified by an anti-human CD8 monoclonal antibody, 
was determined by flow cytometry after 5 days of culture. Assessment of viable cell number by tripan 
blue exclusion provided similar results (data not shown). Mean + standard error of mean of five 
replicates of FTOC are represented, except for day 0 where eight replicates were analyzed. Statistically 
significant differences (p<0.05; Student’s t test) are indicated by an asterisk. 
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4.4.2. IL-7 accelerates leukemia progression and leukemia–associated death. 
The evidence that both recombinant and thymic endogenously produced mIL-7 are 
bioactive upon human T-ALL cells (14) set the basis for testing the in vivo effects of 
IL-7 on human T-cell leukemia development by comparing the disease progression in 
mice that differ in their capacity to produce IL-7. T-ALL cells were transplanted 
through tail vein injection (i.v.) into IL-7 WT (n=3) and IL-7 KO (n=3) mice (10x106 
viable cells/mouse). Both mouse strains lack B, T and NK cells (9), but differ in the 
endogenous production of IL-7. To evaluate the role of IL-7 in the early organ 
engraftment of malignant cells and progression of leukemia through time, we 
established a system to follow longitudinally the leukemia induced by the IL-7-
responsive, but not IL-7-dependent, T-ALL cell line, HPB-ALL. These cells were 
previously stably transduced with a plasmid expressing luciferase and GFP (data not 
shown). In vivo, we monitored T-ALL infiltration 2 and 5 weeks post-cell transfer, by 
scanning the animals with a charge-coupled-device camera and detecting the 
luminescence resultant from the luciferase/luciferin reaction (Figure 3A). Although 
no luciferase signal was detected 2 weeks post cell transfer (data not shown), at 5 
weeks luciferase signals were stronger and more disseminated to intraperitoneal 
cavity and whole body in IL-7 WT animals, as compared to weak or undetectable 
luciferase signals in the IL-7 KO animals but more focused in the posterior members 
(Figure 3A). Quantification of luciferase intensity showed that IL-7 WT animals 
presented more malignant blasts than the IL-7 KO (Figure 3A). We next culled and 
dissected the animals to analyze the organs and establish the exact sources of the 
luciferase signals. Our analysis indicated that the lungs, spleen, liver, kidneys, ovaries 
(animal II) and bone marrow were infiltrated with HPB-ALL cells (Figure 3B). These 
results were in agreement with the data obtained from flow cytometry analysis of 
different organs using GFP to detect HPB-ALL cells (Figure 3C). Despite the low 
number of animals used, these preliminary results showed that IL-7 WT animals 
displayed higher infiltration of HPB-ALL cells in the lymphoid and non-lymphoid 
organs, and suggested that IL-7 accelerated leukemia progression in vivo.  
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Figure 3. IL-7 contributes to the expansion of HPB-ALL T-ALL cells. IL-7 WT (black n=3) and 
IL-7 KO (red n=3) mice were injected with 10x106 of HPB-ALL-GFP-Luc cells and analyzed 5 weeks 
post-transplantation. (A) Animals were ventrally scanned with an IVIS Lumina for total body and 
photograph was overlayed with luciferase signal for each animal. Total body luminescence (total flux) 
was measured by Living Image software, 7 minutes after intraperitoneal injection of 150µg luciferin g-1 
with a 3 minutes exposure with medium binning. (B) Animals were culled and dissected. Lymphoid 
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and non-lymphoid organs from animals with higher leukemic infiltration from each group (II and VI) 
were photographed and quantified for total luminescence (20 minutes after luciferin injection with a 3 
minutes exposure in medium binning), as an example. (C) Lymphoid and non-lymphoid organs were 
disrupted, and cell suspensions were analyzed by flow cytometry for GFP expressing cells.  
To confirm these observations, we next transplanted TAIL7 cells into IL-7 WT and 
IL-7 KO mice. TAIL7 cells are dependent on IL-7 and constitute a surrogate model 
for primary T-ALL. To ensure that any putative differences regarding leukemia 
development were not a consequence of distinct engraftment and homing of TAIL7 
cells in IL-7 WT versus IL-7 KO mice, we first labeled TAIL7 cells with CFSE and 
analyzed the BM and other organs of the transplanted mice for the presence of CFSE-
positive cells 6 hours after i.v. injection. Although very few malignant cells were 
detected in the BM, no difference was observed between the IL-7 WT (36.5+26.7) 
and IL-7 KO (31.6+16.7) mice (Figure 4A). Spleen and several non-lymphoid organs 
were analyzed and all presented very few cells with no differences between the two 
mouse strains (data not shown). We next evaluated disease progression through time. 
Mice were sacrificed when moribund (presenting loss of 20% of body weigh, 
breathing problems or poor reaction to external stimuli). Median survival of IL-7 WT 
mice (97 days) was significantly shorter than that of IL-7 KO mice (138 days; 
p=0.0023; Log-Rank test) (Figure 4B). Postmortem analyses were performed by 
immunohistochemistry, using hematoxilin/eosin staining, and by flow cytometry, 
using a specific human anti-CD2 staining. In all animals tested (IL-7 WT, n=8; IL-7 
KO, n=14), TAIL7 cells engrafted and originated leukemia with involvement of 
multiple organs, specially the BM (Figure 4C-F). Splenomegaly was a common 
occurrence in the transplanted animals of both groups and no significant differences 
were found in the percentage of malignant lymphoblasts infiltrated (Figure 4C and D). 
In addition, tumor cells were also found in non-lymphoid organs such as liver, kidney 
and lung of both IL-7 WT and IL-7 KO animals (Figure 4E and F). These results 
indicate that the death of all animals was leukemia related. Our data further suggest 
that IL-7 is a microenvironmental factor that, although not indispensable for leukemia 
progression, contributes significantly to the expansion of leukemia cells and to 
leukemia acceleration in vivo. 
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Figure 4. IL-7 accelerates leukemia progression and leukemia-related death in mice transplanted 
with TAIL7 T-ALL cells. IL-7 WT (black) and IL-7 KO (red) mice were injected i.v. with 10x106 
TAIL7 cells and followed for disease symptoms. All animals were age and sex matched. (A) TAIL7 
cells labeled with CFSE were detected by flow cytometry analysis in IL-7 WT (n=3) and IL-7 KO 
(n=3) mice, 6h posttranplantation. (B) Kaplan-Meier disease-free survival analysis of TAIL7-
transplanted mice of the indicated genotypes is shown. Disease progression in IL-7 WT (n=8) mice was 
significantly (P=0.0023; Log-Rank test) accelerated compared to IL-7 KO (n=14) group. (C-D) 
Postmortem analysis were performed by flow cytometry and by immunohistochemestry in IL-7 WT 
(n=7) and IL-7KO (n=12) animals. Animals were sacrificed when moribund, dissected and organs of 
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interest such as bone (BM), spleen, liver, kidney and lungs were collected. (C, E) Part of each organ 
was disrupted into cell suspension (or a flush off the bone marrow) to analyze by flow cytometry with 
anti-human CD2 staining that specifically detect TAIL-7 cells. Percentage of human CD2 positive 
cells, for the total number of analyzed animals, are displayed in graphs for the respective organ. Lines 
indicate median values and no significant differences (p> 0.05; Student’s t-test) were observed in 
percentage of cell infiltration in lymphoid organs and non-lymphoid organs of IL-7 WT vs IL-7 KO 
mice. (C) Red area in the BM graphic, highlights the percentages of infiltrating cells considered as 
indicative of leukemia. (D, F). The remaining part of the organs (or an entire bone) were fixed for 24-
48h in 10% formol, processed for immunohistochemistry and stained for hematoxilin/eosin. 
Histological images (magnification 250x) correspond to the indicated organs from a representative 
animal of each group.  
 
We next compared IL-7 WT and IL-7 KO mice at earlier time points (up to 84 days) 
in order to characterize the effects of IL-7 that could account for the differences 
observed in the death rates between the two groups. The percentage of circulating 
TAIL7 cells in the peripheral blood increased through time with consistently higher 
levels in the IL-7 WT mice compared to IL-7 KO mice, although not reaching 
statistical significance (Figure 5A). These differences in the percentage of TAIL7 
cells in the peripheral blood could result from higher BM involvement in the IL-7 WT 
versus IL-7 KO. To confirm this possibility, mice were culled at 84 days post-transfer 
and analyzed for the presence of leukemia cells in different organs. Although none of 
the mice displayed apparent disease symptoms, we observed that all IL-7 WT animals 
presented leukemic (6/9) or pre-leukemic (3/9) BM (Figure 5B). In contrast, only 4/10 
IL-7 KO mice were leukemic and 2/10 pre-leukemic (Figure 5B). Furthermore, 4/10 
IL-7 KO mice did not show signs of BM involvement at this time point (Figure 5B), 
likely because the number of TAIL7 cells in the BM was below the detection limit. 
Independently of IL-7, leukemic and pre-leukemic animals, but not the non-leukemic, 
presented splenomegaly due to infiltration with malignant blasts (Figure 5C and data 
not shown). The non-lymphoid organs analyzed, liver, kidney and lung also presented 
infiltration of leukemic blasts (Figure 6). Importantly, IL-7 KO mice consistently 
displayed a more heterogeneous distribution and lower  median values of malignant 
infiltration in all lymphoid and non-lymphoid organs analyzed (Figures 5B,C and 6). 
These findings provide further evidence that IL-7 accelerates leukemia progression in 
vivo. 
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Figure 5. IL-7 accelerates leukemia progression. Mice, IL-7 WT (black; n=9) and IL-7 KO (red; 
n=10), were injected i.v. with 10x106 TAIL7 cells. All animals were age and sex matched. (A) TAIL7 
cells were monitored in the blood through time by flow cytometry analysis with anti-human CD2 
staining. (B, C) Animals were culled 84 days posttransplantation. BM (B) and spleen (C) were 
analyzed for TAIL7 cells infiltration by flow cytometry with anti-human CD2 staining. Animals were 
classified as leukemic if more than 20% of TAIL7 cells in the BM, pre-leukemic if less than 20% and 
non-leukemic if less than 0.1 %. Lines in (B, C) represent median values. Differences were not 
statistically significant. 
 
Figure 6. TAIL7 cells infiltrate non-lymphoid organs independently of IL-7. IL-7 WT (n=9) and 
IL-7 KO (n=10) mice, were injected i.v. with 10x106 TAIL7 cells. All animals were age and sex 
matched. Animals were culled 84 days post-transplantation and dissected. Non-lymphoid organs were 
disrupted into cell suspension and analyzed for TAIL7 cells infiltration by flow cytometry with anti-
human CD2 staining. Bars indicate median values. Differences were statistically significant only in the 
kidney (p> 0.05; Student’s t-test). 
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4.4.3. IL-7 does not induce phenotypic differentiation of TAIL7 cells in vivo. 
To determine whether the differences in leukemia progression in IL-7 WT versus IL-7 
KO mice were associated with particular immunophenothypic and/or functional 
alterations, we collected TAIL7 cells from the BM of mice sacrificed at 84 days and 
analyzed them ex vivo. Our results showed that TAIL7 cells collected from either IL-
7 WT or IL-7 KO shared an identical phenotype, CD7+ CD5+ CD3-CD4+ (Figure 7A) 
CD2+ (data not shown), similar to in vitro-cultured TAIL7 cells. Furthermore, in vivo 
transplanted TAIL7 cells also maintained their phenotype regarding CD34, CD45RA 
and CD45RO expression (Figure 7A). Although xenotransplanted TAIL7 cells 
slightly upregulated CD1a and CD44, this phenotypic alteration occurred 
independently of IL-7 (Figure 7A). Ovreall, analysis of TAIL7 cells ex vivo showed 
that no significant phenotypic changes occurred, thus suggesting that exposure to 
diverse microenvironmental factors in vivo did not induce cell differentiation. 
Importantly, we observed that IL-7R expression was similar in cells collected from 
both IL-7 WT and IL-7 KO mice and in TAIL7 cells cultured in vitro (Figure 7A). 
Hence, we next evaluated the capacity of ex vivo stimulated TAIL7 cells to respond 
to IL-7. PI3K/Akt and JAK/STAT pathways were extensively described as being 
activated upon IL-7 signaling in T cells (15, 16) and implicated in the survival and 
proliferation of T-ALL cells ((3)and data not shown). To confirm that PI3K/Akt and 
JAK/STAT pathways were activated in TAIL7 cells ex vivo in response to IL-7 we 
used Akt and STAT5 phospho-specific antibodies that recognize the phosphorylated 
Akt residue S473 and the phosphorylated STAT5 residue Y694. We did not observe 
any differences in the “basal” levels of activation of PI3K/Akt and JAK/STAT 
pathways (data not shown), whereas ex vivo IL-7 stimulation induced  a striking 
upregulation of phospho-Akt and phospho-STAT5 in TAIL7 cells collected from both 
IL-7 WT and IL-7 KO mice (Figure 7B). These results suggest that TAIL7 cells 
maintain their capacity to respond to IL-7 in vivo irrespective of the actual availability 
of the cytokine. Our data further indicate that the presence of IL-7 does not affect the 
differentiation of TAIL7 cells in vivo in agreement with previous reports indicating 
that IL-7 does not promote T-ALL differentiation (17).  
 
IL-7  ACCELERATES T-ALL IN VIVO  
142 
 
Figure 7. IL-7 does not induce phenotypic differentiation of TAIL7 cells in vivo. IL-7 WT and IL-7 
KO mice were culled 84 days post-transfection of TAIL7 cells. (A) TAIL7 cells recovered from BM of 
both mouse strains were phenotyped with the indicated specific anti-human antibodies and analyzed by 
flow cytometry. Columns and error bars represent the average and sem of the specific MIF of TAIL7 
cells collected from IL-7 WT (black; n= 9) and IL-7 KO (red; n=6) or of TAIL7 cells cultured in vitro. 
No differences were observed between the phenotype of TAIL7 from IL-7 WT or IL-7 KO mice. (B) 
TAIL7 cells collected from the BM of IL-7 WT (n=3) and IL-7 KO (n=3) mice were stimulated at 37ºC 
for 30 minutes in 1x PBS alone or with IL-7 (50ng/ml). Samples were analyzed by flow cytometry for 
the activation of PI3K/Akt pathway and JAK/STAT5 pathway by intracellular phospho-staining using 
antibodies that specifically recognize S473-phosphorylated Akt (p-Akt) and Y694-phosphorylated 
STAT5 (p-STAT5). Representative MIF results are displayed in the histogram. Differences observed 
between IL-7 WT and IL-7 KO mice were not statistically significant. 
 
 
 
IL-7  ACCELERATES T-ALL IN VIVO  
143 
4.4.4. IL-7 accelerates leukemia induced by xenotransplantation of primary T-
ALL cells.  
To further support our observations using T-ALL cell lines, we next generated IL-7 
WT and IL-7 KO xenotransplants with primary T-ALL cells from two different 
donors. Similarly to TAIL7 cells, we observed an increase in the percentage of 
circulating primary T-ALL cells through time, with consistently higher levels in the 
IL-7 WT compared to IL-7 KO mice (Figure 8A and data not shown). These 
differences correlated with higher BM involvement in the IL-7 WT mice. We 
observed that all IL-7 WT mice presented leukemic (3/3) BM when culled 112 days 
post-transfer (Figure 8B and data not shown). In contrast, only 1 of 4 IL-7 KO mice 
was leukemic and 1of 4 pre-leukemic (Figure 8B and data not shown). Interestingly, 2 
of 4 IL-7 KO mice did not show signs of BM involvement at this time point (Figure 
8B and data not shown). Similar to what occurs in patients with advanced disease, we 
observed that primary T-ALL cells infiltrated peripheral organs such as spleen, liver, 
kidney and lungs of transplanted mice (Figure 8C and data not shown). In addition, 
leukemic mice presented splenomegaly (data not shown). These data indicate that IL-
7 promotes leukemia progression in mice xenotransplanted with primary T-ALL cells. 
Our results provide support to the hypothesis that IL-7 might be a relevant 
microenvironmental factor for leukemia progression in human T-ALL patients. 
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Figure 8. IL-7 accelerates leukemia progression induced by xenotransplantation of primary T-
ALL cells. IL-7 WT (black; n=3) and IL-7 KO (red; n=4) mice were injected i.v. with 5x106 primary 
T-ALL cells. All animals were age and sex matched. (A) Primary T-ALL cells were monitored in the 
blood through time by flow cytometry analysis using an anti-human CD2 antibody. (B,C) Animals 
were culled 112 days posttransplantation. BM (B), spleen, liver and kidney (C) were disrupted into a 
cell suspension and analyzed for primary T-ALL cell infiltration by flow cytometry with an anti-human 
CD5 antibody. Lines in B and C represent median values. Differences were not statistically significant. 
 
4.4.5. IL-7 promotes proliferation and viability of primary T-ALL cells in vivo, 
which correlates with p27Kip1 downregulation and Bcl-2 upregulation. 
We next sought to unravel the mechanisms responsible for the accelerated leukemia 
progression in IL-7 WT versus IL-7 KO mice. Our previous studies demonstrated that 
Bcl-2 upregulation is mandatory for IL-7–mediated promotion of viability of in vitro-
cultured primary T-ALL cells (3). We collected T-ALL cells from the BM of mice 
sacrificed at 112 days and analyzed them ex vivo for Bcl-2 expression and viability. 
Interestingly, we observed that primary leukemia cells collected from IL-7 WT 
animals presented upregulated Bcl-2 levels (Figure 9A and data not shown) and this 
correlated with increased percentage of viable cells (Figure 9B and data not shown). 
In vitro stimulation with IL-7 was shown to downregulate p27Kip1protein expression, 
resulting in CDK activation, ensuing hyperphosphorylation of Rb, and cell cycle 
progression of T-ALL cells (2, 3). We next evaluated whether IL-7 could promote 
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similar effects in vivo. We observed that p27Kip1 levels were downregulated in 
primary T-ALL cells recovered from IL-7 WT as compared with those collected from 
IL-7 KO mice (Figure 9C and data not shown). This associated with increased 
proliferation, as assessed by Ki-67 expression (Figure 9D and data not shown).  
 
 
Figure 9. IL-7 promotes proliferation and viability of primary T-ALL cells in vivo, through 
p27Kip1 downregulation and Bcl-2 upregulation. IL-7 WT and IL-7 KO mice, were injected i.v. with 
5x106 primary T-ALL cells. All animals were age and sex matched. Animals were culled 112 days 
post-transplantation and primary T-ALL cells in the BM were discriminated by flow cytometry with 
anti-human CD2 or CD5 antibodies and analyzed for viability and proliferation markers. Blasts from 
T-ALL#64 were used in this experiment. (A) Bcl-2 protein levels were assessed by flow cytometry 
after intracellular staining of primary T-ALL cells with FITC-conjugated anti–Bcl-2 antibody. 
Representative animal from IL-7 WT (n=3) and IL-7KO (n=4) groups are shown in the histogram. 
Results are indicative of two different patient samples analyzed. Specific MIF, as described in 
Materials and Methods, is indicated in the histogram. (B) Primary T-ALL cells recovered from IL-7 
WT (n=3) and IL-7 KO (n=2) mice were stained with Annexin V–PE and viability was determined by 
flow cytometry analysis. Indicated is the percentage of Annexin V-negative (viable) cells. (C) Total 
BM cells from IL-7 WT (n=4) and IL-7 KO (n=6) mice were lysed, resolved by 10% SDS-PAGE and 
immunoblotted with anti-p27Kip1 antibody. Membrane was stripped and reprobed with Actin to confirm 
equal loading. Lanes 1, 6 and 7 correspond to T-ALL #CS; lanes 2-4 and 8-11 correspond to T-
ALL#64; total lysates of TAIL7 cells were used as a positive control. (D) Ki-67 protein levels were 
assessed by flow cytometry after intracellular staining of primary T-ALL cells with PE-conjugated 
anti–Ki-67 antibody. Results from IL-7 WT (n=3) and IL-7 KO (n=4) mice are indicative of two 
different patient samples analyzed. 
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4.5. Discussion 
T-ALL cells arise from the clonal expansion of lymphocytes arrested at different 
stages of T-cell development (18). They present an immature immunophenotype, and 
similar to immature lymphocytes they respond to microenvironmental factors in vitro, 
such as γC-signaling cytokines (19). We have focused our attention on the role of IL-
7, since it promotes T-ALL cell viability and proliferation in vitro (chapter 3 and (2, 
3, 20)) and it is produced in the leukemic milieu (21). Moreover, IL-7 overexpression 
appears to have oncogenic potential in vivo (4, 22, 23). Despite the evidence, from in 
vitro studies with human T-ALL cells and from IL-7 transgenic mouse models, 
pointing out the possible involvement of IL-7 in T-cell leukemogenesis, it remained 
unclear whether IL-7 participates in T-ALL progression in vivo. By xenotransplanting 
T-ALL cell lines and primary cells into immunodeficient mice that differ solely in 
their ability to produce IL-7, we provide the first evidence that IL-7 can significantly 
accelerate human leukemia development in vivo. 
The prevalent view that mIL-7 does not stimulate human cells (1, 7, 24, 25), was 
challenged by the evidence that this ortholog induced STAT5 activation in human T 
cells (26, 27). Our studies show that mIL-7 simulated the ability of hIL-7 to engage 
MEK/ERK, PI3K/Akt, and JAK/STAT signaling in human leukemic IL-7-dependent 
TAIL7 cells. Because molecular similarities do not necessarily associate with 
identical functional outcomes, it is important to note that mIL-7 and hIL-7 similarly 
modulated distinct cellular functions (viability, size and proliferation) of T-ALL cells 
cultured in vitro. In addition, we used a chimeric human-mouse FTOC, a three-
dimensional and physiologically relevant culture system that permits the development 
of human T cells from hematopoietic precursors (12, 28), to support the expansion of 
IL-7-dependent human leukemia TAIL7 cells. The blockade of endogenous mIL-7 by 
a specific neutralizing antibody inhibited the proliferation of TAIL7 cells within the 
FTOC. This ability to respond to mIL-7 likely played an important role in the 
tumorigenic potential of TAIL7 cells, which engrafted and expanded in nonobese 
diabetic/severe combined immunodeficient mice without exogenous hIL-7 (8). Our 
studies clearly demonstrate that mIL-7 has similar activity to hIL-7 in normal T cells 
and malignant T and B cells (14). These observations also constituted the basis for our 
subsequent xenotransplantation experiments.  
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Although murine leukemia models have provided valuable insights into the 
mechanisms of leukemogenesis, direct in vivo studies of primary human leukemia are 
necessary to understand the pathogenic processes unique to human leukemogenesis 
(29). Xenotransplant experiments of cells from patients or cell lines representing 
hematologic disorders into immunodeficient mice constitute useful models to test new 
drug treatments (30, 31). NOD/SCID and NOD/SCID-β2microglobulin-/- mice have 
been the most widely used hosts to date, being efficiently engrafted by specific 
subsets of human hematopoietic cells (32, 33). These mice have the advantage to 
breed easily. However, they develop fatal endogenous thymomas between 6 and 12 
months of age, which precludes their use for long-term follow up studies (34). An 
alternative that we used in our studies were the long-lived γC KO/Rag2KO (9), since 
there are mice deficient on IL-7 production with the same genotype, IL-7KO/γC 
KO/Rag2KO. Unlike previous studies, where the authors had to precondition 
NOD/SCID mice with irradiation and human cord blood cell transfer prior to T-ALL 
cells transplantation (35), we successfully injected intravenously T-ALL cells in the 
selected mouse strains without the need for pre-conditioning or irradiation of the 
animals.  
Our findings indicate that IL-7 can play a role in the progression of T-ALL cells in 
vivo. These results fit with the proposed hypothesis that increased responsiveness to a 
T cell growth factor dependent on γC signaling, should be relevant to T-ALL 
expansion in vivo (35). Nevertheless, because IL-7-deficient mice also develop 
leukemia, it is conceivable that other γC-signaling cytokines (IL-4, IL-9, IL-15, IL-
21) significantly participate in leukemia development in vivo. In this context it is 
interesting to note that all γC-signaling cytokines were shown to induce the 
proliferation of primary T-ALL cells in vitro (19). Microenvironmental factors other 
than γC cytokines may contribute to T-ALL progression in vivo. Notch-mediated 
signals are obvious candidates. For instance, Indraccolo and colleagues recently 
demonstrated that the cross-talk between tumor cells and the angiogenic tumor 
microenvironment contributes to regulate Notch3 signaling in the malignant cells and 
to regulate tumor dormancy (36). Furthermore, human T-ALL cells, NOTCH-mutated 
or not, appear to require Notch receptor/ligand interaction for sustained activation of 
the Notch pathway and consequent growth and leukemia “stem cell” activity (37). 
Chemokines and their receptors may also be important for T-ALL in vivo. For 
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example, CXCL12 the CXCR4 ligand was shown to play a predominant role in the 
homing of ALL cells to the bone marrow (38), and the CXCL12/CXCR4 axis appears 
to be important for the retention of ALL cells within the supportive BM 
microenvironment, contributing to their in vivo proliferation (39). On the other hand, 
the thymic microenvironment, and particularly IL-7, has an important role in the 
positive control of expression and signaling of CXCR4 in thymocytes (40). Since the 
use of CXCR4 antagonists was proposed to have therapeutic potential for the 
treatment of ALL (39), it would be interesting to evaluate the expression levels of 
CXCR4 in T-ALL cells and correlate to the presence of IL-7 in the 
microenvironment. Other chemokines, such as CCL25 and CXCL13, were shown to 
promote resistance to apoptosis and inappropriate proliferation of T-ALL cells in vitro 
(41-43), and may also be relevant in vivo. Despite the evidence arguing for the 
participation of microenvironmental factors in leukemia progression, they are not 
necessarily indispensable for leukemogenesis, and the exact contribution of each 
factor may vary substantially from patient to patient. In other words, it is conceivable 
that no single factor is absolutely required for T-ALL disease progression. Evidently, 
this does not contend with the possibility that one or more factors might significantly 
contribute to leukemia development by providing survival and/or proliferative signals 
to the malignant cells. In line with this view, we found that the infiltration of T-ALL 
cells into both lymphoid and non-lymphoid organs of IL-7 KO mice has lower 
efficiency compared to the IL-7 WT. However, in some cases organ infiltration was at 
least comparable in both IL-7 KO and IL-7 WT mice. Thus, one can speculate that, in 
the absence of IL-7, some T-ALL cells find alternative mechanisms of survival, 
possibly by responding to other microenvironmental cues. 
Different studies have described the existence of leukemic stem cells and their 
aggressiveness in transplanted animals, compared to the “bulk leukemic population” 
(44). In T-ALL, the existence of a leukemic stem cell population has not been clearly 
determined as yet, despite the evidence that such putative population might be 
enriched in CD34-expressing cells (45). When we analyzed the early engraftment of 
TAIL7 cells (Figure 4A) only a very small number of malignant cells was found in 
the organs. Even so, this minute population expands to the point that animals start 
presenting with disease symptoms 84 days post cell transfer and eventually die of 
leukemia. Also, we failed to observe any luciferase signal from HPB-ALL Luc-GFP 
cells in vivo 14 days post cell transfer (data not shown), indicating that very few cells 
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engrafted. However, 35 days post cell transfer the animals were sacrificed due to the 
large dissemination of malignant cells, especially in the IL7 WT mice (Figure 3A). 
These observations are in agreement with the possibility that only a minor fraction of 
the cells, corresponding to a “leukemic stem cell” population, engrafted and 
originated leukemia in our mouse model. Whether such a putative population 
responds to IL-7 in a similar manner to their progeny, remains to be addressed. In 
general, it would be interesting to study whether T-ALL have a leukemic stem cell 
population irresponsible for leukemia initiation upon cell transfer to immunodeficient 
mice, and to characterize their specific immunophenotype and functional 
characteristics. Unlike AML leukemic stem cells (44), our main model for IL-7-
responsive T-ALL cells (TAIL7 cells) lacks the expression of CD34. Thus, we would 
have to use the low Hoescht 33342-staining properties of hematopoietic stem cells, 
which use an ABC-type transporter to efflux the Hoechst dye, to isolate these “stem 
cells”. These cells are designated as “side population” since their Hoescht 
fluorescence profile in a dual wavelength analysis (405/30 and 670/40 nm) after 
excitation at 350 nm on a triple laser flow cytometer, is localized on the left side of 
the main leukemic population (46). 
The main finding of this study is the demonstration that IL-7 accelerates human 
leukemia progression. This correlates with increased viability and proliferation of 
primary T-ALL cells. We demonstrate that increased T-ALL viability in IL-7 WT 
mice correlate with Bcl-2 upregulation, confirming our in vitro results demonstrating 
the dependence of IL-7-mediated T-ALL cell survival on PI3K activation and Bcl-2 
upregulation (3). Similarly, transgenic IL-7 mice present upregulation of Bcl-2 
protein (47). However, we failed to detect differences in PI3K activation by 
measuring Akt phosphorylation, in T-ALL cells recovered from IL-7 WT and IL-7 
KO mice (data not shown). This could be a technical issue or similar PI3K activation 
in IL-7WT or IL-7KO mice can result from other PI3K-activating stimuli. Expression 
levels of p27Kip1 have been shown to inversely correlate with the aggressiveness of 
tumors of various histological origins and with patient overall survival (48). In 
addition, p27 KO mice show augmented organ size due to increased proliferation, and 
display a tendency to develop pituitary tumors (49-51). Importantly, it has been 
suggested that p27kip1 expression is decreased in primary T-ALL patient cells and, in 
mice, p27kip1 deficiency collaborates with Smad3 overexpression to induce T-cell 
leukemia (52). We observed increased expression of the proliferation marker Ki-67, 
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and p27Kip1 downregulation in IL-7 WT leukemic mice. These results are in 
accordance with our previous studies demonstrating that IL-7 promotes p27kip1 
downregulation and cell cycle progression of T-ALL cells in vitro (4). In short, our 
findings in vivo are mostly in accordance with our previous studies in vitro (2, 3) and 
indicate that IL-7 accelerates leukemia development by promoting p27kip1 
downregulation and Bcl-2 upregulation, with consequent increase in proliferation and 
survival of T-ALL cells. Furthermore, the present work suggests that the integration 
of specific anti-IL-7 agents into current treatment protocols may be of advantageous 
in IL-7-responsive T-ALL cases.    
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5.1. Abstract 
Throughout T-cell development IL-7Rα expression levels at the cell surface are 
tightly controlled. Deregulated expression of IL-7Rα is associated with human T-cell 
acute lymphoblastic leukemia (T-ALL) and mouse thymic lymphomas. In this study, 
we used tetracycline-inducible IL-7Rα (TreIL-7Rα) transgenic mice to analyze the 
role of IL-7Rα in T-cell leukemogenesis. Continuous expression of TreIL-7Rα upon 
doxycycline feeding induces thymus hypertrophy and hyperplasia due to increased 
size and hyperproliferation of T-cells, which subsequently infiltrate lymph nodes, 
spleen and bone marrow, ultimately leading to leukemia/lymphoma-associated death. 
Adoptive transfer of thymic TreIL-7Rα cells to immunodeficient mice confirmed their 
malignant origin. Surprisingly, tumors develop in recipient animals even in the 
absence of doxycycline administration, indicating that they became independent of 
continuous IL-7Rα expression. Interestingly, the tumors mimic several features of 
human T-ALL. First, their immunophenotype varies considerably between animals. 
Second, most tumors display hyperactivation of PI3K/Akt pathway, which sometimes 
associates with absence or decreased PTEN protein expression. Third, the cell cycle 
inhibitor p27Kip1 is frequently downregulated, whereas Bcl-2 expression is generally 
increased. Altogether, our results establish the importance of IL-7R axis in T-cell 
tumorigenesis in vivo. 
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5.2. Introduction 
Interleukin-7 (IL-7) is a nonredundant trophic factor for immune cell development 
that acts primarily by promoting cell survival (1, 2). In the thymus, stromal cells 
produce IL-7 and effective concentrations are achieved locally, perhaps by retention 
in extracellular matrix glycosaminoglycans (3, 4). The receptor for IL-7 is a 
heterodimer of an α subunit (IL-7Rα or CD127) and the common γ chain (γC) (5). 
The latter is shared by other cytokine receptors, including those for IL-2, IL-4, IL-9, 
IL-15, and IL-21 (6, 7). The γC is constitutively expressed at low levels in 
lymphocytes, but IL-7Rα expression is restricted to specific stages of differentiation 
to mediate cellular responses (8, 9). Within the T-cell lineage, IL-7Rα is expressed in 
the early stages of development on CD4−CD8− double negative (DN) cells, while 
CD4+CD8+ (DP) thymocytes do not express or have low IL-7Rα levels. IL-7Rα 
expression increases once again on thymocytes undergoing positive selection and 
mature single positive (SP) cells and is involved in survival and functional responses 
of mature T cells (10). The essential role of IL-7/IL-7R axis in lymphopoiesis is 
underscored by the observations that IL-7 KO and IL-7Rα ΚΟ mice show greatly 
diminished lymphoid development with total T cell numbers decreased 10–20-fold 
and a complete absence of B cells (1, 11). Similarly, humans with mutations in the IL-
7Rα gene exhibit greatly diminished T cell development. In contrast to mice, humans 
have normal B cell development (12, 13).   
Type I cytokine receptors, such as IL-7R, are generally not viewed as potentially 
oncogenic, because they lack intrinsic tyrosine kinase activity and need ligand 
engagement for signal transduction (14). However, upon ligand binding, they acquire 
catalytic activity by recruiting protein tyrosine kinases (9, 15-17), and graded 
differences in signal intensity may be oncogenic. IL-7 acts by binding to IL-7Rα (5) 
and inducing its association with the γC chain (18, 19), bringing their intracellular 
domains together, which are associated with JAK1 and JAK3 kinases (20, 21). 
Engagement of the IL-7R is critical for multiple processes in thymocyte development, 
including induction of both proliferation and survival through Bcl-2 (22-24), and 
differentiation events such as V(D)J recombination of T-cell receptor genes (25). IL-
7R activation has been shown also to initiate the PI3K/Akt pathway (26). In addition, 
several proto-oncogenic mechanisms have been identified downstream of IL-7R 
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signaling such as downregulation p27Kip1 and PTEN (27, 28). Importantly, studies in 
mouse models suggest that high–level IL-7Rα expression can be a causal event in 
leukemogenesis (29). Furthermore, results from a gene therapy trial for γC-deficient 
severe combined immune deficiency (X-SCID) showed that two patients developed 
leukemia (30), possibly because the overexpression of common γC led to increased 
growth factor stimulation via IL-7R, which collaborated with aberrant expression of 
the T-cell oncogene LMO2 (31).  
These evidences led us to ask whether intensive cytokine signaling was associated 
with increased susceptibility to tumors, triggering survival and/or proliferative 
signals. More specifically, we investigated whether inducible forced IL-7Rα 
continuous expression could lead to abnormal T-cell development and tumorigenesis. 
Our results indicate that IL-7Rα constitutive expression on T-cells predisposes to 
leukemia/lymphoma development in vivo, in a manner that resembles many of the 
known immunophenotypic and molecular features of human T-cell acute 
lymphoblastic leukemia/lymphoma.  
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5.3. Methods 
Mice. F5 TreIL7R rtTA.C IL7rKO (F5 TreIL-7Rα), OTII(-/+)TreIL-7Rα rtTA.C 
IL7rKO (OTII+/- TreIL-7Rα) were generated as described in Buentke et al (32) and 
subsequently bred in  a specific pathogen-free facility at the National Institute for 
Medical Research. F5 and OTII were used as appropriate experimental controls. All 
animal work was done in accordance with the Home Office regulation and local 
guidelines. Mice were fed doxycycline (dox) in food (3 mg/g) to induce IL-7Rα 
expression. Experimental mice were weekly weighed and sacrificed in a CO2 chamber 
when presenting clear disease symptoms, such as loss of 20% of body weight, 
breathing impairment, poor reaction to external stimuli and ruff fur appearance. 
Organ analysis. Animals were dissected and organs were collected for analysis. 
Small parts of the collected organs (spleen, thymus and one femur) were preserved in 
formalin at 4ºC for histological analysis with hematoxilin/eosin staining. The 
remaining part of thymus and spleen were mechanically disintegrated into single cell 
suspensions in IMDM/ 2%(w/v) BSA (IMDM/BSA). Bone marrow was extracted by 
flushing off long bones (femur). Cell numbers were determined using an automated 
cell counter (CASY 1, Scharfe System, Reutlingen, Germany) and subsequently 
transferred, immunophenotyped or lysed for immunoblotting as described below.  
Adoptive transfers. To assess the malignancy of thymus-recovered cells, 10x106 
cells/ 250µl IMDM/BSA were injected via tail vein into 6-8 week-old Rag1KO 
animals. Animals were fed with either normal or 3mg/g dox-containing food. Animals 
were monitored daily and sacrificed in a CO2 chamber when moribund or at indicated 
time points. Bones, spleen and thymus were collected for flow cytometry and 
histological analysis. 
Immunophenotype. Splenic, thymic and bone marrow cell suspensions were 
subjected to immunophenotypic analysis using standard methodology as described in 
Chapter 2. Briefly, 0.2-0.5x106 cells were stained for 30 minutes at 4ºC in 
IMDM/BSA with the specific antibodies described in Table 1. The mAbs were 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), 
peridinin chlorphyll protein (PerCP) and pacific blue (PB)-conjugated. Cells were 
washed at 1200 rpm at 4ºC for 7 minutes. Supernatant was discarded and cells 
ressuspended in 1x PBS for acquisition. Four- and 8-color analyses were performed 
on FACSCalibur (Becton Dickinson San Jose, CA, USA) and CyAn (Dako, Fort 
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Collins, CO, USA) flow cytometers. Results were analyzed with FlowJo (Tree Star 
Inc., Ashland, OR, USA) software.  
 
Table 1. Antibody information 
mAbs Fluorochrome Dilution Company 
CD4 PE 1:400 eBiosciences (San Diego, CA, USA) 
CD4 APC 1:400 eBiosciences 
CD4 PB 1:400 CALTAG/Invitrogen (Carlsbad, CA, USA) 
CD8 PerCP 1:200 eBiosciences 
CD8 PE 1:200 eBiosciences 
CD5 FITC 1:400 eBiosciences 
HSA FITC 1:400 eBiosciences 
CXCR4 PE 1:200 BD Biosciences (San Jose, CA, USA) 
IL7R PE 1:200 eBiosciences 
VαII PE 1:200 eBiosciences 
TCR APC 1:400 BD Biosciences 
 
 
Immunoblotting. Cells were lysed as described in Chapter 2. Equal amounts of 
protein (50 µg/sample) were analyzed by 10% SDS-PAGE, transferred onto 
nitrocellulose membranes, and immunoblotted with the antibodies at 1:1000 dilution: 
p27Kip1, Bcl-2 and Actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); p-
STAT5 (Zymed, San Francisco, CA, USA); PTEN, p-Akt (S473) (Cell Signaling 
Technology, Danvers, MA, USA). Immunodetection was performed by incubation 
with horseradish peroxidise-conjugated anti-mouse (1:5000), anti-rabbit IgG 
(1:10,000) or anti-goat (1:5000) (Promega, Madison, WI, USA) and developed by 
enhanced chemiluminescence (Amersham-Pharmacia, Piscataway, NJ, USA). Blots 
were stripped and reprobed as described in Chapter 2. 
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5.4. Results 
5.4.1. Age-dependent thymic hyperplasia in doxycycline-fed F5 TreIL-7Rα mice. 
The tight coordination of IL-7Rα expression during T-cell maturation strongly 
suggests that the precise and timely regulation of IL-7R signaling is necessary for 
normal T-cell development. Indeed, high levels of IL-7Rα were shown to be 
associated with lymphomagenesis (29). In contrast, there is also evidence that forced 
IL-7Rα expression in T-cells negatively impacts early T-cell development and 
associates with an age-dependent thymic hypoplasia (33). To clarify these apparently 
discrepant observations, we used an inducible mouse model for IL-7Rα transgenic 
expression, F5 TreIL-7Rα, where the use of dox food induced the constitutive 
expression of TreIL-7Rα in T-cells (32). We found age-dependent thymic hyperplasia 
(strikingly increased thymus cellularity) associated with constitutive expression of IL-
7Rα (Figure 1A and data not shown). This was paralleled by hypertrophy (increased 
thymocyte cell size) and phenotypic changes in the thymus, as shown by flow 
cytometry analysis of FSC and anti-CD4, -CD8 staining (Figure 1C). However, mice 
with thymus hyperplasia had a normal peripheral T cell compartment (Figure 1C). 
Analysis of thymus structure by hematoxylin and eosin staining showed disruption of 
the thymic medulla and dominance of the thymic cortex in hyperplasic F5 TreIL-7Rα 
thymi (Figure 1B). Our data suggests that thymus, but not spleen, undergoes 
hyperplasia prior to or concomitantly with tumor formation.  
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Figure 1. Age-dependent thymic hyperplasia in doxycycline-fed F5 TreIL-7Rα mice. F5TreIL7-Rα 
transgenic mice (n=26) were culled at the indicated ages and dissected. Thymus and spleen were 
analyzed for size, structure and phenotype. Experimental mice were fed with dox food to induce 
transgenic IL-7Rα expression, whereas control animals were fed with normal food (A) Total thymus 
cellularity from F5 TreIL-7Rα mice on dox food was measured by casi quantum system and cell 
number was plotted in a graph versus animal age. (B) Representative hematoxilin/eosin image of a 
hyperplasic thymus from an F5 TreIL-7Rα animal on dox food (250x magnification). (C) Cell size and 
immunophenotypic characterization of thymus and spleen from F5 TreIL-7Rα (on dox food) and F5 
control mice were assessed by flow cytometry. Cell size was determined through forward scatter (FSC) 
and complexity through side scatter (SSC). For the immunophenotype we used an anti-CD4-PE and -
CD8-FITC staining.  
 
5.4.2. Doxycycline-fed F5 TreIL-7Rα mice develop leukemia/lymphoma with 
variable phenotype. 
Overexpression of growth factor receptors can contribute not only to 
hyperproliferation but also to malignancy (29). Our studies did not determine whether 
the cells present in the hyperplasic thymus were malignant at their origin. However, 
several lines of evidence indicate that they were malignant at least at advanced stages 
of disease. First, thymic hyperplasia was paralleled by hypertrophy (Figure 1C), 
suggesting the presence of leukemia/lymphoma blasts in the thymus. Second, the 
hyperplasia/hypertrophy was very aggressive, and generally resulted in thymi that 
almost filled the thoracic cavity (data not shown). Third, each animal displayed an 
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accumulation of cells with a homogeneous immunophenotype (Figure 1C and 2A), 
hinting on their possible clonal origin. Fourth, the TreIL-7Rα-expressing thymocytes 
eventually spread to and accumulated in the lymph nodes, spleen and BM (Figure 
2A). To confirm their malignant origin, the thymocytes with ‘abnormal’ phenotypes 
(e.g., ISP8/SP8) from moribund mice were transferred into Rag1 KO recipient mice. 
Transferred thymocytes rapidly infiltrated the thymus, spleen, lymph nodes and BM, 
inevitably causing animal death within 4 weeks (Figure 2B and data not shown). 
These data strongly argue that the lymphoproliferative disease, with probable origin 
in the thymus, present in dox-fed F5 TreIL-7Rα animals corresponds to a T-cell 
leukemia/lymphoma, which characteristically becomes more aggressive upon 
transplantation to secondary recipients. Importantly, all dox-fed F5 TreIL-7Rα mice, 
expressing TreIL-7Rα transgene, displayed excessive weight loss and eventually died 
with signs of widespread tumor infiltration (Figure 2A,C). In contrast, dox-fed F5 
mice lacking the TreIL-7Rα transgene (F5 Rag1KO Il7rKO rtTA.C), and F5 TreIL-
7Rα mice fed with normal food, thus not expressing the TreIL-7Rα transgene, failed 
to develop such tumors (Figure 2C). These data indicate that tumor development is 
dependent upon the induced, continuous expression of TreIL-7Rα transgene and 
cannot be attributed to either the introduction of the TreIL-7Rα transgene or the 
feeding of mice with dox food.  
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Figure 2. Doxycycline-fed F5 TreIL-7Rα mice develop leukemia/lymphoma with variable 
phenotype. F5 TreIL-7Rα mice continuously expressing TreIL-7Rα (on dox) were sacrificed when 
moribund. (A) Different organs were evaluated by flow cytometry and hematoxylin/eosin histological 
analysis: Thymus I) and II); Slpeen III)-V); BM VI) and VII); LN VIII)-X) (B) Thymocytes were 
isolated, and phenotypically characterized by flow cytometry analysis with anti-CD4-PE, -CD8-FITC 
staining (I). Thymocytes from the same mouse (10x106) were intravenously transplanted into Rag1 KO 
mice, which were subsequently fed with dox-containing food (n=4). After 4 weeks, mice were culled 
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and lymphoid organs were analyzed by flow cytometry with anti-CD4-PE and -CD8-FITC staining (II). 
One representative animal from 3 independent experiments with groups of 4 transplanted animals is 
shown. (C) Mice of the indicated genotype were followed for tumor-free survival, by controlling their 
body weight. Kaplan-Meier leukemia/lymphoma-free survival curves of mice with the indicated 
genotypes and with or without IL-7Rα expression (on/off dox food) is shown. (D) Schematic 
representation of the CD4/CD8 phenotypes of TreIL-7Rα tumors analyzed and a representative case of 
each phenotype observed by flow cytometry analysis with anti-CD4-PE and anti-CD8-PercP staining. 
(E) Analysis of tumor cell size (using FSCxSSC), IL-7Rα expression (IL-7Rα/CD127-PE staining) 
and HSA expression (HSA-FITC staining) were compared within the CD4+CD8+ double positive 
population of either F5 or F5 dox-fed Tre-IL7Rα mice. Histogram results are expressed in mean 
intensity of fluorescence. 
 
Different criteria are important to define T-cell differentiation in the thymus: CD4 
versus CD8 distribution in total thymocytes and the level of expression of CD5 and 
TCRαβ in the bulk population. According to these criteria, Buentke et al (32) showed 
that thymus from young dox-fed F5 TreIL-7Rα mice presented normal T-cell 
differentiation as compared with age-matched F5 control mice. In contrast, leukemic 
F5 TreIL-7Rα mice showed significant alterations in T-cell development, consistent 
with leukemia/lymphoma incurrence. Namely, the F5 TreIL-7Rα thymi were mainly 
composed by homogeneous cell populations of either DN, SP8, DP or SP4 phenotype 
(Figure 2A,D). CD5 and TCR analysis of malignant cells revealed different ranges of 
cell maturation, but there was no correlation with the CD4/CD8 phenotype (Figure 3A 
and data not shown). Unlike the studies of Laouar et al., where leukemic thymocytes 
presented an immature phenotype (29), F5 TreIL-7Rα leukemic cells accumulated at 
different stages of development (Figure 2A,D), mimicking the immunophentypic 
heterogeneity that characterizes human T-ALL. Interestingly, all tumors presented 
blast-like thymocytes with increased cell size and high levels of the immature marker 
HSA (Figure 2E) when compared to DP population of F5 control mouse. As expected, 
most of the tumors expressed higher IL-7Rα levels compared to control cells (Figure 
2E), although intriguingly some malignant cells completely lost IL-7R expression 
(data not shown). 
 
5.4.3. F5 TreIL-7Rα tumors associate with PI3K/Akt pathway activation and 
downregulation of the tumor supressors PTEN and p27Kip1. 
Multiple downstream signaling pathways are linked to IL-7Rα signaling. Activated 
IL-7Rα binds to PI3K and ultimately leads to cell cycle progression, proliferation and 
resistance to apoptosis (34-37). In order to better characterize tumors in this model, 
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we performed ex vivo biochemical analysis of the PI3K pathway on malignant cells 
collected from F5 TreIL-7Rα thymus. Constitutive hyperactivation of the PI3K/Akt 
pathway was detected in most of F5 TreIL-7Rα tumors in comparison to thymocytes 
from F5 control mice, as evaluated by increased phosphorylation of Akt (Figure 3). 
Hyperactivation of PI3K/Akt pathway was in some cases associated with lack of its 
negative regulator, the tumor suppressor PTEN (Figure 3). Similar to what has been 
described for human T-ALL cells analyzed ex vivo (38), we observed that the cell 
cycle inhibitor p27Kip1 was downregulated in malignant cells (Figure 4), possibly as a 
consequence of permanent IL-7/IL-7R signaling. This analysis showed that malignant 
cells frequently presented hyperactivation of PI3K/Akt pathway and downregulation 
of the tumor supressors PTEN and p27Kip1, all of which are features of human T-ALL 
(38, 39). Coincidentally, IL-7-mediated signaling was shown to promote PI3K/Akt 
pathway activation (40) and p27Kip1 downregulation (27) in primary T-ALL cells 
cultured in vitro. 
 
Figure 3. F5 TreIL-7Rα tumors associate with PI3K/Akt pathway activation and downregulation 
of the tumor supressors PTEN and p27Kip1. Thymocytes from F5 control mice (n=4) and F5 TreIL7-
Rα tumors (n=6) were isolated, disrupted into single cell suspension and lysed for immunoblot 
analysis. Thymic whole cells extracts were resolved with 10% SDS-PAGE and immunoblotted with the 
indicated antibodies. Levels of phosphorylated Akt, were analyzed by using antibodies that specifically 
recognize S473-phosphorylated Akt (p-Akt). Levels of PTEN and p27Kip1 were detected with specific 
antibodies that recognize the total protein. Blots were reprobed with Actin to confirm even protein 
loading. 
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5.4.4. F5 TreIL-7Rα malignant cells are independent of IL-7Rα  expression. 
An important question was to determine the precise requirement for continuous 
transgenic IL-7Rα expression for tumor maintenance. Since transgenic IL-7Rα 
expression is under the control of a tetracycline responsive promotor, we were able to 
terminate the expression of IL-7Rα by feeding the animals with normal food and 
observing the faith of malignant cells in vivo. Within a group of aged-matched mice, 
we withdrew the dox-containing food when the first tumor case appeared, in order to 
switch-off IL-7Rα expression. The first tumor presented a DN (CD4- CD8-) CD5+ 
TCRhi aberrant phenotype (Figure 4A - Day 0 On Dox). Curiously, both animal #1 
and #2, which were kept off dox for 2 weeks, still presented tumors with cells that 
were IL-7Rα high (Figure 4B) and displayed aberrant phenotypes (Figure 5A; 
animal#1 - DP, CD5lo and TCRhi; and animal#2 - DN/SP8, CD5hi and TCRhi). IL-7Rα 
expression was completely abrogated only in malignant cells from animals that were 
fed off dox for 4 weeks (Figure 4B). These animals still presented tumors with an 
aberrant phenotype (Figure 4A - Off Dox animals #3 and #4).  
 
 
Figure 4. F5 TreIL-7Rα  malignant cells are independent of IL-7Rα  expression. Age matched F5 
TreIL-7Rα animals (n=5), were taken off dox upon first tumor case appear and animal sacrificed (Day 
0 – On Dox). Animals were cull after 2 and 4 weeks off dox food. (A) F5 TreIL-7Rα thymocytes were 
analyzed for cell size and phenotype by flow cytometry, with FSCxSSC and anti-CD4-PE, -CD8-
PercP, -CD5-FITC and -TCR-APC staining. (B) IL-7Rα expression was measured in F5 TreIL-7Rα 
thymocytes. Mean intensity of fluorescence (MIF) was compared to DP (CD4+CD8+) population of F5 
control mouse. Results are representative of two independent experiments. 
 
TRANSGENIC IL-7Rα MICE DEVELOP T-CELL LEUKEMIA/LYMPHOMA  
169 
To further characterize the role of IL-7Rα in the maintenance and expansion of 
tumors, malignant cells isolated from F5 TreIL-7Rα tumors were transferred into 
Rag1 KO recipient mice. Rag1 KO mice were kept off- or on-dox, to either repress or 
maintain IL-7Rα expression, respectively. Both groups of mice were culled 4 weeks 
posttransplant due to disease symptoms (≥20% weight loss). The presence of 
malignant cells in lymphoid organs was determined by flow cytometry using anti-
CD4, -CD8, -CD5, -TCRαβ antibodies. We found no major differences in phenotype 
between the secondary tumors developed in recipient mice and the primary tumors in 
the donor mice (Figure 5A). Furthermore, cells recovered from Rag1 KO mice off 
dox, which did not express IL-7Rα, presented similar phenotype and total numbers to 
cells recovered from mice on dox (Figure 5A,B). Altogether, our results suggest that, 
although necessary for leukemia/lymphoma initiation, continuous IL-7Rα expression 
was not absolutely required for the maintenance of malignant cells, since late 
abrogation of IL-7Rα expression did not revert the tumorigenic process.  
 
 
Figure 5. Phenotype of malignant cells is maintained after loss of IL-7Rα .  (A) Tumor cells were 
isolated from the thymus of a sick TreIL-7Rα mouse, that continuously expressed IL-7Rα (on dox). 
Primary tumor was phenotypically characterized by flow cytometry with anti-CD4-PE, CD8-PercP, 
CD5-FITC and TCR-APC staining. 10x106 malignant cells from the thymus were transplanted into 
Rag1 KO mice, which were either fed with or without dox-containing food. After 4 weeks, mice were 
culled and BM was phenotypically analyzed as previously. (B) IL-7Rα expression was measured in F5 
TreIL-7Rα primary tumor cells and after the adoptive transfer. Mean intensity of fluorescence (MIF) of 
primary tumor cells was compared to DP (CD4+CD8+) population of an F5 control mouse. MIF of 
malignant cells transplanted into Rag1 KO was compared between On and Off dox groups. Results are 
representative of 4 animals per group (On and Off Dox) and from two independent experiments. 
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5.4.5. IL-7R-induced tumorigenesis is independent of TCR transgene specificity. 
The tumorigenic effects of IL-7Rα expression became apparent in dox-fed F5 TreIL-
7Rα rtTA.C Il7rKO mice, in which tumors develop with a very high incidence 
(Figure 2C and 6A, red line). Since all the T-cells in these mice express the F5 TCR, 
an MHC Class I-restricted TCR transgene specific for nucleoprotein of influenza 
virus (41), it was possible that tumorigenesis depended on TCR signaling during 
thymic selection. To test this hypothesis, we determined the incidence of tumor 
development in non-TCR transgenic, polyclonal OTII(-)TreIL-7Rα rtTA.C Il7rKO 
(OTII(-)TreIL-7Rα) mice (Figure 6A, blue line), and MHC Class II-restricted TCR 
transgene specific for ovalbumin, OTII TreIL-7Rα rtTA.C Il7rKO - OTII TreIL-7Rα 
mice fed with dox-containing food (Figure 6A, black line). Our preliminary results 
showed that IL-7Rα transgene expression induced tumors at a similar rate 
independently of TCR signaling (Figure 6A). Similarly to F5 TreIL-7Rα tumors 
(Figure 4A), the malignant phenotype from TreIL-7Rα and OTII TreIL-7Rα was 
irreversible even after 4 weeks in the absence of dox-containing food (Figure 6B). 
Furthermore, these tumors presented a tendency to downregulate PTEN (Figure 6C) 
similar to those from F5 TreIL-7Rα mice (Figure 3). Interestingly, they frequently 
displayed increased Bcl-2 basal levels when compared to control thymocytes (Figure 
6C). These data suggest that tumor incidence resulting from constitutive IL-7Rα 
expression in T-cells is independent of MHC-TCR restriction and can affect any T-
cell lineage. 
 
 
TRANSGENIC IL-7Rα MICE DEVELOP T-CELL LEUKEMIA/LYMPHOMA  
171 
 
Figure 6. IL-7R-induced tumorigenesis is independent of TCR transgene specificity. (A) Mice of 
the indicated genotypes, monoclonal OTII(+) and F5(+) and polyclonal OTII(-) TreIL-7Rα mice, with 
IL-7Rα expression (on dox food) were followed for tumor free survival, by controlling their body 
weight. Mice were sacrificed when moribund and post-mortem analysis by flow cytometry was 
performed to confirm tumor-associated death (data not shown). (B) OTII(+) TreIL-7Rα mice, age-
matched, were kept on or off dox-containing food, upon identification of first tumor case. 3 weeks later 
animals were culled and thymocytes phenotype was analyzed by staining with anti-CD4-PE and -CD8-
FITC antibodies. (C) Mixed thymocytes from OTII control and OTII(+) or (-) TreIL7-Rα tumors were 
isolated into cell suspension and lysed for immunoblot analysis. Thymic whole cells extracts were 
resolved with 10% SDS-PAGE and immunoblotted with the indicated antibodies. Levels of Bcl-2, 
PTEN and p27Kip1 were detected with specific antibodies that recognize the total protein. Blots were 
reprobed with Actin to confirm even protein loading.  
 
TRANSGENIC IL-7Rα MICE DEVELOP T-CELL LEUKEMIA/LYMPHOMA  
172 
5.5. Discussion 
IL-7Rα expression has been associated with several types of cancers such as 
cutaneous and nodal large T-cell lymphomas (42), thyroid lymphomas (43), Hodgkin 
disease (44), and B and T-lineage acute lymphoblastic leukemia (45, 46). Furthermore 
when two X-SCID patients underwent gene therapy with constitutive expression of 
common γC cDNA they developed leukemia (30), possibly due to increased growth 
factor stimulation via the IL-7R pathway. In fact high levels of IL-7 were detected in 
these patients (47). This suggests that IL-7R signaling may play an important role in 
the development of some hematological cancers. In light of this evidence, we 
evaluated the role of IL-7R in T-cell tumorigenesis in vivo and showed that 
continuous expression of TreIL-7Rα  promotes leukemia/lymphoma of thymic origin. 
The thymus is the major site of T-cell differentiation, a process that depends on the 
tight regulation of IL-7Rα expression (48). Interestingly, we observed that continuous 
expression of TreIL-7Rα promoted thymic hyperplasia in mice. Whether these 
aberrant phenotypic cells of increased size are pre-leukemic or leukemic remains to 
be determined. Interestingly, hyperplasic cells seem to be dependent on thymic 
factors, since initially they do not disseminate to the periphery. Notwithstanding, 
abnormal T-cell development in TreIL-7Rα -expressing mice ultimately leads to 
leukemia/lymphomagenesis and tumor-associated death. A similar observation was 
made by Laouar and collegues using AKR/J mice, which constitutively overexpress 
IL-7R (29). The advantage of our experimental system relies on the ability to induce 
the continuous expression of TreIL-7Rα at endogenous levels (32). Our mice 
developed tumors with variable CD4/CD8 phenotype and presented different stages 
of maturation (CD5/TCR), despite high expression of the immature marker HSA (heat 
shock antigen). Importantly these observations were independent of TCR-signaling 
[monoclonal Class I (F5) or II (OTII+); and polyclonal (OTII-)]. Interestingly, these 
tumor characteristics, as well as those related to PI3K/Akt hyperactivation, p27Kip1 
and PTEN downregulation, and Bcl-2 upregulation, are strikingly reminiscent of 
human T-ALL (27, 38-40), where most patient samples are IL-7-responsive (49).  
Common γC is constitutively expressed in hematopoietic cells (50). Together with the 
induced constitutive TreIL-7Rα expression, γC could support continuous IL-7 
signaling in the thymus, which in turn would trigger the continuous activation of the 
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pro-oncogenic PI3K/Akt pathway and consequent p27Kip1 downregulation and Bcl-2 
upregulation. The phenotypic heterogeneity of the tumors (including PTEN protein 
deletion in some cases) raises the provocative hypothesis that continuous IL-7/IL-7R-
mediated signaling could also contribute to genomic instability, thereby promoting 
malignant transformation. However, IL-7 itself may become a limiting 
microenvironmental factor, particularly for rapidly proliferating cells. Therefore, it is 
likely that cells that become independent of TreIL-7Rα due to acquired and 
accumulated cell-autonomous lesions will have a survival and proliferative advantage 
in the long-run. In agreement, our results suggest that, although necessary for 
leukemia/lymphoma initiation, continuous IL-7Rα expression was not absolutely 
required for the maintenance of malignant cells, since late abrogation of IL-7Rα 
expression did not revert the tumorigenic process. Nonetheless, the oncogenic profile 
observed in the analyzed tumors, such as PI3K/Akt pathway activation and Bcl-2 
upregulation (40) can be linked to an intense TreIL-7Rα  signaling. In addition, 
decreased expression of p27Kip1 and/or PTEN proteins observed in TreIL-7Rα  
tumors, could be a consequence of IL-7R signaling (28) and/or genomic instability. 
Further studies are necessary to identify the period during which T-cells are 
dependent of continued IL-7Rα signaling that will culminate in malignancy. It also 
remains to be established whether the tumorigenic process is reversible following 
abrogation of IL-7Rα expression at earlier time points, before the onset of widespread 
disease. 
Interestingly, IL-7Rα heterodimerizes with either γC or the thymic stromal derived 
lymphoprotein (TSLP) receptor, transmitting IL-7 or TSLP signals respectively (51). 
Although TSLP signals are not crucial for B or T cell development, they have been 
shown to prevent pre-B leukemia apoptosis in response to mTOR inhibitors (52) In 
our studies, it is possible to consider a role for TSLP in the formation of T-cell 
malignancies. Moreover, if IL-7 becomes a limiting factor, TSLP could be an 
alternative cytokine to signal through the TreIL-7Rα. In addition to cell-autonomous 
alterations, TSLP signaling could contribute to the survival and cell growth in a 
scenario where IL-7 is absent or scarce.  
In summary, our work supports and extends previous evidence that IL-7R has the 
capacity to act as an oncogene in vivo, since its continued expression induces T-cell 
leukemia/lymphoma. In addition, the mouse model described herein may constitute a 
TRANSGENIC IL-7Rα MICE DEVELOP T-CELL LEUKEMIA/LYMPHOMA  
174 
valuable tool for the study of T-ALL and for testing novel therapeutic tools for this 
disease.   
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6. Discussion  
In this study we demonstrated that cell-autonomous mechanisms and 
microenvironmental factors are implicated in the survival and the expansion of T-
ALL cells in vitro and in vivo. Results and some possible mechanisms to further 
explore were integrated in a model (Figure 1). 
 
Figure 1 - Model of signaling pathways activation by endogenous mechanisms and 
microenvironmental factors in T-ALL cells. 
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6.1. PTEN in T-ALL. 
PTEN loss-of-function has been extensively associated with tumorigenesis (1). 
Although PTEN KO mice are embryonic lethal (2), PTEN heterozygous mice develop 
a variety of tumors in multiple tissues similar to what is seen in humans (2-4). Of the 
cancers developed in PTEN heterozygous mice, 88% were classified as T-ALL (5). 
Furthermore, mice reconstituted with PTEN KO hematopoietic stem cells (HSCs) 
developed T-ALL that harbored translocations resulting in aberrant expression of c-
Myc (6). In the present studies, we found that T cell malignancies originated in TreIL-
7Rα mice, lacked PTEN protein (Chapter 5). Whether these tumors harbor PTEN 
mutations or other genetic lesions and translocations due to genomic instability, 
remains to be demonstrated. In any case, it should be noted that absent PTEN protein 
expression may itself contribute to genomic instability (7, 8).  
Several T-ALL cell lines present inactivating mutations and/or PTEN loss that 
promote PI3K/Akt pathway hyperactivation (9). However, we demonstrated in 
Chapter 2 (10), that posttranslational modifications cause non-deletional PTEN 
inactivation in a majority of primary T-ALL cases, ultimately leading to increased 
leukemia cell survival due to PI3K/Akt signaling pathway hyperactivation (Figure 1). 
 
6.2. IL-7-induced PI3K signaling and survival in T-ALL: the role of ROS and 
PTEN. 
In Chapter 2 we described PTEN inactivation by increased phosphorylation and 
oxidation of PTEN (10). These posttranslational modifications might occur only 
within some cellular compartments and/or affect particular PTEN pools, while PTEN 
at other locations in the cell remains with normal activity. We demonstrated in 
Chapter 3 that in T-ALL, IL-7-mediated signaling can further upregulate intracellular 
ROS levels in a PI3K-dependent manner. (Figure 1) This raises the possibility that 
PTEN activity in T-ALL cells can be further inactivated by extrinsic factors such as 
IL-7, due to their capacity to upregulate ROS. Increased ROS can promote the 
activation of PI3K/Akt pathway activity. Whether this is dependent on PTEN 
oxidation remains to be demonstrated. Interestingly, it is known that high ROS levels 
can also trigger T cell apoptosis (11). Malignant T cell blasts can be more resistant to 
high ROS levels due to upregulated ROS scavenger mechanisms, yet undetermined, 
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or because IL-7-mediated signaling activates many pro-survival mechanisms, such as 
upregulation of Bcl-2, PI3K/Akt and JAK/STAT5 pathways, that finally balance 
towards T-ALL cell survival. 
Other γC-signaling cytokines, such as IL-4, can promote T-ALL proliferation and 
growth (12). Recently, a study revealed that ROS act as second messengers in the 
amplification of IL-4-mediated signal transduction, since IL-4-generated ROS oxidize 
a phosphatase responsible for the negative regulation of IL-4 receptor (13). In T-ALL 
cells, it is possible that not only IL-7 but also other γC-cytokines act through their 
specific receptors generating ROS. ROS, as small and diffusible radicals or 
molecules, would promote the oxidative inactivation of phosphatases regulating 
cytokine receptors (e,g. PTP1B that deactivates IL-4R) or phosphatases regulating 
PI3K pathway (e.g. PTEN). Therefore, other cytokine-generated ROS may amplify 
the signaling of “non-activated” receptors in the same cell.  
Another possible and non-exclusive mechanism for increased PTEN oxidation upon 
IL-7-mediated signaling in T-ALL, regards the thioredoxin-interacting protein 
(TXNIP). TXNIP has been shown to associate with reduced thioredoxin, thereby 
decreasing thioredoxin expression and activity (14), therefore inhibiting one of the 
major thiol-reducing systems in the cells (15). Interestingly, TXNIP is present in T-
cells (16, 17), and accumulating evidence suggests that increased glucose metabolism 
upregulates TXNIP (18, 19). In turn, we have previously shown that glucose uptake is 
regulated by IL-7-mediated PI3K activation in T-ALL cells (20), and our present 
work demonstrated that inhibition of glucose transporters prevents IL-7-mediated 
ROS upregulation (Chapter 3). Therefore, it is tempting to speculate that IL-7 may 
originate increased ROS in T-ALL cells, at least in part by upregulating glucose 
levels in the cell and consequently TXNIP protein expression.  
 
6.3. IL-7 and CK2: is there a link in T-ALL? 
CK2 is a constitutively active protein kinase implicated in cellular transformation and 
development of tumorigenesis (21). Many human cancers display CK2 
overexpression and/or hyperactivity (21), and mouse models with targeted 
overexpression of both CK2 and either c-Myc (22) or Tal1 (23) in T-cells eventually 
develop lymphomas. CK2 protein and activity regulation remains largely unknown. 
Despite some instances where CK2 was demonstrated to be regulated by external 
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factors (24), there is limited support for the role of phosphorylation regulating the 
activity of CK2 in response to cellular stimulation (25). Although we showed that T-
ALL cells express high levels of CK2 protein and activity (Chapter 2), it would be 
interesting to determine whether IL-7 could play a role in the regulation of CK2 
activity, promoting for example cross- or auto-phosphorylation of CK2 subunits. In 
alternative, IL-7 could indirectly alter the ratio of alpha- and beta-subunits due to 
protein-protein interactions with other binding partners, and ultimately facilitate the 
availability of CK2 subunits to generate fully active holoenzyme CK2 tetramers. 
Interestingly, it is known that CK2 interacts with p27Kip1 (24), and that p27Kip1 is 
downregulated in T-ALL by IL-7 signaling (26). Although it has been shown that IL-
7-mediated p27Kip1 downregulation in T-ALL is PI3K-dependent (20), it is not known 
whether CK2 could also take part in the process. Finally, ROS levels, which are 
upregulated by IL-7, could theoretically regulate CK2 activity in T-ALL (Figure 1). 
Although the mechanisms responsible for H2O2-mediated activation remains unclear 
for most protein kinases, it is known that cysteine oxidation likely contributes to the 
activation of certain serine–threonine kinases and protein tyrosine kinases (27). On a 
different note, increased CK2 activity in T-ALL could be the cause of elevated ROS 
levels. However, any of these hypotheses remain to be tested.  
 
6.4. IL-7 in leukemia: from in vitro to in vivo models.  
Immunodeficient mouse models (28-30) provide powerful tools for preclinical testing 
of novel therapeutic agents using primary human ALL samples (31-34). Our results in 
Chapter 2 and 3 unraveled new mechanisms responsible for T-ALL cell survival in 
vitro. However, our major goal is to determine the relevance of these mechanisms in 
vivo. Primary T-ALL cells undergo spontaneous apoptosis when cultured in medium 
alone, indicating that cell-autonomous mechanisms are not sufficient per se for T-
ALL cell survival. Nevertheless, pharmacological inhibitors of CK2 and PI3K, further 
increase the apoptotic levels of T-ALL cells in vitro in a very significant manner, 
suggesting a high degree of dependence on PI3K activation for survival of leukemic 
cells, which might be very relevant in vivo. This is consistent with the observation 
that, in vivo, both primary T-ALL and TAIL7 cells, which display basal 
hyperactivation of PI3K/Akt pathway (Chapter 2), were able to engraft and establish 
leukemia in IL-7 KO mice. This suggests that the cell-autonomous degree of 
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PI3K/Akt pathway activation in T-ALL cells is sufficient for the transplanted cells to 
induce leukemia in vivo independently of IL-7, although not as efficiently and rapidly 
as in the presence of the cytokine. On the other hand, the heterogeneity of results 
among the IL7 KO animals (Chapter 4) suggests that T-ALL cells might adapt and 
respond to other microenvironmental factors such as SDF-1 (35) LFA-1 (36) and 
other cytokines (37), which may compensate, to different levels, the absence of IL-7. 
We have shown in Chapter 3 and in previous reports (20, 26) that addition of IL-7 
promotes T-ALL viability in vitro. In accordance, others have demonstrated that IL-7 
is an important cytokine for ALL survival and proliferation in BM stromal cells co-
cultures (38, 39). The results reported in this thesis (Chapter 4) are, to the best of our 
knowledge, the first observations regarding the role of IL-7 in human T-ALL 
expansion in vivo. Our data suggest that IL-7-mediated signaling may contribute to T-
ALL cell expansion in vivo. In turn, this raises an important question on the capacity 
of IL-7 to induce resistance to T-ALL chemotherapeutic treatments. Sherr and 
colleagues showed that imatinib resistance in BCR-ABL+ mouse models was 
associated with cytokine-mediated rescue within the host hematopoietic 
microenvironment, more specifically with γC receptor signaling (40). Moreover, drug 
resistance in vivo to imatinib or mTOR inhibitors, can be related with the IL-7-
protective effect seen in ALL cells in vitro. To avoid these mechanisms of resistance, 
Williams suggest a multi-target therapy including JAK inhibitors (40). If in fact IL-7 
contributes to chemoresistance of T-ALL cells, an issue that is yet unexplored, 
another possibility would be to combine IL-7 neutralizing antibodies with 
chemotherapeutic agents. 
 
6.5. IL-7/IL-7R axis in leukemia: the role of IL-7Rα .  
Part of this thesis emphasizes the relevance of thymic or lymphoid organ 
microenvironment in assisting T-cell leukemia development. Others and we have 
identified IL-7 as a leukemia-promoting factor (38, 41). The role of IL-7 in T-cell 
leukemia increased our interest in the respective receptor. Golub and co-workers 
identified ALL samples as highly expressing IL-7Rα mRNA compared to AML 
samples (42). However, it remains to be established whether this difference is 
characteristic of the leukemogenic process in T-cells, or merely arises from the fact 
that normal T-cell precursors generally express higher levels of IL-7Rα than myeloid 
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precursors. In mice, T-cell lymphoma cell lines appear to express significantly higher 
levels of IL-7Rα at the cell surface than thymocytes from normal CBA/N or B6 mice 
(43). Yet, this receptor is expressed in T-ALL cells at lower levels than normal T cells 
(44-47). Moreover it is known that IL-7Rα surface expression is upregulated upon IL-
7 withdrawal and that the downstream targets of Akt, FOXO transcription factors, are 
responsible for the IL-7Rα transcription (48). Therefore, our observations of PI3K 
overactivation can explain the low IL-7Rα levels and receptor downregulation upon 
IL-7 stimulation in T-ALL.  
This suggests that IL-7Rα levels are also regulated in malignant T cells. In this study 
we demonstrated that IL-7Rα dysregulation, continuous expression, led to abnormal 
T-cell development and thymic lymphomas. Other study achieved similar results but 
with different mice models (49). In contrast to our results, Munitic and colleagues 
observe that IL-7Rα transgenic mice undergo normal negative selection and an age-
dependent thymic hypoplasia. It is possible that thymus hypoplasia precedes thymic 
lymphomas but this was not seen in the short window of time analyzed. This can be 
justified due to competition between the expanding numbers of IL-7Rα DP 
thymocytes and their DN precursors for limiting amounts of endogenous IL-7, and 
therefore normal IL-7Rα downregulation is necessary to maintain a functional 
balance between IL-7 production and IL-7 consumption. However the fact that this 
mouse model has a wild type background while ours TreIL-7Rα has an IL-7R KO 
background can constitute a major difference in IL-7 availability since in a recent 
study Mackall et al (50) showed that the availability of IL-7 is dependent on its 
consumption and not production. Although, our data indicates that the thymic 
lymphomas developed in the TreIL-7Rα were dependent on TreIL-7Rα expression 
for initial tumor onset, the malignant cells became growth factor-independent with 
cell autonomous lesions. For example the lack of PTEN, that has been recently 
associated with genomic stability(51). Moreover, in chromosomally unstable mouse 
tumors and human cancers PTEN is frequently deleted(7). In addition PTEN is less 
expressed in T cells upon high stimulation with IL-7 (52). It would be interesting to 
demonstrate whether the intense TreIL-7Rα signaling is associated with 
leukemogenesis by increased genomic instability and loss of PTEN. 
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6.6. New potential therapeutic targets for cancer. 
Current therapeutic strategies for T-ALL treatment are very successful (53). However, 
a significant number of relapses still occur. Moreover, those patients that respond to 
therapy can often suffer from long-term side-effects due to the intensiveness of 
combined chemotherapy. These facts drive the quest for novel, more effective and 
specific therapies. In this work we unraveled the posttranslational regulation of PTEN 
by CK2 and ROS, and subsequent impact on PI3K/Akt axis, as a key cell-autonomous 
mechanism for T-ALL cell viability. Importantly, this mechanism might be common 
to other leukemias and/or solid tumors. In this study we used LY294002, a reversible 
ATP-competitive PI3K inhibitor, to promote cell death specifically in leukemia cells. 
However, this compound is very unstable in vivo (54). Intensive work has been done 
to overcome the pharmacodynamic limitations of LY294002, and some new 
LY294002-derived PI3K inhibitors are already in clinical trials, such as SF-1126 (55). 
Also, other derivative compounds of wortmannin, an irreversible PI3K inhibitor (56), 
are being tested but yet not in clinical trials, such PWT-458 and PX-866 (57, 58). 
Furthermore, a new generation of PI3K inhibitors with improved selectivity have 
been synthesized and are now in clinical trials, such as NVP-BEZ235, PI103 and 
XL147 (59). The enormous effort placed by the pharmaceutical industry in 
developing and testing these compounds eloquently states the expectations that 
inhibition of PI3K/Akt pathway holds for cancer treatment. Despite the promising 
results obtained in vitro (10, 60, 61), it remains to be seen whether inhibition of 
PI3K/Akt pathway will become a clinically relevant therapeutic approach for the 
treatment of T-ALL.  
In Chapter 2, we demonstrated that CK2 should be considered as a potential 
therapeutic target in T-ALL, since its inhibition increases cell death in leukemic cells 
without affecting their normal counterparts. This could be achieved with a CK2 
inhibitor, CX-4945 (Cylene Pharmaceuticals) that is already in phase I clinical trials 
for other cancers (www.cylenepharma.com/cylene/pr_1230934977) or with a novel 
proapoptotic peptide that impairs CK2 phosphorylation and activity, CIGB-300, 
exhibiting anticancer properties both in vitro and in vivo (62).  
Finally, our in vitro (Chapter 3) and in vivo (Chapters 4 and 5) data suggest that the 
IL-7/IL-7R axis might be a relevant molecular target for treatment of at least some T-
ALL cases. Our studies suggest that IL-7 is a microenvironmental factor with 
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relevance for T-ALL expansion in vivo (Chapter 4) and that IL-7R signaling can be 
involved in the onset of mouse T cell tumors that phenotypically and molecularly 
resemble human T-ALL. The possible use of JAK inhibitors, which are associated 
with IL-7R, or neutralizing antibodies for IL-7 and/or IL-7R, might increase T-ALL 
cell death per se and furthermore sensitize leukemic cells to other drugs.  
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